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Abstract
To substantiate the hypothesis that multiple infection by human herpesvirus 8 (HHV- 
8) and by cytomegalovirus (CMV) commonly occurs, intraperson nucleotide 
variation in DNA amplified from hypervariable subgenomic domains of HHV-8 and 
CMV was evaluated in a group of people living in Malawi, where both viruses 
circulate hyperendemically.
Mouth rinses, throat gargles, palatal exfoliates and blood were sampled from 89 
people (age range: 4 m to 45 y). In 24 people (27%), HHV-8 DNA could be 
amplified in >1 sample; 9 (38%) were seropositive for human immunodeficiency 
virus-1 and 7 (29%) exhibited Kaposi’s sarcoma. Sequence variation was sought in 
DNA segments derived from: the domain in open reading frame (ORF) 73 that 
encodes latent nuclear antigen; the Bam330 segment of ORF 26; and the VI region 
of ORF Kl. Restriction ffagment-length polymorphism analysis, nucleotide 
sequencing, PCR cloning and denaturing gel gradient electrophoresis were applied to 
study the sequence diversity of these segments. Significant intraperson/inter- and 
intra-sample sequence polymorphisms could be found in 15 people (62.5%). 
Variation in urine-derived VI sequences could, in addition, be evaluated: in 5 
people, the sequences were monotypic, and in 2, urinary and oral sequences were 
genotypically different.
Variation in hypervariable domains in the gO and gN regions of CMV was studied in 
urine and saliva samples of 77 people. In 41 individuals (53%), DNA could be 
amplified from at least one domain, and, in 14 (18%), from both domains. In 4 
individuals (5%), urinary and oral sequences were genotypically different. The
2
Multiple Infection by Human Herpesvirus-8 and Cytomegalovirus
extent of inter- and intra-person variation in the 2 CMV domains studied was 
significantly less than in K l/V l of HHV-8.
Multiple infection by HHV-8 and by CMV is common. It would be important to 
determine if such infection reflects coinfection occurring during initial transmission 
or superinfection, as the latter implies that vaccination might be ineffective to 
prevent and control the spread of the viruses.
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1.1 Herpesviridae
Herpesviridae is the name assignment to a family of enveloped, double-stranded 
DNA viruses with relatively large complex genomes. ‘Herpes’ means ‘to creep’ and 
reflects how herpesviruses infections obtrusively spread from infected cells to 
adjacent healthy cells. The viruses replicate in the nucleus of a wide range of 
vertebrate hosts. Such viruses have been isolated from humans, horses, cattle, mice, 
pigs, chickens, turtles, lizards, fish, and even in some invertebrates, such as oysters 
(Roizmann et al., 1992).
1.1.1 Virion structure
All herpesvirus virions have four structural elements:
• Core, which consists of a single linear molecule of dsDNA.
• Capsid, which surrounds the core, which is icosahedral, consists of 162 
capsomeres, and is 100 nm in diameter.
• Tegument, which is situated between the capsid and envelope, and is 
amorphous, and consists of viral enzymes, some of which are needed to 
subvert the host cell's chemical processes to direct them towards virion 
production, some to defend against the host cell's immediate responses, and 
others for which the function is not yet understood.
• Envelope, the outer layer of the virion, which is composed of altered host 
membrane and comprises a dozen unique viral glycoproteins (Roizmann et 
al, 1992).
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1.1.2 Genome characteristics
Herpesvirus genomes range in length from 120 to 230 kbp and contain 60 to 120 
genes. Because replication takes place inside the nucleus, herpesviruses can exploit 
both the host's transcription machinery and its DNA repair enzymes to support a 
large genome with complex arrays of genes. Herpesvirus genes may be characterized 
as either essential or dispensable for growth in cell culture. Essential genes regulate 
transcription and are needed to construct the virion. Dispensable genes for the most 
part function to enhance the cellular environment for virus production, to defend the 
virus from attack by host immune system and to promote cell-to-cell spread. Large 
numbers of dispensable genes are required for a productive in vivo infection: it is 
only in the restricted environment of laboratory cell cultures that they are 
dispensable. All herpesvirus genomes contain lengthy terminal repeats, both direct 
and inverted (Roizmann et al., 1992; Roizmann and Pellett, 2001).
1.1.3 Biological properties
Four biological properties characterize members of the Herpesviridae family.
1. Herpesviruses express a large number of enzymes involved in metabolism 
of nucleic acid (e.g. thymidine kinase), DNA synthesis (e.g. DNA 
helicase/primase) and processing of proteins (e.g. protein kinase).
2. Synthesis of viral genomes and assembly of capsids occurs in the nucleus.
3. Productive viral infection is accompanied by inevitable cell destruction.
4. Herpesviruses are able to establish and maintain a latent state in their host 
and reactivate following cellular stress. Latency involves stable 
maintenance of the viral genome in the nucleus with limited expression of 
a small subset of viral genes.
20
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1.1.4 Strategies for success
The success of herpesvirus infections depends upon several strategies. The first is the 
fast, efficient way, which involves the virion invading the host cell, turning off host 
protein synthesis and releasing viral DNA into the nucleus, thereby permitting 
replication and virion production to start immediately. Another strategy is to thwart 
attacks from the host. Tactics include inhibiting splicing of mRNA, blocking 
presentation of antigenic peptides on the cell surface and blocking apoptosis (cell 
death) induced by viral gene expression. A third strategy is to hide their bare, 
circularized genome in the nucleus of lymphocytes, neurons and other host cells, and 
then to revert to productive infection months, even years later. These latent 
herpesvirus infections are often benign, but reactivation from that state can be 
devastating in newborns and in immuno-suppressed individuals.
1.1.5 Herpesviridae subfamilies
The members of the family Herpesviridae have been classified by the Herpesvirus 
Study Group of the International Committee on the Taxonomy of viruses (ICTV) 
into three subfamilies (i.e., the alphaherpesvirinae, the betahepesvirinae, and the 
gammaherpesvirinae) based on biologic properties. The same study group classified 
a small number of herpesviruses into genera based on DNA sequence homology and 
similarities in genome sequence arrangement (Figure 1.1).
a-herpesvirinae: The members of this subfamily are classified on the basis of 
variable host range, relatively short reproductive cycle, rapid spread in culture, 
efficient destruction of infected cells, and capacity to establish latent infections 
primarily but not exclusively in sensory ganglia. This subfamily contains
21
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Gammaherpesviruses
Rhadinovirus 
EHV2HVS K S H V
I EBV, 
Lymphocryptovirus
HSV1 
**HSV2 
EH VI
PRV
VZV
Alphaherpesviruses0.2 Divergence
HHV6
HHV7
Betaherpesviruses
CMV
Figure 1.1 Classification of Herpesviridae (Reproduced from Moore et al., 1996b).
22
Chapter 1 Introductory Considerations
the herpes simplex viruses (HSV) 1 and 2, and varicella-zoster virus (VZV).
p-herpesvirinae: A characteristic of the members of this subfamily is the restricted 
host range. The reproductive cycle is long and the infection progresses slowly in 
culture. Infected cells frequently enlarge (cytomegalia). The virus can be maintained 
in latent form in secretory glands, lymphoreticular cells, kidney and other tissues. 
This family contains the genera cytomegalovirus (CMV), human herpes virus-6 
(HHV-6) and human herpes virus-7 (HHV-7).
y-herpesvirinae: In vitro, all members of this subfamily replicate in lymphoblastoid 
cells and some cause lytic infections in some types of epithelioid and fibroblastic 
cells. Viruses in this group are usually specifically tropic for either T or B 
lymphocytes. Latent virus is frequently demonstrated in lymphoid tissue. This 
subfamily contains Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated 
herpes virus (KSHV), also known as human herpes virus-8 (HHV-8).
1.1.6 Human herpes viruses
The rest of this chapter reviews key features of herpesviruses that are shed in the 
mouth, which particular emphasis on HHV-8 and CMV.
1.1.6.1 Herpes simplex virus
1.1.6.1.1 Pathogenesis and epidemiology
HSV infects the skin, mucous membrane and neurones of the dorsal root ganglia, in 
which it maintains lifelong latent infection. The virus can reactivate and spread 
centrifugally down neuronal axons in spinal or trigeminal nerves. It may be shed
23
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asymptomatically in saliva (for HSV-1 predominantly) or genital secretions (for 
HSV-2 predominantly), and potentially cause destruction of the skin, mucosa and, 
occasionally, the major organs (Dwyer and Cunningham, 2002).
Primary HSV-1 infection occurs when a susceptible person, usually a child, comes 
into close contact with a person with primary or recurrent infection. Primary 
infection in children is often asymptomatic, but can cause stomatitis severe enough 
to require hospitalisation. Symptoms are more common in adolescents and adults. 
Most HSV-1 seroconversions occur in the first five years of life, and by adulthood, 
80% of individuals possess HSV antibodies. However, as the HSV-1 seroprevalence 
in children is falling in many developed countries, the risk of primary HSV-1 
infection in adults is increasing. HSV-1 may also cause genital herpes; the increasing 
prevalence of this infection may be due to increasing practice of orogenital contact.
HSV-2 infection is usually acquired sexually from early adulthood, often in people 
with pre-existing HSV-1 infection. Accordingly, clinical infection with HSV-2 may 
be considered an initial rather than a primary infection (the latter occurs when an 
adult acquires HSV-2 in the absence of HSV-1 antibodies). HSV-2 usually causes 
genital herpes, but is also a rare cause of herpes labialis. The major influence on 
HSV-2 acquisition is the number of lifetime sexual partners, with women generally 
infected at an earlier age than men. Most transmissions occur via asymptomatic viral 
shedding in genital secretions (Johnson et al., 1989). Both HSV-1 and HSV-2 
infections recur often, with genital infections more likely to recur if caused by HSV- 
2 than HSV-1.
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1.1.6.1.2 Clinical features
1.1.6.1.2.1 Orofacial infection
In primary HSV infection of the oropharynx, the most common manifestation is 
gingivostomatitis. Shallow ulcers form at the buccal mucosa and under the tongue, 
and may also occur at the hard palate (this feature differentiates HSV infection from 
herpangina caused by coxsackie virus). These ulcers may be accompanied by fever 
and submandibular lymphadenopathy. Autoinoculation from the primary infection 
may transmit infection elsewhere on the body (e.g., herpetic whitlow) (Stanberry et 
al, 2000).
Recurrent orolabial infections ("cold sores") may be triggered by stimuli such as 
fever, stress, cold, menstruation and ultraviolet radiation. Lesions usually occur on 
the vermilion border of the lips but may develop elsewhere on the face, including 
inside the nose. There is often a prodromal tingling or itching at the site of 
recurrence. Asymptomatic oral shedding of HSV is common and can transmit the 
virus. Lesions may be widespread in people with eczema and severe in those who are 
immunocompromised (Stanberry et al, 2000).
1.1.6.1.2.2 Genital infection
Symptomatic primary genital infection is moderately severe (more so in women) and 
lasts up to three weeks. Common signs include fever, dysuria, widespread ulceration, 
inguinal lymphadenopathy, malaise and pain. It may be accompanied by 
radiculomyelitis, with urinary retention and neuralgia, and secondary bacterial 
infection. Perianal infections and proctitis may occur, especially in homosexual men. 
Genital infection often leads to significant emotional and psychosexual disturbance.
25
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About 20% of HSV-2-seropositive patients experience overt recurrences of genital 
herpes; lesions are more limited in area and severity than primary infection. About 
60% of HSV-2 seropositive patients have lesions but may not recognise their 
herpetic nature, especially if they are small or atypical. The remaining 20% have true 
asymptomatic viral shedding. Genital HSV-2 recurrences usually last longer than 
oral HSV-1 recurrences and are more frequent in the six to 12 m after initial 
infection (Johnson et al., 1989; Koutsky et al., 1992).
1.1.6.1.2.3 Neonatal infection
This varies in prevalence around the world, from 1 in 2500 live births in the United 
States to 1 in 13 000 births in Australia, reflecting the wide variation in HSV-2 
seropositivity in different regions and socioeconomic groups (Mindel et al., 2000). 
Most neonatal HSV infection occurs peripartum through an infected birth canal, 
although rarely it may occur in the postpartum period from direct contact or even 
from congenital infection. Although most cases (about 70%) are due to HSV-2, more 
cases of HSV-1-associated neonatal disease are being observed in the course of the 
current rise in HSV-1 genital infections. Primary maternal genital herpes in the last 
trimester, particularly around the time of labour, leads to infection in about a third of 
babies. Neonatal HSV may also follow symptomatic or asymptomatic recurrences; 
most babies with neonatal herpes are bom to mothers with asymptomatic viral 
shedding. The clinical picture ranges from disease localised to the skin, eyes and 
mouth to encephalitis and disseminated disease. Neonatal herpes may recur, 
necessitating long-term antiviral therapy (Brown et al., 1997).
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1.1.6.1.2.4 Other infections
HSV-1 keratitis may present with conjunctivitis or a unilateral dendritic (branching) 
ulcer. If recurrences are frequent and severe, they may involve deeper corneal layers, 
leading to interstitial or disciform keratitis and possible loss of vision. Adult herpes 
encephalitis is a severe focal encephalitis caused by direct viral invasion of the brain 
(usually by HSV-1), typically in the frontotemporal and parietal areas. It occurs in all 
age groups but is uncommon — about 1 in 106 population per year. 
Immunocompromised people are at risk of severe HSV infection, including 
progressive and extensive oral and genital herpes and disseminated herpes (Siegal et 
al, 1981; Whitley et al, 1989).
1.1.6.2 Varicella—zoster virus
1.1.6.2.1 Pathogenesis and epidemiology
VZV is acquired through the respiratory route. From the upper respiratory tract, it 
disseminates to lymph nodes and then via lymphocytes back to the skin, resulting in 
the rash of chickenpox. Most people in developed countries are infected with VZV in 
childhood, with 90% seropositive by adulthood. Chickenpox is usually a mild 
disease in healthy children, but more severe in adults. It is often itchy and heralded 
by posterior cervical lymphadenopathy and fever, after an incubation period of two 
weeks. The rash is centripetal, being concentrated on the body rather than the limbs, 
and the lesions evolve through papular, vesicular and crusting stages (Dwyer and 
Cunningham, 2002).
After primary infection, VZV becomes latent in dorsal root or cranial nerve ganglia. 
In 0.3% to 0.5% of the population, the virus reactivates causing herpes zoster
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(shingles). The dermatomes most affected are C-3, T-5, L-l and L-2 (Greenberg, 
1996). Prodromal neurological symptoms of herpes zoster relate to pain rather than 
the typical paraesthesiae observed in recurrent herpes simplex. The rash of zoster is 
often intensely pruritic and spreads throughout the course of affected nerve, evolving 
through papular, vesicular and crusting stages and usually presenting unilaterally. It 
lasts two to four weeks. The most troubling symptom is pain, which may be self­
limited or persist beyond the rash for up to a year ("postherpetic neuralgia"). Another 
relatively common complication is zoster ophthalmicus (2%—4%), which follows 
involvement of the first division (ophthalmic) of the trigeminal nerve. Infection 
ranges from keratitis to the more severe iritis. About 1% of immunocompromised 
people with herpes zoster develop severe complications involving the eye, brain or 
liver (Dworkin et al., 1997; Cohen et al., 1999). The oral lesions of primary infection 
are of minor significance compared to cutaneous manifestations. Oral lesions of 
zoster are pathognomonic and characterized by a prodrome, followed by a unilateral 
vesicular eruption that soon ulcerates. Though oral complications are rare, 
postherpetic neuralgia, tooth exfoliation and mandibular necrosis have been reported 
(Manz et al., 1986).
1.1.6.3 Epstein-Barr virus
1.1.6.3.1 Pathogenesis and epidemiology
The discovery of EBV was reported in 1964 by Epstein and co-workers (Epstein et 
al., 1964). More than 90% of adults worldwide are infected with EBV and carry the 
virus as a life-long persistent infection, with latent infection of B lymphocytes. The 
virus is spread by infected saliva and occasionally by blood transfusion. However, 
there are some reports of EBV detection in genital secretions, suggesting the
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possibility of sexual transmission. Transmission from a transplanted organ can also 
occur with subsequent infection of a previously seronegative recipient (Macsween 
and Crawford, 2003).
It is now known that there are two types of EBV (1 and 2, or A and B) circulating in 
the community, which show variation in DNA sequence of the latent genes. They 
show no specific disease association. Type 1 is more prevalent in the West, whereas 
types 1 and 2 are equally prevalent in Africa.
Primary infection in childhood is often subclinical or mild, whereas in adolescents or 
young adults primary EBV infection causes infectious mononucleosis (IM), also 
known as kissing disease because of its association with saliva exchange. IM is 
typified by fever, pharyngitis, lymphadenopathy and splenomegaly. Rashes, 
including macular erythema, petechiae and urticaria may occur, and concurrent 
administration of ampicillin results in a rash (Cohen, 2000).
EBV has been implicated in a wide variety of other diseases such as Burkitt's 
lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma 
and T-cell lymphomas (Cohen, 2000; Macsween and Crawford, 2003). An important 
oral lesion caused by EBV is hairy leukoplakia, which occurs in HIV-infected 
individuals as well as in some immunocompromised patients. It is present as a white 
corregated lesion involving the lateral borders of the tongue, although involvement 
of other part of oral mucosa has also been described. It is characterised by 
hyperkeratosis, acanthosis, koilocytosis and lack of an inflammatory response. EBV
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DNA is abundantly present in the upper, keratinised epithelial cells of the lesions. 
(Triantos et al., 1997).
1.1.6.4 Cytomegalovirus
This will be discussed at length in a separate section, Section 1.3.
1.1.6.5 Human herpes virus-6
The discovery of HHV-6 was first reported in 1986 (Salahuddin et al., 1986). It is 
tropic mainly for CD4+ T cells; however, replication can also occur in CD8+ cells, 
macrophages, and epithelial cells. CD46 has recently been identified to be a cellular 
receptor for HHV-6 (De Araujo et al., 2002). The virus is ubiquitous in the 
population, with greater than 90% seropositivity in adults, and has a worldwide 
distribution. Infection with HHV-6, transmitted by saliva, usually occurs during the 
first 2 years of life (Stoeckle, 2000). Immunocompromised patients, especially those 
who have undergone solid transplant, are at greater risk of HHV-6 disease (Emery,
2001). Two distinct variants of HHV-6 have been characterized, designated A and B. 
The virus is the cause of exanthema subitum which is a common self-limiting febrile 
disease of infants. It is may also lead to mononucleosis, pneumonia, meningitis and 
encephalitis. There is also evidence suggesting that HHV-6 is a cofactor in HIV 
infection in its speeding of the progress of immunosuppression (De Araujo et al.,
2002).
1.1.6.6 Human herpes virus-7
The isolation of HHV-7 was first reported in 1990 (Frenkel et al., 1990) from CD4+ 
cells of healthy adults. DNA analyses have shown that HHV-7 is related closely to
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HHV-6. HHV-7 shares with HHV-6 similar cell tropisms, disease associations and 
antigenic epitopes. Infectious HHV-7 has been isolated from the saliva of as many as 
90% of healthy individuals in different parts of the world, and saliva is also the most 
likely vehicle of transmission. Primary infection usually occurs during childhood but 
later than that caused by HHV-6, usually in children of 2 y, with prevalence greater 
than 90% by the ages of 6 to 10 y. There is no clear association between HHV-7 and 
a specific clinical disorder, although it has been associated with febrile illness in 
children, exanthema subitum and pityriasis rosea (De Araujo et al., 2002).
1.1.6.7. Human herpes virus-8
The virus will be discussed in a separate section below.
1.2 Human herpes virus 8
Kaposi’s sarcoma (KS) is a vascular tumour that was brought to the attention of the 
medical community over a century ago in 1872 by the report of purple-coloured 
nodular skin lesions in five elderly men by Moritz Kaposi. Four epidemiological 
forms of KS based on clinical and epidemiological differences are now recognised: 
classic KS, endemic-HIV-negative KS found in Africa, iatrogenic KS, and HIV- 
associated or epidemic KS. In 1994 Chang and co-workers reported the identification 
of fragments of herpesvirus-like DNA in AIDS-KS biopsy samples. HHV-8 is now 
accepted as the etiological agent for all the various forms of KS (Chang et al, 1994).
1.2.1 Epidemiological forms of KS
Figure 1.2 illustrates clinical aspects of the 4 forms of KS. Classic KS was the form 
described by Kaposi. It occurs predominantly in elderly patients of Mediterranean,
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F igure  1.2 Different forms o f  KS. Upper left: classic KS; brownish, livid, confluent plaques 
and papules on the forefoot and toes. Lower left: immunosuppression KS; multiple livid 
papules and nodules on the dorsum o f  the foot; note the swollen ankle. Upper right: AIDS- 
KS; red-purple macules and papules on the medial aspect o f  the sole and foot. Lower right: 
endemic African KS; multiple confluent nodules and plaques on the thigh with prominent 
oedema o f  the lower thigh and ankle; some tumours are ulcerated (Reproduced from Hengge 
et al., 2002a)
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East European, Arabic or Jewish ancestry (Franceschi and Geddes, 1995; Antman 
and Chang, 2000). The incidence peaks after the 6th decade of life (DiGiovanna and 
Safai, 1981). It affects the extremities, is generally indolent and is more common in 
men than women (sex ratio estimated to be from 3:1 to 10:1) (Franceschi and 
Geddes, 1995). Classic KS runs a chronic course and rarely metastasises. Patients 
survive an average of 10-15 y before dying of unrelated causes. Complications 
include lymphoedema, hyperkeratosis and other neoplasms such as non-Hodgkin’s 
lymphoma and cutanous malignant melanoma (Iscovich et al., 1999).
KS was already present in equatorial Africa for many decades preceding the HIV 
epidemic (Oettle, 1962): a 1971 report, e.g., showed that KS accounted for 3% to 9% 
of all reported cancers in Uganda (Taylor et al., 1971). A study published in 1993 
showed that KS in HIV-negative and HIV-positive patients accounted for 
approximately 50% of all tumours diagnosed in men in some countries in central 
Africa (Wabinga et al., 1993). African or endemic KS is usually more aggressive 
than the classic form of KS (D'Oliveira and Torres, 1972). It presents as benign 
nodular cutaneous disease predominantly in young adults (mean age 35 y) or as a 
florid mucocutaneous oral visceral disease. In young children, it can be aggressive, 
with localised cutaneous disease progressing to invade adjacent soft tissues and 
bones or rapidly disseminating to lymph nodes and visceral organs, usually in the 
absence of cutaneous lesions. In the absence of HIV infection an underlying 
immunodeficiency is generally not found (Kestens et al., 1985).
The third form of KS has been described in iatrogenically immunosuppressed organ 
transplant recipients and in wide spectrum of patients receiving chronic
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immunosuppressive therapy (Qunibi et al, 1988; Farge, 1993; Szende et al, 1997). 
It occurs more frequently in some ethnic groups in whom endemic or classic KS 
occurs (Qunibi et al, 1988; Franceschi and Serraino, 1995). This variant of KS may 
also be aggressive, involving lymph nodes, the mucosa and the viscera but remission 
can occur spontaneously after discontinuation of immunosuppressive therapy 
(Brooks, 1986).
AIDS-KS or the epidemic is the fourth variant of KS. It was observed about 20 y ago 
in western homosexual men with AIDS, and was the most common neoplasm 
occurring in patients with AIDS before highly active anti-retroviral therapy 
(HAART) became available (Beral et al, 1990; Rabkin et al, 1995). The overall risk 
of KS in AIDS patients is estimated to be more than 20 000 times greater than that of 
the general population and 300 times that of other immunosupressed patients (Beral 
et al, 1990). Striking differences in risks of acquiring AIDS-KS were observed 
between different HIV transmission groups, with the risk in homosexual men being 
more than men with haemophilia and the risk in women acquiring HIV from 
bisexual men being higher than heterosexual intravenous drug users (Haverkos and 
Drotman, 1985; Beral et al, 1990). This variant is typically lymphoadenopathic and 
tends to involve the viscera and mucosa as well as the skin (Figure 1.3). It is 
commonly multifocal and symmetrical at presentation. Before HAART became 
available oral KS was among the first clinical manifestations of AIDS (Silverman S 
Jr et al, 1986). The KS lesion may appear as a red-purple macule, an ulcer, or as a 
nodule or mass. Intraoral KS occurs on the heavily keratinized mucosa, the palate 
being the site of predilection in more than 90% of reported cases; other affected sites 
include the gingiva, tongue and the buccal mucosa (Silverman et al, 1986).
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F igure 1.3 Manifestations o f  AIDS-KS. Upper left: multiple livid, irregular papules and 
plaques. Note the prominent periorbital and perinasal oedema. Upper right: disseminated 
purple-black nodules and tumours on the chest in Christmas tree-like distribution along the 
lines o f Blaschko. Lower left: mucous membrane involvement with reddish tumours and 
livid plaques on the upper gum. Lower right: violaceous well demarcated plaque with 
prominent borders on the tip o f  the glans penis (Reproduced from Hengge et al, 2002a).
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1.2.2 Histogenesis of KS
The 4 clinico-epidemiological forms of KS have indistinguishable histological 
features. KS is a complex multifocal vascular lesion at the early stage, “the patch 
stage”; the histological picture is that of endothelial-lined spaces surrounding normal 
blood vessels; there is often a variable degree of inflammatory infiltrate. The 
“plaque” stage is characterised by an increased growth of spindle-shaped vascular 
processes in the dermis, along with the formation of slit-like vascular spaces filled 
with erythrocytes. In the late, “nodular” stage, the lesion is comprised primarily of 
spindle shaped cells arranged in large sheets, some of which are undergoing mitosis, 
with slit-like vascular spaces and haemosiderin pigmentation (Cockerell, 1991). 
Figure 1.4 shows a schematic diagram of the histogensis of KS and its surrounded 
microenvironment.
The spindle cells are thought to be the tumour cells that form the bulk of established 
KS but their histogenesis is unknown. The majority express lymphatic endothelial 
cell markers, including CD31 and CD34 markers. However, some express markers 
for smooth muscle cells, macrophages and dendritic cells (Nickoloff and Griffiths, 
1989; Sturzl et al, 1992) suggesting that spindle cells represent a heterogeneous 
population of cells, or cells that arise from a pluripotent mesenchymal precursor cell. 
All KS spindle cells express vascular endothelial growth factor receptor VEGFR-3, 
which is usually expressed only by lymphatic endothelium and by neoangiogenic 
vessels, but not by mature vascular endothelial cells, indicating that KS spindle cells 
may be of the endothelial lineage that can differentiate into lymphatic cells (Dupin et 
al., 1999).
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F igure  1.4 Schematic o f  KS pathogenesis. Some HHV 8-infected endothelial cells together 
with HIV -infected monocytes and lymphocytes (marked with a "+") will eventually lead to 
development o f atypical endothelial cells that may be transformed when exposed to a 
particular microenvironment resulting in a polyclonal cell population with spindle-shaped 
morphology. These spindle cells bearing a number o f growth factor receptors will contribute 
to the formation o f  slit-like vessels with a discontinuous endothelial lining. During the 
course o f  the disease a few (or a single) predominant clones may grow out leading to an 
oligo or mono-clonal cell population in advanced KS stages (Reproduced from Hengge et 
al, 2002b)
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KS, like most tumours, produces and responds to cytokines. Spindle cells or 
infiltrating CD8+ lymphocytes and macrophages express high levels of interleukin 6 
(IL-6), basic fibroblast growth factor (bFGF), gamma interferon, and a variety of 
other cytokines (Ensoli et al, 1989; Miles et al., 1990; Sirianni et al., 1998; Fiorelli 
et al., 1998; Dupin et al., 1999).
AIDS-KS cell lines have been shown to secrete large amounts of biologically active 
IL-6, which can promote spindle cell proliferation (Miles et al., 1990; Dupin et al.,
1999). Gamma-interferon can promote the formation of KS spindle cells with an 
angiogenic phenotype and transform endothelial cells to resemble spindle cells.
bFGF is an angiogenic factor, highly expressed in early lesions that promotes spindle 
cell growth (Fiorelli et al, 1998). Gamma-interferon can induce KS-like tumour 
formation in nude mice and these tumours in turn produce bFGF (Ensoli et al., 
1989).
HIV-1-associated KS exhibits a more aggressive clinical course than the other types 
of KS. Therefore, it has been proposed that HIV-1 gene products may positively 
influence KS development (Ensoli et al, 1994). The tat gene in HIV-1 codes for an 
early trans-activator protein (Tat) essential for HIV-1 viral replication (Fisher et al, 
1986). It is released into the extracellular fluid during acute HIV infection, can 
promote spindle cell growth in vitro (Ensoli et al, 1993) and induces an angiogenic 
phenotype in nude mice (Vogel et al, 1988). Normal endothelial cells display a 
spindle cell-like morphology when exposed to Tat in the presence of other cytokines 
(e.g. IL-1, tumor necrosis factor, and gamma interferon) in culture. Indeed, it has
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been proposed that these cytokines, whose production is up-regulated in persons with 
HIV-1 infection, work synergistically with Tat in KS development (Barillari et al, 
1992). Recent studies have indicated that Tat may influence the specific tissue 
distribution of KS (nose, oral and genital mucosa) observed in HIV-associated KS 
(Prakash et al, 2000).
1.2.3 The discovery of HHV-8
A viral aetiology for KS was suspected long before the onset of the AIDS epidemic 
(Oettle, 1962). During the 1970s herpesvirus-like particles were found by electron 
microscopy in tumour cells which were thought to be CMV (Giraldo et al., 1972). 
Subsequent studies identified, in lesional tissues, the DNA of CMV, HHV-6, human 
papilloma viruses (HPVs) and other viral or bacterial pathogens, all put forward as 
candidate aetiological agents. However, a minority of KS lesions was found to carry 
DNA of the implicated viruses (Huang et al., 1992; Kempf et al., 1995; Monini et 
al, 1996b).
Although no etiologic agent was identifiable, epidemiologic studies in the late 1980s 
suggested that a sexually transmitted agent was the cause of KS and was being 
transmitted independently of HIV. The suspected agent was presumed to be more 
efficiently transmitted through homosexual than heterosexual contact, resulting in a 
much higher incidence rate among gay male AIDS patients than other AIDS risk 
groups. The agent was also likely to be poorly transmissible through blood products 
since KS prevalence rates among HIV-infected transfusion recipients and 
haemophiliacs were relatively low (Beral et al, 1990; Beral, 1991; Beral et al, 
1992).
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Given that there may be a separate KS agent, it was reasoned that the genomic 
difference between proposed infected (KS) and uninfected (skin) tissues from an 
individual patient with AIDS-KS should be that of the infectious agent. A subtractive 
hybridization technique, representational difference analysis (RDA), based on 
polymerase chain reaction (PCR) (Lisitsyn et al., 1993) enrichment of unique DNA 
fragments was employed by Chang and colleagues (Chang et al., 1994). With the use 
of genomic DNA from an AIDS-KS lesion that was compared to unaffected DNA 
from the patient, two unique DNA fragments were isolated. These two DNA 
fragments (KS330Bam and KS631Bam), which showed high homology to known 
herpesvirus sequences, were used as Southern hybridization probes and for the 
generation of PCR primers. Both segments were homologous to two members of the 
y-herpesvirus sub-family. KS330Bam was 51% homologous to opening reading 
frame (ORF) 26 of Herpesvirus saimiri (HSV) and 39% homologous to ORF 
BDLF1 of EBV. KS631 Bam was homologous to a tegument protein coded by ORF 
75 of HSV and ORF BNRF1 of EBV. The unique sequences were found in 90% of 
KS lesions from AIDS patients. Subsequent studies showed evidence that the vast 
majority of KS lesions from patients with AIDS and from other groups at risk of KS 
carry DNA of this novel virus (Ambroziak et al., 1995; Boshoff et al., 1995; 
Schalling et al., 1995; Chang and Moore, 1996).
1.2.4 Establishing the causal role of HHV-8 in KS
Four observations linked HHV-8 causally to the aetiopathogenesis of KS:
i) HHV-8 DNA is present, by PCR in all epidemiological forms of KS, in all fresh 
biopsies tested and in the vast majority of paraffin-embedded material (Ambroziak et 
al., 1995; Boshoff et al., 1995; Schalling et al., 1995; Moore and Chang, 1995;
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Chang and Moore, 1996). The virus is found in HIV-positive and HIV-negative 
patients with KS (Ambroziak et al, 1995). To strengthen the molecular 
epidemiological association between HHV-8 and KS further, it was demonstrated by 
PCR in situ hybridization, RNA in situ hybridization and immunohistochemistry that 
HHV-8 is present in spindle cells in nearly all KS lesions (Boshoff et al., 1995; Li et 
al, 1996; Staskus et al., 1997; Rainbow et al, 1997; Davis et al, 1997; Sturzl et al, 
1997; Dupin et al, 1999; Kellam et al, 1999).
ii) HHV-8 sequence may be detected by PCR in the peripheral blood of HIV-positive 
individuals before the onset of KS lesions (Whitby et al, 1995; Lefrere et al, 1996; 
Moore et al, 1996c), indicating that those at risk of KS have a higher viral load than 
those not at risk.
iii) Seroprevalence studies indicated that in general populations at risk of developing 
KS, there was a higher prevalence of HHV-8 infection (to be discussed in more 
detail later). The incidence of developing KS correlated with the prevalence of 
HHV-8 infection in a given population.
iv) Like most other human herpes viruses, HHV-8 may be in a latent stage of 
infection early in the course of the clinical disease (Reitz et al, 1999), infecting a 
small proportion of spindle cells, but, as KS advances, HHV-8 can be detected in 
nearly all tumour spindle cells (Dupin et al, 1999; Sturzl et al, 1999).
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1.2.5 Other diseases associated with HHV-8
1.2.5.1 Primary effusion lymphoma
Primary effusion lymphomas (PELs), also known as body cavity-based lymphomas, 
are a type of high grade non-Hodgkin’s lymphoma that develop nearly exclusively in 
the pericardial, peritoneal and pleural cavities as lymphomatous effusion, usually in 
the absence of any identifiable tumour mass. Most cases occur in HIV-infected 
individuals (Cesarman and Knowles, 1997), but a small number of patients with PEL 
who are HIV-seronegative have been identified (Klepfish et al, 2001). Cesarman 
and co-workers reported that HHV-8 was specifically associated with PEL, and they 
noted that PEL contains high viral copies when grown in vivo, rendering them useful 
for the characterisation of individual strains of the virus (Cesarman et al, 1995). 
Most tumour cells are immunoblast-like cells, but some large anaplastic lymphocytes 
multilobulated nuclei may also be present (Cannon and Cesarman, 2000). 
Phenotyping may be difficult because the cells characteristically lack the lineage- 
restricted markers of both T and B lymphocytes. Clonal immunoglobulin gene 
rearrangement found in all cases studied has firmly established PEL as a B-cell 
neoplasm (Cesarman and Knowles, 1999). Co-infection of PEL cells by both EBV 
and HHV-8 has been observed, but association with HHV-8 alone has also been 
reported. Notably, most of PEL in HIV-seropositive patients are EBV-positive. (Said 
et al, 1996; Cesarman et al, 1996). PEL lacks rearrangements of the c-myc gene, 
which in the presence of EBV may play a role in development of Burkitt’s 
lymphoma. Thus it is possible that HHV-8 acts in conjunction with EBV to induce 
full transformation (Miller, 1990; Cesarman et al, 1995). Thus far, no effective 
therapy has been established for HIV-associated PEL. Consequently, the prognosis is
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poor, and the reported median survival is about 18 weeks. Of interest are reports of 
clinical improvement after HAART (Oksenhendler et al, 1998).
1.2.5.2 Multicentric Castleman’s disease
Castleman’s disease (angiofollicular lymphoid hyperplasia or giant lymph node 
hyperplasia) is a rare, nonmalignant, usually polyclonal form of lymphadenopathy 
(Frizzera, 1992). Castleman’s disease is classified histologically into the hyaline- 
vascular type and the plasma cell type. Clinically, it may be classified into two 
forms: (i) localized Castleman’s disease, which is usually of hyaline-vascular 
histologic type, is located in the mediastinum in 70% of affected patients, and can 
usually be cured by surgical excision; or (ii) a systemic variant, multicentric 
Castleman disease (MCD), usually of plasma cell type (Frizzera, 1992). MCD adopts 
an aggressive, often fatal clinical course and usually presents with multifocal 
lymphadenopathy and a variety of systemic symptoms, such as fever, rash, 
cytopenia, and hypergammaglobulinemia. This disease is common among AIDS 
patients: HHV-8 DNA sequences could be found in all HIV-related cases of MCD in 
contrast to less than half in HIV-seronegative cases. (Soulier et al., 1995). Moreover, 
HHV-8 viral load in the peripheral blood of MCD patients tends to correlate with the 
increased severity of symptoms, worse prognosis (Grandadam et al., 1997) and 
exacerbations (Oksenhendler et al, 2000). The clinical course of HHV-8-positive 
MCD tends to be worse, particularly among HIV-seropositive individuals, and is not 
always improved by therapy with HAART (Zietz et al, 1999; Dupin et al, 2000). 
HHV-8 DNA has been localised in plasmablasts of B cell lineage in the mantle zone 
of the B-cell follicles (Kellam et al, 1999; Katano et al, 2000). The role of HHV-8 
pathogenesis in MCD is not clear. However, viral IL-6 (vIL-6) is highly expressed in
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a subset of plasmablasts (Dupin et al., 1999) and may drive HHV-8-infected naive B 
cells to become plasmablasts and to develop various lymphoproliferative lesions. In 
addition, patients with MCD may develop other HHV-8-associated diseases: PEL 
(Ascoli et al., 2001), KS (Soulier et al, 1995), or both (Codish et al., 2000).
1.2.5.3 Other disorders
HHV-8 infection has been proposed as an aetiological agent in a number of diseases 
including multiple myeloma (Rettig et al., 1997), some reactive lymphadenopathies 
(Luppi et al., 1996), pemphigus vulgaris (Memar et al., 1997), a variety of skin 
carcinomas and lymphomas, and sarcoidosis (Di Alberti et al., 1997). Despite these 
associations, no conclusive evidence has been found to strongly link any of these 
diseases to infection with HHV-8.
1.2.6 HHV-8 taxonomy
Shortly following the discovery of HHV-8, the entire HHV-8 genome of 165 
kilobases was reported (Russo et al, 1996; Moore et al, 1996b). The virus was 
assigned the trivial name, Kaposi’s sarcoma-associated herpesvirus and the proper 
name, human herpesvirus-8, now used interchangeably in the literature. The y- 
herpesviruses are known to infect lymphocytes (Roizmann et al., 1992) and are often 
implicated in the development of lymphomas (Neipel et al., 1998). The y-herpesvirus 
subfamily is further divided into two genera, rhadinovirus (y-2) and 
lymphocryptovirus (y-1). EBV is a y-1 herpesvirus and is the prototypic member of 
this group.
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When HHV-8 was discovered, it was thought to be very closely to herpes virus 
saimiri (HVS) of New World monkeys, the prototype y-2 related herpes viruses 
{rhadinovirus) that infects squirrel monkeys (Albrecht et al., 1992). However, it has 
recently become apparent that rhadinoviruses are more closely related to HHV-8 of 
Old World monkeys, including several macaque species and African green monkeys 
(Rose et al., 1997; Greensill et al., 2000). Extensive studies have been done to find 
evidence of herpesvirus infection in primates and as a result, many species of Old 
World primates are being revealed to be infected with y-2 herpesviruses. Old World 
primate rhadinoviruses can be divided into two distinct lineages: RV1 and RV2. 
HHV-8 belongs to the RV1 lineage, and is closely associated phylogenetically to 
primate rhadinoviruses. Other viruses belonging to RV1 are retroperitoneal 
fibromatosis herpesvirus (RFHVMm) from rhesus macaque (Macaca mulatto), 
RFHVMn from pig-tailed macaque {Macaca nemestrina) (Rose et al., 1997); 
ChRVl from the African green monkey (Chlorocebus aethio) (Greensill et al.,
2000), pan rhadino-herpesviruses (PanRHVla and b) from the chimpanzee {Pan 
troglodytes) and GorRHVl from the gorilla {Gorilla gorilla) (Lacoste et al., 2001). 
RV2 viruses include rhesus rhadinovirus (RRV) from the rhesus macaque {Macaca 
mulatto) (Searles et al., 1999), MneRV2 from the pig-tailed macaque {Macaca 
nemestrina) (Schulz, 2000), ChRV2 from the African green monkey (Chlorocebus 
aethiops) (Greensill et al, 2000), and MndRHV2 from the mandrill/drill {Mandrillus 
sphinx Mandrillus leucophaeus) (Lacoste et al., 2000). The presence of RV1- and 
RV2-type rhadinoviruses in many Old World primates points to possibly yet 
undiscovered rhadinoviruses of the RV2 lineage capable of infecting humans 
(Lacoste et al., 2001).
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1.2.6.1 The HHV-8 genome
Complete genome sequences of two HHV-8 isolates have now been determined, one 
from a PEL cell line (Russo et al, 1996) and the other from a KS specimen (Neipel 
et al, 1997), both revealing the characteristic co-linear genomic organization of the 
rhadinoviruses (Figure 1.5). HHV-8 genome is 140.5 kb in length and is of low GC 
content (53.5%). It comprises a segment called L-DNA or long unique region (LUR) 
that is flanked by numerous 801-base pair terminal repeat (TR) regions of high GC 
content (84.5%) called H-DNA. The L DNA region of HHV-8 genome has at least 
81 ORFs and five internal repeat regions (Russo et al, 1996; Neipel et al, 1997). 
HHV-8 ORFs are named according to their homology with HVS ORFs. Unique 
regions are numbered consecutively and given K as a prefix (i.e. K1 to K15) with 
newly discovered unique ORFs designated by the addition of a decimal point (i.e. 
K4.1) (Russo e ta l, 1996; Schulz, 1998).
As with other y-herpesviruses, essential ORFs that code for viral replication and 
assembly proteins are arranged in blocks and are referred to as the conserved genes. 
There are approximately 67 such genes conserved among members of herpesvirus 
subfamilies. In HHV-8, these include: ORF 25, coding for the major structural 
protein; ORF 9, for DNA polymerase; and ORF 17, for a proteinase and assembly 
protein (Moore et al, 1996b). Non-conserved gene blocks in the HHV-8 genome lie 
between the conserved blocks and contain some ORFs that are found in other 
rhadinoviruses including homologues to mammalian proteins. A characteristic of 
HHV-8 and other y-herpesvirus is the similarity of a large number of the ORFs to 
known cellular genes, suggesting that some of these genes may have been pirated 
from the host chromosomes during the process of virus/host co-evolution.
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Figure 1.5 The HHV-8 genome. The genome consists o f a long unique region (140.5 kb) encoding for over 80 
open reading frames (ORFs), surrounded by terminal repeat regions (TRs) consisting o f 801 base pair direct 
repeat units with a high G+C content. The ORFs are named after the corresponding genes in herpesvirus saimiri, 
and genes without significant homology are given the designation ‘K’. Three large regions (I, II and III) contain 
genes conserved among the Rhadinoviruses, whereas the regions between them contain unique genes. Many o f  
these unique genes encode homologues for host cellular proteins (shown in red with dotted outlines; genes 
without known homologues are shown in yellow with dotted outlines). Genes that are potentially important in the 
pathogenesis o f KS are labelled.
Abbreviations: CCP, complement control protein; v-cyc, viral D-type cyclin; vFLIP, viral FLICE inhibitory 
protein; vGPCR, viral G-protein-coupled receptor; vIL-6, viral interleukin 6; vIRF, viral interferon regulatory 
factor; kb, kilobase; LANA, latency-associated nuclear antigen; vMIP, viral macrophage inflammatory protein 
(Reproduced from Neipel et al. 1999).
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Some of these genes are involved in down-modulating the immune response, 
evading cellular systems important for targeting infected cells, nucleotide 
biosynthesis and for cell growth and differentiation. They include the vBcl-2, vIL- 
8R, and vMIP-IK, vIL-6, and the D type viral cyclin, whose functions are usually 
similar to that of their cellular homologues (Russo et al., 1996; Neipel et al., 1998).
1.2.6.2. HHV-8 genotyping
The HHV-8 genome is well conserved, with most coding regions in isolates obtained 
from PEL cell lines or in sub-genomes characterised from KS biopsies showing only 
0.1% nucleotide variation between the sequences at central genomic region (Russo et 
al., 1996; Neipel et al., 1997). Initial studies conducted on the genetic variability and 
polymorphism of HHV-8 focused on two small gene fragments of the ORF 26 
(minor capsid gene) and ORF 75 (tegument region) from KS specimens. They 
showed the existence of three groups (A, B and C), with a very low overall 
nucleotide variability up to 2%, but less than 0.1% within each group (Zong et al, 
1997; Kasolo et al., 1998; Fouchard et al., 2000). Type A was predominant in areas 
associated with classical KS, whereas the B and C strains were more prevalent in 
Africa. All the three strains were represented among American AIDS patients but the 
A type predominated (Zong et al., 1997; Luppi et al., 1997).
The left end of the genome where ORF K1 is located has a hot spot of genetic 
variability. ORF K1 encodes a transmembrane protein with structural similarity to 
the immunoglobulin receptor family of proteins and is expressed in the early lytic 
phase after induction by TPA in PEL cell lines (Lagunoff and Ganem, 1997; Lee et 
al., 1998). The transforming potential of the ORF K1 protein in vivo was reported by
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Lee et a l (1998). While it has no homologues in other herpesviruses, there is an 
equivalent position in the HVS genome from which transforming proteins are 
encoded (Lee et al., 1998).
The K1 encodes 289 amino acids. The predicted protein comprises a single peptide 
in the N-terminal region (amino acids 1-19), a predicted hydrophobic transmembrane 
domain in the C-terminal region, a small intracellular domain (amino acids 227-276), 
and a highly variable extracellular domain in the central region (amino acids 20- 
226). In the central region, the position between amino acids 51 -92 (variable region 
1 or VR1) and between amino acids 191-231 (VR2) are the most heterogenous. 
Certain segments within and connecting these two blocks are conserved presumably 
to maintain the tertiary structure of the protein (Meng et al., 1999).
Meng et al. (1999) reported a K1 sequence-based system for HHV-8 strain 
differentiation and genotyping and have shown that HHV-8 falls into at least four 
distinguishable genotypes (I-IV). Genotype I may be further divided into four 
subtypes, A-F. Among 63 distinct ORF K1 proteins, Zong et al. (1999) also 
identified four main genotypes, A-D, which differed from each other by between 
15% and 30% of their amino acids; they further observed 13 clades or subtypes 
based on amino acid differences of 5% or greater (i.e. A1...A5, Cl etc). A more 
recent comprehensive study of 139 samples, from which at least VR1 sequence data 
were available, has yielded 22 defined ORF K1 subtypes (Zong et al, 2002).
The B subtype is almost exclusively associated with patients in or from sub-Saharan 
Africa and the D subtype has been found only in patients of Pacific Island heritage,
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whereas the A and C subtypes are distributed throughout the USA, Europe, Asia and 
the Middle East (Zong et al, 1999; Zong et al., 2002). Subtype E is hyperendemic in 
Amerindians in Brazil (Biggar et al., 2000) and Ecuador (Whitby et al., 2004). In 
addition, a novel subtype has been identified only in South Africa, classified as 
subtype N (Alagiozoglou et al., 2000). B subtype sequences are divergent in ORF 
K1 but show little phylogenetic clustering, thus allowing only three further 
subgroups to be distinguished (Bl, B2 and B3) based on 4 amino acid changes in the 
VR2 regions (Zong et al., 2002) and a deletion in the B3 variant (Treumicht et al.,
2002). AIDS KS patients in the US are normally infected with subtypes A l, A4 and 
C3. The predominance of these few subtypes indicate reactivation of endogenous 
HHV-8 variants associated with the AIDS epidemic in USA and may have been 
introduced by immigrants from endemic Europe, the Middle East, and Africa, as 
well as horizontal transmission events occurring locally (Zong et al., 1999; Zong et 
al., 2002).
The wide geographical and ethnic distribution of ORF K1 subtypes suggests that the 
major subgroups originated in paleolithic times through isolation and founder 
effects, associated with the expansionary migrations of anatomically modem humans 
first into sub-Saharan Africa starting 100,000 years ago (B subgroup), then into 
South Asia, Australia and the Pacific beginning 60000 years ago (D subgroup), and, 
finally, as two major branches into Europe and North Asia (both via the Middle East) 
about 35,000 years ago (A and C subgroups). These patterns also imply that (outside 
of the AIDS epidemic) the vims is primarily transmitted familially (e.g., parent to 
child and between siblings) and that recombination events associated with multiple 
infection are relatively rare (Zong et al., 1999; Hayward, 1999).
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At least two major variants of HHV-8 can be distinguished using the K15 gene 
between the ORF75 and the terminal repeat, situated at the right-end of the genome. 
The two variants, named P (predominant or prototype) and M (minor) alleles, show 
only 30% amino acid sequence identity (Poole et al., 1999). Each allele comprises 
eight exons specifying a protein with 12 membrane-spanning domains and a C- 
terminal cytoplasmic domain. This structure resembles latent membrane protein 2 
(LMP2) of EBV, except that LMP2 possesses an N-terminal, rather than a C- 
terminal, cytoplasmic domain (Sample et al., 1989). The K15 proteins possibly play a 
role in signal transduction (Hayward, 1999). The P allele is the more frequent among 
HHV-8 genomes characterized, and has been found in association with all five K1 
subtypes (Poole et al., 1999). The rarer M allele has thus far been found in 
association with the A, B and C subtypes (Poole et al., 1999).
Other loci across the genome have been investigated to determine whether the 
clustering patterns as suggested by ORF K1 sequencing can be confirmed. Data 
from three major loci, ORF 26, T0.7/K12 and ORF 75, confirm that a linkage exists 
across the genome with ORF K1 subtype patterns. In most instances, the four major 
ORF K1 subtypes can also be discriminated at these loci (Poole et al., 1999). 
Nevertheless, in 20-30% of genomes studied, there is some evidence of 
recombination between internal loci. At the right end of the genome, the divergent 
ORF K15 M allele is thought to be the result of a recombination event with an 
exogenous primate virus, followed by recombination events, first with subtype C 
viruses of the P form and then with A and B types (Poole et al., 1999). Zong et al. 
(2002) demonstrated that 4 of 32 A subtype and 23 of 37 C subtype genomes studied 
presented M alleles at their K14.1 and K15 loci. In addition, only two cases of B
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subtype genomes have been found to carry M alleles, both of which were from 
patients in North America.
1.2.6.3 Gene expression
As with the other herpesviruses, HHV-8 exhibits both latent (nonproductive) and 
lytic (productive) replication, both of which are characterized by virtually distinct 
gene expression programs. HHV-8 establishes latency in the host (Gao et al., 1996a) 
and is under stringent latent replication control in PEL cell lines (Russo et al., 1996). 
While a minority of cells in culture may express lytic cycle proteins at any given 
time, chemical induction with tetradecanyl phorbol acetate (TPA) is needed for the 
full expression of lytic gene products in PEL cells in vitro. Three broad categories 
(classes) of gene expression have been described (Sarid et al., 1998), based on their 
expression outcomes after TP A induction: class I (which are constitutively expressed 
regardless of TPA treatment under standard growth condition); class II (which are 
expressed without TPA but are induced to higher transcription levels by TPA 
treatment and typically represents regulatory and viral DNA replicative genes, as 
well as the majority of the viral homologues of cellular genes); and class III (which 
are transcribed only following TPA treatment and encoded most of the viral 
structural and replication genes). Table 1.1 show latent, immediate early, early and 
late genes in HHV-8
1.2.6.3.1 Latent infection
HHV-8 becomes latent in the majority of cells it infects. During this stage of the 
virus life cycle the viral genome resides in the nucleus as closed circular episomal
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Latent genes K10.5, K11.5, K12, K13, ORF72,ORF73
Immediate early 
genes K3, ORF70, K4, K4.1, K4.2, ORF45, ORF50
Early genes ORF6, ORF7, ORF8, ORF9, ORFIO, ORF11, ORF16, ORF18 
ORF21, K5, K6, ORF31, ORF34, ORF35, ORF36, ORF37 
ORF38, ORF40, ORF41, ORF54, ORF56, ORF57, K9, K10 
ORF58, ORF59, ORF60, ORF61, ORF62
Late genes ORF4, K7, ORF 17, ORF 19, ORF20, ORF23, ORF24,ORF25 
ORF26,ORF28, ORF32, ORF33, ORF39, ORF43, ORF44, K8 
K8.1, ORF53, ORF64, ORF65, ORF66, ORF68, ORF69, ORF75
Table 1.1 Latent, immediate early, early and late genes of HHV-8.
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DNA expressing a small subset of viral genes. Potentially, this minimises the number 
of viral epitopes that are presented by infected cells to cytotoxic T lymphocytes 
(CTLs). It seems likely that the genes expressed during latency play a major role in 
the pathogenesis of HHV-8 (Renne et al, 1996a). These genes can be represented as 
transcripts of class I genes. The right hand cluster of three latent adjacent genes in 
genome are co-transcribed on two polycistronic mRNAs: latent transcript-1 (LT1) 
(transcribed by ORF71/ORF72/ORF73), and LT2 (by ORF 71/ORF72) (Dittmer et 
al, 1998; Talbot et al, 1999).
The major latent loci are as follows:
(i) ORF 71
ORF71 produces vFLIP, a homologue to cellular FLICE (FADD [Fas-associated 
death domain]-like interleukin-1 beta-converting enzyme) inhibitory proteins (FLIP), 
also called caspase-8. vFLIPs found in other herpesviruses are known to inhibit fas- 
mediated apoptosis by preventing the recruitment of caspase-8 (FLICE) to the death- 
induced signalling complex (Thome et al, 1997). vFLIP in HHV-8 has a similar 
function and can prevent apoptosis in latently infected cells (Djerbi et al, 1999). 
ORF71 utilises internal ribosome entry site (IRES)-mediated initiation to produce a 
functional protein and that ensures the protection of infected cell from CTL-induced 
cell killing throughout the cell cycle (Bieleski and Talbot, 2001).
(ii) ORF 72
The ORF 72-encoded vCyclin is the viral homolog to cellular cyclin, and is most 
closely related to cyclin D (Li et al, 1997). Cellular cyclin D binds with cyclin- 
dependent kinases (CDK) 4 and 6 (Radkov et al, 2000), and this complex
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phosphorylates retinoblastoma protein (pRb), releasing the transcription factor E2F. 
E2F, in turn, activates the transcription of S-phase genes, including cyclin E, which 
is needed for G l-S  phase transition. vCyclin, like cellular cyclins, is also able to 
phosphorylate pRb in vitro in complexes with CDKs. The vCyclin-CDK complexes 
are insensitive to CDK inhibitors (plb1^ 48, p21CIP1 and p27KIP1). Thus, exogenous 
expression of vCyclin from the infecting viral genome prevents CDK inhibitor- 
imposed G1 arrest, stimulates entry into S-phase, and substitutes for cyclinA/CDK2 
to initiate DNA replication (Swanton et al, 1997).
(iii) ORF 73
Latent nuclear antigen-1 (LANA-1) is expressed by ORF 73 and is detected in the 
majority of KS lesions as well as in cell lines derived from PELs. LANA-1 plays a 
role in HHV-8 maintenance by tethering the viral episome through the terminal 
repeat to host chromosome ensuring persistence in the daughter cells after successful 
rounds of cell division (Ballestas et al., 1999; Cotter and Robertson, 1999). This 
interaction creates the characteristic pattern of intra-nuclear dots observed in 
immunofluoresence assays. In normal uninfected cells, Gl/S progression is 
negatively regulated by binding of pRb to E2F transcription factor. In infected cells, 
LANA-1 competes with E2F for binding of pRb thus freeing E2F to activate the 
transcription of genes involved in cell cycle progression. LANA-1 also binds p53 
and blocks p53-mediated apoptosis (Friborg et al., 1999).
(iv) ORFs K10.5, K11.5 and K12
K10.5, K11.5 and K12 are considered as latent genes but can be induced by TPA 
during lytic replication of the virus, and are therefore classified as class II transcripts
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(Sand et al, 1998; Jenner et al., 2001). K10.5 expresses LANA-2 protein, which 
inhibits p53-induced transcription and apoptosis. LANA-2 is expressed latently only 
in cells and cell lines (i.e. PEL, PEL cell lines and MCD) of haematopoietic origin 
but not in KS tumours (Rivas et al., 2001).
The ORF Kl l . l  gene encoding vIRF-2 is latently expressed in PEL cell lines 
(Burysek et al, 1999). While IRFs have the ability to bind nucleotides, vIRF-2 can 
bind oligonucleotides corresponding to nuclear factor kappa B (Nf-kappaB) 
(Burysek and Pitha, 2001). NF-kappa B is a transcriptional regulatory factor that in 
turn up regulates the expression of a wide variety of inflammatory cytokines and 
adhesion molecules (Pati et al., 2001). vIRF-2 is constitutively expressed in the 
nucleus of PEL cells and inhibits the effects of cellular IFN through its interaction 
with a double stranded RNA activated protein kinase (PKR) (Burysek and Pitha, 
2001). PKR is normally induced by IFN and mediates the anti-viral and anti­
proliferative effects of IFN (Hovanessian, 1989; Sen and Ransohoff, 1993). By 
down-regulating the antiviral response caused by PKR, vIRF-2 may be important for 
maintenance of viral latency (Burysek and Pitha, 2001). Kaposin A encoded by ORF 
K12 has been shown to induce tumorigenic transformation and is expressed in the 
PEL cell lines BCBL-1 and KS-1 (Muralidhar et al., 2000).
1.2.6.3.2 Lytic infection
The majority of the HHV-8 genome remains silent during latent infection. The 
programme of gene expression during lytic replication was revealed by DNA array 
expression profiling of PEL cell lines without (Jenner et al, 2001) and with 
stimulation by TPA (Paulose-Murphy et al, 2001). The lytic genes mainly express
56
Chapter 1 Introductory Considerations
class II and class III transcripts (Sarid et al., 1998). The first group of genes 
expressed after the induction of lytic replication are typically regulators of gene 
expression, including the immediate early transactivators. Homologues of cellular 
genes involved in regulation or signal transduction are mostly expressed after the 
viral transactivators followed by the expression of sets of genes, involved in 
replication of the viral DNA including the DNA polymerase and its processivity 
factor. The structural genes and those involved in virus expression and maturation 
are expressed later, generally after 24 h post-induction (Jenner et al., 2001).
Class II transcripts major lytic genes that are transactivators and homologues of 
cellular genes are as follows:
(i) ORFs 50, K8 and 57
The first groups of genes expressed after the induction of lytic replication are 
typically regulators of gene expression including the immediate early transactivators 
ORF 50 (Rta or Lyta), K8 (Zta or Kb-ZIP) and ORF 57 (post-transcriptional 
regulator of gene expression) (Jenner et al., 2001). The ORF 50/Rta promoter region 
is heavily methylated. Demethylation of the promoter by TPA induces lytic cycle 
replication; demethylation of the Rta promoter region is essential for expression of 
Rta (Chen et al., 2001). Studies have identified an ORF50 similar to EBV immediate 
early transactivator, which functions as an immediate early transactivator of HHV-8 
lytic replication. It was demonstrated that its protein is capable of stimulating HHV- 
8 lytic genes through transcription cascades resulting in replication of the virus in 
vitro similar to the Zta and Rta proteins of EBV (Renne et al., 1996b).
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(ii) vMIPs
HHV-8 encodes three secreted chemokines (chemoattractant cytokines) that have 
unique properties. Viral macrophage inflammatory proteins (vMIP-I, vMIP-II and 
vMIP-III) are encoded by ORFs K4, K4.1 and K6, respectively, located at the left 
end of LUR (Moore et al., 1996a). The three chemokines have been shown to induce 
angiogenesis, suggesting their roles in the pathogenesis of KS. vMIP-I is a specific 
agonist of CCR8 (Dairaghi et al., 1999; Endres et al., 1999), vMIP-II of CCR3 
(Boshoff et al., 1997) and vMIP-III of CCR4 (Stine et al, 2000). All the three major 
receptors, CCR3, CCR4 and CCR8, are chemoattractant receptors for Th-2 
lymphocytes and their recruitment, and inhibit the Th-1 immune response thus 
potentially protecting HHV-8-infected cells (Stine et al., 2000). vMIP-II acts as an 
antagonist for co-receptors CCR3, CCR5 and CXCR3 which allow HIV-1 to infect 
host cell, and can block its entry (Feng et al., 1996; Deng et al., 1996; Boshoff et al., 
1997; Kledal et al., 1997).
(iii) vBcl-2
The vBcl-2 is encoded by ORF 16, and shares about 60% homology with human 
Bcl-2 family members such as Bcl-2 and Bax (Sarid et al., 1997). Bcl-2 is a potent 
cell death-suppresser that operates by inhibiting apoptosis (Reed, 1994). When over­
expressed in cell culture, vBcl-2 prevents apoptosis and prolongs cell life (Cheng et 
al., 1997). vBcl-2 different from Bcl-2 because it does not dimerise with other 
member like Bax and is not cleavable by caspases (Bellows et al., 2000). It interacts 
with and inhibits the proapoptotic function of cellular Bcl-2 family member. All 
these prolong cell survival to allow for production of viral progeny (Inohara et al., 
1998).
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(iv) vGPCR
ORF 74 of the HHV-8 genome encodes viral G-protein-coupled receptor (vGPCR) 
and is most related to the human interleukin 8 (IL-8) receptors (Arvanitakis et al,
1997). vGPCR expressed in NIH3T3 cells has been shown to induce tumour 
formation when injected into nude mice. Before the discovery of HHV-8, AIDS- 
associated KS was already known to express elevated levels of vascular endothelial 
growth factor (VEGF) that lead to angiogenesis, and it was found that vGPCR- 
transfected cells secrete elevated level of VEGF (Bais et al., 1998). HHV-8 GPCR 
activates NF-kappa B which in turn up-regulates the expression of a wide variety of 
inflammatory cytokines and adhesion molecules (Pati et al., 2001).
(v) Viral interferon regulatory factors (vIRFs)
In addition to the latently expressed vIRFs discussed above, HHV-8 encodes two 
other homologues of cellular interferon regulatory factors (IRFs) lytically: vIRF-1 
and vIRF-3. Interferons (IFN) are a group of cytokines with wide ranging effects 
including defence against viral infection and inhibition of cell growth. IRFs regulate 
the transcription of IFNs thereby modifying the effects brought about by IFN activity 
(Reis et al., 1992; Taniguchi et al, 1995).
The ORF K9-encoded vIRF-1 is homologous to cellular IRFs. It inhibits cellular 
responses to IFNs (Gao et al, 1997; Zimring et al, 1998), and can down-regulate the 
transcriptional activation induced by IFNs a, p, and y (Gao et al, 1997; Li et al,
1998). This activity suppresses the host’s IFN-mediated innate immune response to 
viruses. vIRF-1 also acts as an oncogenic protein by transforming rodent fibroblasts 
in vitro and causing tumour formation in nude mice (Gao et al, 1997; Li et al,
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1998). It has been demonstrated that vIRF-1 can bind to p53 (Nakamura et ah,
2001), a tumour suppressor gene involved in many types of human cancers 
(Vogelstein et ah, 2000). By suppressing phosphorylation and acetylation of p53, 
vIRF-1 inhibits its activity and prevents apoptosis in the infected cell (Nakamura et 
al, 2001).
The other lytic viral IRF, vIRF-3, has homology to the cellular IRF-4 and the latent 
vIRF-2 and also blocks IFN signalling by functioning as a dominant negative 
inhibitor of IRF-3 and IRF-7. Overexpression of vIRF-3 in mouse L929 cells inhibits 
virus mediated synthesis of biologically active interferons (Lubyova and Pitha, 
2000).
(vi) Viral interleukin 6 (vIL-6)
vIL-6, encoded by ORF K2, is approximately 24% homologous to human IL 6 (hlL- 
6) (Moore et ah, 1996c). vIL-6 is readily secreted by HHV-8-infected cells in PELs 
during latency and MCD and, to a lesser extent, in KS lesions (Moore et ah, 1996c; 
Parravicini et al., 2000). Similar to hIL-6, vIL-6 activates signal transduction 
pathways through its interaction with the gpl30 receptor, but unlike hIL-6, does not 
need to interact with the IL6 co-receptor (IL-6R) to activate signalling. However, 
interaction with both gpl30 and IL-6R may increase signalling efficiency (Wan et 
ah, 1999). Both hIL-6 and vIL-6 are able to inhibit apoptosis and induce B-cell 
proliferation (Moore et ah, 1996a). Mice inoculated with vIL-6-transfected NIH3T3 
cells develop more highly vascularised tumours than control mice and the tumours 
also express higher levels of VEGF (Aoki et ah, 1999). Although most cells in PEL 
or MCD do not secrete vIL-6, this cytokine has a paracrine effect on the surrounding
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tissue and could be important in HHV-8-related disease progression. For instance, in 
cases of HHV-8 infected MCD, vIL-6 appears to cause a proliferation of uninfected 
B cells that comprise the majority of the tumour mass (Parravicini et al, 2000).
Lytic genes encode as class III transcripts (Sarid et al., 1998). They include 
structural protein genes, such as the gene that encodes major capsid protein (ORF 
25), a gene encoding small capsomer-interacting protein (SCIP) (ORF 65), DNA 
polymerase (ORF9) and thymidine kinase (TK) (ORF 21). Their functions are 
probably to replace or enhance cellular DNA biosynthesis to aid in virion production 
(Russo et al., 1996; Neipel et al., 1997).
1.2.7 HHV-8 transmission
1.2.7.1 Sexual transmission
Transmission of HHV-8 is primarily sexual among homosexual men. Thus, in this 
population, AIDS KS can primarily be considered to be a sexually transmitted 
disease (Vieira et al., 1997; Martin et al., 1998; Melbye et al., 1998; Dukers et ah, 
2000). However, the specific mechanisms of transmission remain controversial. 
Some of the early studies on the relationship between KS and sexual practices report 
an association between oral-anal sex and AIDS KS (1993; Grulich and Kaldor, 1996; 
Vieira et al., 1997). Cross-sectional studies have demonstrated an association 
between the presence of HHV-8 antibodies and anal-genital sex, oral-anal sex, and 
deep kissing with an HIV-1-positive partner (Melbye et al.y 1998; Grulich et al, 
1999; Pauk et al, 2000). One study associated specific sexual techniques to 
serococonversion (Dukers et al, 2000), implicating recent oral-genital sex as a 
strong risk factor. Few studies have prospectively examined the risk factors for
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recent HHV-8 infection, and all have found evidence of sexual transmission among 
homosexual men, e.g., recent sexual contact with an HIV-infected partner (Martin et 
al, 1998; Casper et al, 2002).
On the assumption that HHV-8 can be sexually transmitted, the virus would need to 
be shed at high titres in semen. Indeed, HHV-8 DNA has been detected in prostate 
tissue biopsies of HIV-seropositive men without KS (Staskus et al, 1997; Diamond 
et al, 1998) indicating that HHV-8 can be shed from the prostate into the semen. 
Moreover, HHV-8 DNA detection was reported in semen samples of healthy donors 
(Monini et al, 1996a). However, later studies have rarely reported positive samples 
in the semen of patients with KS, and almost never in healthy semen donors 
(Boshoff and Weiss, 2001). Longitudinal studies of viral shedding have shown that 
HHV-8 is not substantially shed in semen or rectal tissue, but is persistently found in 
the oral cavities of some individuals (Pauk et al, 2000; Corey et al, 2002). 
Infectious HHV-8 have now been recognised to be detected in high titres in saliva of 
HHV-8-seropositive individuals (Vieira et al, 1997; Koelle et al, 1997; Blackboum 
et al, 1998; Pauk et al, 2000). Since oral-genital sex is a common practice among 
homosexual men, as is deep kissing, saliva rather than semen is now considered as 
significant vehicle of HHV-8 transmission. The risk of HHV-8 transmission through 
receptive ano-genital or insertive oro-anal sex may be even lower, because little or 
no virus has been detected in semen or faeces (Dukers et al, 2000).
Among heterosexuals, correlations with sexual transmission have not been 
consistently maintained (Smith et al, 1999; Wawer et al, 2001). Heterosexual 
transmission is not likely to be a major route and seems to require frequent sexual
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exposure to occur. HHV-8 prevalence is elevated mainly in heterosexuals who have 
a high number of sexual partners (Bestetti et al, 1998; Tedeschi et al, 2000; de 
Sanjose et al, 2002).
1.2.7.2 Parenteral transmission
Many studies have provided some evidence that HHV-8 can be transmitted by blood 
or blood products (Blackboum et al, 1997; Regamey et al, 1998; Engels et al, 
1999; Cannon et al, 2001). Some studies, which were performed in intermediate or 
high endemic populations, have shown that the prevalence is somewhat higher 
among injecting drug users (IDUs) compared with the general population, or an 
association between HHV-8 infection and injecting behaviour (Cannon et al, 2001; 
Sosa et al, 2001; Parisi et al, 2002). In countries or populations that are highly 
endemic for HHV-8, transmission by blood is not believed to be important, but could 
play a role.
On the other hand, low-prevalence areas generally show similar prevalence of HHV- 
8 between IDUs and the general population. Although syringe sharing among IDUs 
is a common means of transmitting HIV-1, hepatitis B virus and hepatitis C virus, it 
does not result in a similar spread of HHV-8 (Renwick et al, 2002). In a study of 
persons who received blood products from HIV-1- and HHV-8-coinfected donors, 10 
of 14 recipients seroconverted for HIV-1, whereas none seroconverted for HHV-8 
(Operskalski et al, 1997). Nonetheless, transmission through blood products cannot 
be excluded.
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1.2.7.3 Vertical transmission
Whether HHV-8 infection may be transmitted from mother to child is still unclear, 
with studies showing conflicting results. A study in South Africa suggests a rate of 
vertical transmission as high as 30% (Bourboulia et al, 1998). Another study 
showed that transmission appears to increase with increasing maternal antibody titres 
(Sitas et al, 1999). However, most studies have shown that HHV-8 prevalence in 
children increases with age (Bourboulia et al, 1998; Lyall et al., 1999; Serraino et 
al., 2001), and that most children bom to HHV-8-seropositive mothers possess 
passively transmitted antibodies and then serorevert by 24 m of age (Calabro et al, 
2000). On the other hand, a study in Zambia demonstrated no association between 
the HHV-8 infection rates among infants bom to HHV-8-seropositive mothers 
(Brayfield et al, 2003). This study showed detection of viral DNA in peripheral 
blood mononuclear cells (PBMCs) at the time of delivery for 2 of 89 infants bom to 
HHV-8 -seropositive mothers, which suggests that in utero infection occurs but 
rarely (Brayfield et al, 2003). However, a more recent study in Italy suggests that 
vertical transmission of HHV-8 is unlikely or, at least, very rare (Sarmati et al, 
2004).
1.2.7.4 Non-sexual person-to-person transmission
Non-sexual person-to-person transmission and childhood transmission are rare in the 
developed countries. Blauvelt et al. (1997) showed that transmission before puberty 
rarely occurs in the United States. In contrast, findings from countries where HHV-8 
infection is more widespread, such as African and Mediterranean countries, suggest 
that the vims can be transmitted among family members and that transmission is 
associated with close contact and crowding.
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A study of HHV-8 prevalence within families reported equally high rates among 
individuals with classic KS and their relatives; these rates were considerably higher 
than those among a sample of individuals from the general population who were 
matched by sex and age. Clustering of HHV-8 seroprevalence between spouses, 
children, and siblings was demonstrated in a Sardinian study population (Angeloni et 
al, 1998).
In Middle Eastern countries, evidence of HHV-8 infection in children also supports 
non-sexual transmission. In Egyptian children, HHV-8 seroprevalence of antibodies 
exceeded 50% in children older than 6 y and increased steadily up to 10 y, thereafter 
stabilising (Andreoni et al., 1999). In Egyptian children HHV-8 primary infection 
may be associated with a febrile illness and skin rash, and HHV-8 infection has been 
positively associated with close contact with at least two other children in the 
community, pointing to saliva as in important route of paediatric infection (Andreoni 
et al, 2002)
Moreover, for Israeli children, HHV-8 seroprevalence also rises with age. 
Davidovici et al, (2001) found that HHV-8 infection in children of a seropositive 
mother was influenced by the antibody titre of the mother, but was unassociated with 
HHV-8-infected father.
Gessain et a l (1999) found that in Cameroon, HHV-8 infection was also common 
among children. Seroprevalence steadily increased from 27% at age of 4 y to 39% in 
the 12-14 y group to above 48% in children over 15 y, approaching the level of 
HHV-8 infection in adults. Correlation with hepatitis B infection suggests that HHV-
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8 is transmitted horizontally in conditions of close contact and crowding (Mayama et 
al, 1998). Plancoulaine et al. (2000) studied a population of villagers of African 
origin in French Guiana and showed that the HHV-8 seroprevalence was 15% by age 
of 15 y and rising sharply to about 30% after 40 y; they provided evidence to 
implicate horizontal familial transmission between children and their mother but not 
their fathers, and between children and their siblings. A more recent similar study 
conducted in rural Tanzania also found associations between the HHV-8 serostatus 
of spouses and between the serostatus of a father and that of his children (Mbulaiteye 
et al., 2003). In a study of KS patients and their first-degree relatives in Malawi, both 
identical and non-identical HHV-8 sub-genomic sequences were observed between 
family members, suggesting transmission of HHV-8 along both intra- and extra- 
familial transmission routes (Cook et al., 2002b).
A recent study in sub-Saharan Africa demonstrated the absence of HHV-8 DNA in 
the breast milk of seropositive mothers, suggesting that contact with breast milk is 
not a likely source of horizontal transmission of virus to infants (Brayfield et al., 
2004). However, a study by Dedicoat and co-workers in South Africa showed 
presence of HHV-8 DNA in 12 out of 43 breast milk samples (Dedicoat et al., 2004).
The high prevalence of infection before adolescence in endemic areas and the higher 
frequency of the detection of HHV-8 in saliva compared with semen (Pauk et al., 
2000) provide indirect evidence of non-sexual transmission. It is thus hypothesized 
that viral spread through salivary contact might be involved in childhood 
transmission in endemic countries, although this is not definitely shown (Cattani et 
al, 1999). However, a recent study in South Africa reported that HHV-8 DNA was
66
Chapter 1 Introductory Considerations
detectable in 145 of 978 maternal saliva samples (mean virus load: 488,450 
copies/mL), suggesting saliva is also a significant vehicle of mother-to-child 
transmission (Dedicoat et al, 2004). Other than close contact and the use of shared 
items (spoons, plates, etc) in endemic area like Africa, behavioural practices 
associated with saliva exchange in sub-Saharan Africa may play a role in 
transmission of HHV-8. The use of saliva in healing medical practices, religious 
initiation or ritual practices, and feeding practices have been implicated (Wojcicki,
2003).
The source of salivary HHV-8 is unclear. Corey et al. (2002) compared HHV-8 
DNA content in whole saliva versus parotid duct secretions and found HHV-8 to be 
absent or markedly lower in parotid fluid than whole saliva; minor salivary gland 
biopsies performed in 4 HHV-8 seropositive persons who shed HHV-8 in their saliva 
showed no evidence of HHV-8 in the biopsy tissues using in situ hybridization. A 
model of reactivation and shedding similar to EBV has been suggested in which 
HHV-8 shed into the mouth originates from activation in latently infected B cells 
infecting the epithelial cells that line the lymph nodes (Sixbey et al, 1984; Ivarsson 
et al, 1999). In palatine tonsils of two HIV infected HHV-8 seropositve persons, the 
lytic gene products of HHV-8 in B cells within germinal centre and the epithelium 
lining of tonsil could be detected, suggesting that lytic replication of HHV-8 in B 
cells within germinal centre may transfer HHV-8 to epithelium surface either by its 
migration to the surface epithelium or by contiguous infection (Corey et al, 2002).
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1.2.7.5 Transmission to organ transplant recipients
Cases of seroconversion to HHV-8 have been observed after heart transplantation 
(Emond et al, 2002) and kidney transplantation (Luppi et al., 2000; Luppi et al.,
2002). These indicate that HHV-8 may be transmitted from the donor organ during 
transplantation. Few organ donation recipients develop KS in areas of low 
seroprevalence, but a higher incidence may be found in areas of higher KS 
incidence. In most cases, transplant patients are infected with HHV-8 prior to 
transplantation (Parravicini et al, 1997) and KS may develop as a result of viral 
reactivation due to drug-induced immunosuppression.
1.2.8 HHV-8 epidemiology
1.2.8.1 Methods used to determine HHV-8 prevalence
Some prevalence studies have relied on detection of HHV-8 DNA using PCR 
methods. However, only half of KS patients have detectable levels of HHV-8 DNA 
in PBMCs, indicating that viremia may not be frequent (Whitby et al, 1995; Moore 
et al, 1996c). For most immunocompetent patients who are infected with HHV-8, 
clinical signs of KS are not present and DNA is even more difficult to detect in 
PBMCs. Thus, HHV-8 DNA testing is not suitable for estimating prevalence of 
infection. Nested PCR may increase the sensitivity of the PCR by 100 to 1000 times 
(Moore et al, 1996c). Increased sensitivity of PCR can, however, create problems 
with contamination, creating false PCR positive results and rendering sequence data 
unusable (Moore and Chang, 1998). Thus, when detection of HHV-8 DNA in semen 
of a large proportion was reported in healthy Italian blood donors (Monini et al, 
1996a), the finding could not be corroborated by other groups suggesting that PCR
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contamination had indeed occurred in that study (Howard et al., 1997; Pellett et al,
1999).
Serologic assays for HHV-8-specific antibodies are more sensitive than PCR for 
detecting either current or past infection with the virus. Current assays can detect 
viral infection in more than 90% of infected patients (Gao et al, 1996b). First- 
generation assays were developed using HHV-8-infected PEL cell lines as sources of 
antigen in either an immunofluoresence assay (IFA) or in immunoblotting assay 
formats. LANA was the first serologic antigen identified by indirect IFA; while it is 
specific, it is generally less sensitive (about 80% sensitivity) (Gao et al, 1996b). IFA 
using lytic antigens can yield higher sensitivity rates than LANA assays. However, 
they suffer from problems associated with cross reactivity to other herpesvirus 
antibodies, particularly as no HHV-8-negative PEL cell lines are available to act as 
controls for non-specific reactions (Lennette et al, 1996). Recent assays using 
recombinant HHV-8 antigen expressed from another unrelated virus (e.g. Semliki 
Forest virus) allow high levels of antigen to be expressed and appropriate negative 
controls to be included. This approach has enhanced both the specificity and 
sensitivity of the IFA assay. Thus, in the assay developed by Inoue et a l (2000) the 
ORF K8.1 gene product was used as the antigen, and as it has no homologue to other 
herpesviruses, cross-reactivity does not occur.
A purified whole virion enzyme-linked immunosorbent assay (ELISA) has been 
developed to facilitate high throughput testing (Chatlynne et al, 1998). To increase 
sensitivity and specificity, other ELISAs have been developed using, as antigens, 
various recombinant proteins and oligopeptides (Davis et al, 1997; Andre et al,
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1997; Pau et al., 1998). Antigens commonly utilised in this type of serological assay 
include products from ORF 65 (Pau et al., 1998), ORF 73 (Gao et al., 1996a) and 
ORF K8.1.
Evidence suggests that patients show heterogeneous serologic responses to defined 
HHV-8 antigens; therefore, combinations of antigen assays may achieve the best 
detection rates (Lang et al., 1999; Spira et al., 2000). Although early studies 
suggested wide differences in infection rates in populations at risk of KS based on 
the type of antigen used (Rabkin et al., 1998), properly performed assays in 
standardized formats have been found to be highly concordant (Schatz et al., 2001).
1.2.8.2 HHV-8 seroprevalence
Seroprevalence studies show that, unlike most human herpesviruses, HHV-8 does 
not spread universally among all human populations. The lowest HHV-8 prevalence 
has been reported in northern Europe and the United States, where the prevalence of 
infection ranges from 0% to 5% among blood donors (Simpson et al., 1996; Gao et 
al., 1996b). Initial studies among children in these geographical regions indicated 
that HHV-8 infection is rare or nonexistent, with 0% prevalence among those HIV- 
seronegative or -seropositive (Simpson et al., 1996; Moore, 2000). A more recent 
study of 787 serum specimens obtained from children living in two areas where 
HHV-8 is not endemic, Germany and USA, showed seroprevalences of between 3% 
to 4% (Martro et al., 2004). In these areas, HHV-8 infection is mostly concentrated 
among homosexual men (Martin et al., 1998; Stine et al., 2000). HIV-infected 
homosexual men have the highest seroprevalence of any risk group. A study in the 
San Francisco area using samples dating to 1984 reported a seroprevalence of 48%
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among homosexual or bisexual men who were HIV-positive but did not have KS 
(Martin et al, 1998). A similar study conducted in Amsterdam between 1984 and 
1996 reported a baseline HHV-8 incidence of 30% among homosexual men who 
were also HIV-seropositive but had not developed KS (Dukers et al., 2000). In 
Europe and North America, HIV-1-seronegative homosexual men consistently show 
a lower seroprevalence of HHV-8 infection than HIV-1-seropositive homosexual 
men, and higher than observed among blood donors (Kedes et al., 1996; Martin et 
al., 1998; Melbye et al., 1998). In a recent study on HIV-infected patients without 
KS in Germany, the seroprevalence was up to 52% of 398 patients (Albrecht et al.,
2004). Heterosexual men and women with multiple partners in these Western 
countries show slightly increased seroprevalences when compared to the general 
population (Melbye et al., 1998; Whitby et al., 1999).
In South East Asia, prevalence of HHV-8 is variable: in Japan, it ranges between 0.2 
-  1.4% (Fujii et al., 1999; Satoh et al., 2001). However, Chen et al. (2004) in 
Northern Thailand showed a relatively high HHV-8 seroprevalence: of 992 persons 
studied, consisting of 400 married couples in which the husband and the wife were 
HIV-seropositive (200 couples), and in which the husband was HIV-seropositive but 
the wife HIV-seronegative (200 couples), and 200 HIV-seronegative men from a 
sexually transmitted diseases (STD) clinic: the HHV-8 seroprevalence was 24% in 
the total population, 28% in the HIV-seropositive group and 18 % in the HIV- 
seronegative group.
HHV-8 seroprevalences in South America have also been documented. The 
seroprevalence in blood donors from Central and South America is between 1.9% to
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6.7%, with the variability thought to be linked to variation in immune status and 
exposure to HIV patients in the cohorts tested (Perez et a l, 2004). In Brazil, varying 
seroprevalences, 53% among Amerindians (Biggar et al., 2000) and 16% in urban 
communities (Freitas et al., 2002), have been reported.
Countries surrounding the Mediterranean and the Middle East are regions of high 
HHV-8 seroprevalences. In Italy, the prevalence varies between less than 10% in the 
North to more than 20% in the South (Whitby et al., 1998), with the highest rates 
observed on the islands of Sicily and Sardinia (Vitale et al., 2001). Wide variations 
have been observed even within smaller areas, such as northern Italy, where the 
prevalence ranges from less than 5% in Milan to more than 20% at the lower end of 
the Po Valley (Whitby et al., 1998; Calabro et al., 1998). An HHV-8 prevalence of 
4% has been reported among Italian children younger than 11 y (Whitby et al.,
2000). The highest prevalence in the Mediterranean area, exceeding 50%, has been 
reported among children in Alexandria, Egypt (Andreoni et al, 1999). HHV-8 
seroprevalence is also higher in Israeli Jews (10%) than in European and North 
American blood donors (Davidovici et al, 2001).
In Africa, HHV-8 seroprevalences are very high (de The et al, 1999), particularly in 
sub-Saharan Africa, where endemic KS has been reported. In this area, the HHV-8 
seroprevalence among children ranges from 13% in Cameroon to 37% in Uganda 
(Mayama et al, 1998; Gessain et al, 1999), and from 36% in Ghana to 47% in 
Zambia (Olsen et al, 1998; Nuvor et al, 2001). The prevalence among adults ranges 
from 22% in central Africa to 48% in Zambia (Belec et al, 1998; He et al, 1998). 
Very high rates, between 76% and 87%, have been reported in the Congo and in
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Botswana (Engels et ah, 2000), and among older adults in Ghana (43%) and Zambia 
(71%) (Olsen et ah, 1998; Nuvor et ah, 2001). The HHV-8 prevalence among 
prepubescent children from Central Africa ranges between 40% to 50% and shows a 
positive correlation with age (Kasolo et ah, 1997; Mayama et ah, 1998; Gessain et 
ah, 1999).
1.3 Cytomegalovirus
CMV is ubiquitous. The virus infects most individuals by adulthood and in 
developed countries. CMV infection is generally asymptomatic and leads to 
persistence. Primary and persistent infection may lead to severe disease in the 
absence of an effective immune response, as in the immunologically immature and 
the immunocompromised. Its impact on mortality and morbidity has become 
prominent in recent decades due to the rise in organ allografting, immunosuppressive 
treatment, and HIV infection. CMV is a leading causal agent of birth defects 
(Griffiths, 2000; Pass, 2001).
1.3.1 Virology
1.3.1.1 Virion structure
CMV shows typical structural features characteristic of the herpesvirus family. The 
DNA is contained within a capsid of 162 hexagonal capsomeres. The capsid is 
surrounded by the ill-defined tegument, which is itself surrounded by a loosely 
applied lipid envelope. The mature virion particle is 150-200 nm in diameter 
(Mocarski and Courcelle, 2001).
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1.3.1.2 Structure of the CMV genome
The CMV genome is the largest of all herpesviruses and has a high G+C content. It 
contains an arrangement of unique long (UL), unique short (US) and repeat regions 
(Mocarski and Courcelle, 2001). The AD 169 laboratory strain is the only one in 
which the genome has been completely sequenced. Analysis of its 230-kbp genome 
has revealed that it encodes 225 ORFs of -100 or more amino acids (Chee et al, 
1990; Novotny et al., 2001). These ORFs are designated sequentially according to 
their location within the unique and repeated regions. Comparison of the AD 169 
amino acid sequences with those of other herpesvirus genomes has shown that the 
protein products of more than 40 ORFs share high similarity to proteins encoded by 
a- and y-herpesviruses (Chee et al, 1990; Karlin et al, 1994), and provided further 
evidence of a common origin of the three subfamilies. Of the herpesvirus-conserved 
ORFs, -25% appear to encode functions related to viral DNA metabolism and 
replication, whereas the remaining 75% are thought to be involved in the maturation 
and structural organization of virions. The UL ORF-encoding functions are involved 
in DNA replication and repair, nucleotide metabolism, or virion structure; the ORFs 
are grouped in seven conserved gene blocks (A-G) also found in other 
herpesviruses, such as HSV-1 and EBV. The US ORFs and ORFs located within the 
repeated regions of the CMV genome are less well conserved than in the other 
herpesviruses (Chee et al, 1990).
1.3.1.3 CMV proteins
The International CMV Workshop of 1993 agreed on a nomenclature for the 
description of CMV proteins (Landini and Spaete, 1993). The system designates p 
for protein, gp for glycoprotein, and pp for phosphoprotein, followed by a numerical
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assignment to the genetic locus. Of the more than 30 viral proteins found in the 
complete infectious virion, 4 constitute the capsid; encoded by UL46, UL48.5, UL85 
and UL86. Assembly protein (AP), encoded by UL80, is associated with the capsid 
and may play roles in maturation (Mocarski and Courcelle, 2001).
The phospholipid envelope contains 6 virus-encoded glycoproteins: gpUL55 (gB), 
gpUL73 (gN), gp UL74 (gO), gpUL75 (gH), UL100 (gM), and gpUL115 (gL). 
These glycoproteins play essential roles in virus entry into host cells, cell-to-cell 
spread and virion maturation (Britt and Mach, 1996). Mutational analysis has 
revealed that disruption of gB, gH, gL, and gM ORFs results in failure to produce 
infectious progeny (Hobom et al., 2000).
The remaining 20-25 structural virion proteins probably are located in the still 
poorly characterized amorphous layer between the nucleocapsid and the envelope 
(Baldick and Shenk, 1996). The tegument proteins may be involved in the 
maturation of progeny virions, or may influence viral and cellular events in the early 
stages of infection, such as release of viral DNA from disassembling virus particles. 
Most tegument proteins are phosphorylated and are highly immunogenic. The most 
abundant are ppUL32 (ppl50 or basic phosphoprotein) and ppUL83 (pp65). Owing 
to the large amount produced, pp65 is frequently the target antigen used in 
antigenemia assays for the rapid diagnosis of CMV infections. Tegument proteins 
such as ppUL69 and ppUL82 (pp71) may play important regulatory roles in both 
viral and cellular gene expression. They are transactivators of viral gene expression, 
and can dysregulate cell cycle progression. UL69 is required for efficient viral 
replication, and arrests cells in Gi by an unknown mechanism (Lu and Shenk, 1999).
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UL82 is a transcriptional activator of activating transcription factor (ATF)/cyclic 
AMP-response element binding protein (CREB) or the activator protein-1 (AP-1)- 
containing promoter. It also increases the infectivity of transfected viral DNA, is 
required for viral replication at low multiplicities of infection, and accelerates the Gi 
to S transition of quiescent cells (Liu and Stinski, 1992; Baldick et al, 1997).
1.3.1.4 CMV protein-coding genes used for genotyping
(i) gB (gpUL55)
Glycoprotein B (gB; gpUL55), a component of the envelope complex gC-I, is the 
most widely studied polymorphic viral glycoprotein. It is used for the virus to attach 
to, and penetrate into, the cell. There are specific receptors on the cell surface for 
which gB constitutes the ligand. It has been shown that antibodies to gB inhibit virus 
penetration into the cells and block transmission of infectious virus from cell to cell 
(Rasmussen et al, 1991; Navarro et al, 1993). Four main gB genotypes (gB-1, gB- 
2, gB-3 and gB-4) have been found (Chou and Dennison, 1991; Fries et al, 1994; 
Meyer-Konig et al, 1998), although some rare non-prototypic variants have been 
described (Shepp et al, 1998; Trincado et al, 2000). Data on the functional role of 
the main gB types in CMV pathogenesis and their relationship with the clinical 
outcome of CMV disease and virus cell/tissue tropism are conflicting, and, in some 
cases, contradictory (Fries et al, 1994; Chem et al, 1998; Gilbert et al, 1999).
(ii) ULI 44
ULI44 ORF encodes a homologue of the tumor necrosis factor receptor. Three 
phylogenetic groups have been identified based on this ORF, with variability as high 
as 21% in amino acids among variant groups (Lurain et al, 1999).
77
Chapter 1 Introductory Considerations
(iii; gN (UL73j
gpUL73-gN is encoded by the ORF UL73, is a component of the envelope gC-II 
complex in association with gM and is able to elicit neutralizing antibodies (Mach et 
al, 2000; Dal Monte et al., 2001; Pignatelli et al., 2002). UL73 shows 4 main 
genomic variants, denoted gN-1, gN-2, gN-3 and gN-4. The gN-3 genotype can be 
divided further into two subgroups (gN-3a and gN-3b) while the gN-4 genotype can 
be divided further into 3 subgroups (gN-4a, gN-4b and gN-4c) (Pignatelli et al., 
2001; Pignatelli et al., 2003). These gN genomic variants are stable during in vitro 
and in vivo virus replication and show no correlation with gB genotypes. 
Furthermore, the UL73 gN-encoding gene seems more polymorphic than the gB 
(Pignatelli et al., 2001). The variants gN-1, gN-3 and gN-4 and their subgroups have 
been detectable in four geographical areas of North America, Europe, China and 
Australia, although with different frequencies. The rarest genotype, gN-2, has been 
observed in people residing in Northern America and Europe, but not identified in 
Chinese or Australians (Pignatelli et al., 2003).
(iv) gO (UL74)
gpUL74-gO is encoded by the ORF UL74, a newly discovered hypervariable locus in 
CMV (Paterson et al., 2002; Rasmussen et al, 2002). gO region complexes with 
UL75 (gH) and ULI 15 (gL) to form the gCIII viral-envelope complex (Rasmussen et 
al., 2002). gO has a role in infection by facilitating cell fusion and cellular spread 
(Paterson et al, 2002). The gO genotypic variants can differ by up to 50% of amino 
acids (Paterson et al., 2002; Rasmussen et al, 2002).
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1.3.2 Epidemiology
The CMV is transmitted both vertically and horizontally. Transmission may occur 
following primary infection, or reactivation. CMV is shed in various body fluids 
including saliva, semen, urine and cervicovaginal secretion, frequently in the 
absence of symptoms. In populations living under good socioeconomic conditions, 
approximately 40% are seropositive by adolescence, this figure increasing thereafter 
by approximately 1% annually. By contrast, almost all children from low 
socioeconomic populations are already infected by the onset of puberty (Griffiths, 
2000; Pass, 2001). About 10% of infants are infected by the age of 6 m, following 
transmission from their mothers via the placenta, during delivery, and by breast 
feeding (Pass, 1985; Stagno et al, 1986).
1.3.3 Routes of transmission
1.3.3.1 Intrauterine
The frequency of congenital acquired CMV infection in developed countries ranges 
from 0.5 -  2.2% of all live births (Fowler et al., 1992; Trincado and Rawlinson,
2001). Infection results from either primary maternal infection contracted in 
pregnancy or from reactivation during pregnancy of CMV in a previously infected 
mother. The risk of primary maternal infection in a non-immune mother in 
pregnancy is about 1%, and it carries a 40% risk of congenital infection. Foetal 
infection is more likely to occur, and to be severe when a seronegative mother 
acquires primary infection in early pregnancy. The risk of symptomatic congenital 
infection from reactivation of maternal CMV in pregnancy is lower, although not 
absent, as pre-existing maternal immunity limits spread to the foetus (Fowler et al, 
1992; Pass, 2001).
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1.3.3.2 Perinatal
Infection during delivery is the outcome of shedding from the vagina or cervix, 
followed by ingestion of infected secretions by the offspring. Shedding close to the 
time of delivery has been noted in 2% to 28% of mothers (Reynolds et al, 1973; 
Stagno et al, 1982). Breast-feeding is another significant route of perinatal 
transmission. Transmission is a function of its duration and the relatively low virus 
load in the milk (Dworsky et al, 1983). It has been shown, for example, that infants 
nursed for <1 m do not become infected, compared to almost 40% of those nursed 
longer. Moreover, 70% of infants are infected when the virus can be isolated from 
the milk, whereas only 10% are infected when the mother is seropositive, but was 
culture-negative for virus in the milk. PCR studies have also demonstrated a strong 
relationship between the presence of viral DNA in milk and transmission to the 
infant (Vochem et al, 1998).
1.3.3.3 Postnatal
The absence of symptoms following postnatal infection makes it difficult to 
determine what the principal transmission routes are. CMV transmission occurs from 
child to child in day care centres. Among young children, saliva and urine are the 
most common vehicles. Infection in children is usually asymptomatic, but infectious 
toddlers may transmit the virus to adult nursery staff or to mothers (Pass et al, 
1990). If any of these adults are pregnant, there is a risk of fetal damage, especially if 
the mother is seronegative.
Sexual transmission may be significant, particularly as high CMV seroprevalences 
among patients attending clinics for sexually transmitted disease have been observed
80
Chapter 1 Introductory Considerations
(Shen et al, 1994). Heterosexual contact is a major mode of transmission of CMV 
among some young adults who shed strains of CMV in the cervix secretion and in 
semen (Handsfield et al., 1985). Primary infection with CMV via blood transfusions 
was noted in the mid-1960s, although epidemiological studies have demonstrated 
that this is an uncommon route. Attempts to culture CMV from fresh donor blood 
have rarely been successful. It is thus assumed that the virus is latent in the blood 
cells of healthy donors and is reactivated following transfusion when they encounter 
an allogeneic stimulus. The nature of the leukocytes carrying latent virus is 
unknown, although attention is being increasingly focused on those of the 
monocyte/macrophage lineage (Soderberg-Naucler et al., 1997; Soderberg-Naucler 
et al, 2001).
CMV is a significant post-allograft pathogen. Several studies have shown that 
seronegative recipients of an organ from a seropositive donor are at much greater 
risk of acquiring a primary infection (Peterson et al, 1980; Pollard, 1988). The 
incidence of CMV infection following allogenic bone marrow transplant (BMT) 
ranges from 32% to 70%, with an average of 50%, regardless of the prior serological 
status of the recipient and donor (Ruutu et al, 1990; Rubie et al, 1993).
1.3.4 Diagnosis of CMV infection
1.3.4.1 Viral culture
CMV has been traditionally isolated in fibroblast tissue culture. Fibroblasts undergo 
a focal cytopathogenic effect (CPE) that is easily confirmed by fluorescent antibody 
stains. The virus can be recovered from a variety of specimens: urine, tissues, 
respiratory swabs and washes, body fluids and blood. Conventional viral culture is
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the gold standard for diagnosing CMV despite shortcomings such as poor predictive 
value, difficulties in quantitation, and a long turnaround time (1-3 weeks). Falsely 
negative cultures may occur if the interval between specimen collection and cell 
culture inoculation is prolonged. Cell cultures show a lower sensitivity when 
compared with PCR and nucleic acid probe methods (Sandin et al., 1991). Rapid 
viral culture (using the shell vial method) is a modification of conventional culture 
that leads to a reduced reporting time to 48 h from 7 to 14 days. In this method, 
specimens are centrifuged onto fibroblast monolayers, incubated briefly, then stained 
before the appearance of CPE with a monoclonal antibody to early antigens (Gleaves 
et al, 1989; Rabella and Drew, 1990).
1.3.4.2 Histopathology
CMV infection of a cell is recognized by the presence of characteristic intranuclear 
“owl’s eye” inclusions, which have a surrounding halo and marginated chromatin. 
Cells that bear these inclusions may be found in the kidney, lung, oesophagus, liver 
and salivary glands. While histopathologic diagnosis is specific, false negatives due 
to sampling error are common (Mattes et al., 2000).
1.3.4.3 PCR detection of CMV DNA
PCR has provided an invaluable diagnostic tool in virology because of its ability to 
detect minute amounts of viral nucleic acid in clinical specimen. PCR-based 
techniques are increasingly being used to detect and quantitate CMV load in blood or 
plasma. As the virus is seldom detected in plasma (as opposed to leucocytes) in 
healthy carriers, the presence of CMV DNA in plasma indicates active viral 
replication (Spector et al., 1998). The use of quantitative PCR techniques allows a
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measurement of 'viral load' in plasma: such assays have been advocated for the 
monitoring of immunosuppressed patients, and a rise in viral load above a 
predetermined threshold necessitates anti-CMV prophylaxis, even in the absence of a 
clinical syndrome attributable to CMV (Emery et al., 2000).
1.3.4.4 Antigen detection
The assay consists of direct staining of leukocytes with monoclonal antibodies 
directed against the lower matrix protein (pp65) (Grefte et al, 1992). pp65 is present 
in the CMV virion and is detectable in infected peripheral mononuclear cells. The 
results are expressed as the number of antigen-positive cells relative to the number of 
the cells used to prepare the slide. This assay is a sensitive method of estimating the 
systemic CMV load. Its advantages include a short processing time (less than 6 h) 
and lack of requirement of highly specialized laboratory. However, it needs to be 
processed immediately, and the results are subject to variation in personal skills 
(Boeckh and Boivin, 1998).
1.3.4.5 Serology antibody detection
Serological determination of a past or recent CMV infection in immunocompetent 
individuals rests on detection of virus-specific IgG or IgM antibodies. Occurrence of 
a primary infection is conventionally deduced from the seroconversion response. A 
specific IgM response may be serologic evidence of a recent primary infection. IgM 
testing time is not reliable because false positive reactions may result in the presence 
of rheumatoid factor or antinuclear antibodies, and true positive reaction may appear 
in patients who had experienced past CMV infection. Testing the avidity of CMV- 
specific IgG is another way of CMV serologic diagnosis and has proven to be a
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powerful tool for distinguishing primary from past or recurrent CMV infection in 
pregnant women and solid organ transplant recipients (Blackburn et al, 1991; 
Lazzarotto et al., 1999). It is defined as the strength with which the IgG attaches to 
antigen. IgG avidity matures with the length of time following primary infection. 
Thus, IgG produced within the first 3 to 5 m following primary infection exhibits low 
avidity, whereas IgG produced several months or years later exhibits high avidity and 
indicates past or recurrent infection (Prince and Leber, 2002).
1.3.5 Clinical features
1.3.5.1 Congenital infection
Approximately 30% of congenitally infected newborns develop symptomatic 
disease, including the most severe manifestation of cytomegalic inclusion disease, 
which includes growth retardation, jaundice, hepatosplenomegaly, 
thrombocytopenia, retinitis, along with CNS involvement in the form of encephalitis 
and seizures. 18% develop long-term sequelae such as hearing loss (Gaytant et al., 
2002). Children infected during the first trimester of pregnancy are at increased risk 
of complications, although infections at any stage of pregnancy can produce 
symptomatic disease (Boppana et al, 1999). Prior maternal CMV antibodies are 
protective against transmission of the virus, but not against development of 
symptomatic disease once infection has occurred (Boppana et al, 1999; Gaytant et 
al., 2002). Infection during pregnancy is often asymptomatic; however, infected 
pregnant women when questioned closely, often admit to fatigue (Revello and 
Gema, 2002).
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1.3.5.2 Infection in immunocompetent hosts
Most perinatally infected infants do not develop acute symptoms, although 
occasionally pneumonitis may occur in first 3 m of life (Brasfield et al, 1987). 
Postnatal infection in the immunocompetent child or adult is almost always 
asymptomatic, but may account for 8% of all the cases of mononucleosis (Nesmith 
and Pass, 1995). Clinical manifestations of mononucleosis due to CMV are very 
similar to that caused by the more common EBV. Persistent fever, myalgia, 
headache, cervical lymphadenopathy, splenomegaly and nonspecific constitutional 
symptoms are common, and may persist for weeks.
1.3.5.3 Infection in the immunocompromised host
CMV is a significant opportunistic pathogen in immunocompromised patients, e.g., 
solid organ transplant recipients, bone marrow transplant (BMT) recipients and 
AIDS patients. Primary infection, reactivation of latent virus, and reinfection are all 
possible and are often clinically silent. The onset of infection is marked by spiking 
pyrexia, which may resolve in a few days. Its severity is roughly parallel with the 
level of immunosuppression, and is most prominent in BMT recipients and AIDS 
patients (Pass, 2001).
1.3.5.4 Disease in solid organ transplant recipients
Clinical signs of CMV infection in transplant recipients may be absent or severe, 
although severe infection is now less frequent as a result of better prophylaxis. CMV 
infection may be associated with chronic rejection and renal artery stenosis in renal 
transplant recipients (Brennan, 2001), with accelerated coronary artery stenosis in 
heart transplant recipients (Hosenpud, 1999), and with the ‘vanishing bile duct’
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syndrome in liver transplant recipients (van den Berg et al., 1996). None of these 
associations has been definitively established as being caused by CMV.
1.3.5.5 Disease in bone marrow transplant recipients
Pneumonitis is the most serious manifestation of CMV infection after BMT, 
occurring in 10-15% of allogeneic BMT recipients with a mortality of 80% prior to 
the advent of antiviral therapy. The clinical picture is that of interstitial pneumonitis 
in the absence of any other identifiable pathogen, with increasing arterial 
hypoxaemia, and progression to respiratory failure. It is suggested that graft versus 
host disease (GVHD) may contribute to the lung injury in CMV pneumonitis in 
BMT recipients. The relationship between CMV and GVHD is controversial, with 
proposals that CMV may predispose to GVHD, and vice versa (Broers et al, 2000).
1.3.5.6 Disease in patients with AIDS
The incidence of CMV infection in HIV-seropositive patients is close to 100%, and 
coinfection with multiple strains is common (Baldanti et al, 1998). Retinitis and 
gastrointestinal disease are common manifestations of CMV infection in HIV- 
infected patients, but the commonest is retinitis, which may be seen in up to 25% of 
patients with AIDS. It is characterized by haemorrhagic retinal necrosis, spreading 
along retinal vessels; when disease encroaches on the macula sight is threatened 
(Jacobson, 1997). However, HAART has significantly decreased the incidence of 
CMV-induced disease (particularly retinitis) (Jabs et al, 2002).
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1.4 Hypothesis and aim of the current study
The molecular epidemiology of HHV-8 and CMV was investigated in patients with 
KS and their relatives in Malawi, a region of high HHV-8 and CMV endemicity. It 
was hypothesised that hosts living in such a hyper-endemic region are prone to 
multiple HHV-8 infection and multiple CMV infection. To substantiate this 
hypothesis, nucleotide and amino acid sequence polymorphisms in hypervariable 
regions of the HHV-8 and CMV genomes carried in samples obtained from various 
anatomical compartments were investigated.
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2.1 Amplification of HHV-8 sub-genomic DNA
2.1.1 Patients and samples
The study group included patients with presumptive cutaneous, oral and nodal KS (n 
= 22) attending the Central Hospital of Blantyre, Malawi, Africa, and their first- 
degree relatives (« = 67). In all cases of nodal KS, the diagnosis was confirmed 
histologically. Ethical approval for the study was granted in the United Kingdom and 
locally (Cook et al., 2002b). An identification system described in a previous 
publication (Cook et al, 2002b) was applied: index cases of KS were assigned the 
"i" suffix, and their family members assigned numerals; letters denoted family 
assignments. Venous blood, urine and oral samples were obtained after informed 
consent was given. The following oral samples were collected: mouth rinse, throat 
gargle, and palatal exfoliate. Table 2.1 shows the characteristics of the study group. 
This study group is the same as that reported by Cook et al. (2002b). Table 1-5 in 
Appendix 2 shows DNA detectbilty of all samples for different regions of HHV-8 
and CMV from all patients in this study.
2.1.2 Preparation of whole blood
Peripheral blood was collected in EDTA-treated vacutainers and stored, if necessary, 
for not more than two days at 4° C. Plasma was separated from blood by 
centrifugation at 1200 rpm for 5 m with 1 ml of supemate being then removed. The 
remaining blood was resuspended. To separate different leukocyte fractions from the 
blood, Dynabeads (Dynal A.D., Oslo, Norway) were utilised. Dynabeads are small 
magnetically charged uniformly shaped beads coated with a specific monoclonal 
antibody. For this study Dynabeads coated with antibodies (mouse IgG2a
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Index case Family members tested
Vincristine
Age/sex Site of KS given? Spouse (age) Children/siblings (age/sex) Mother Father
(age) (age)
A ».c,d,e 7y/F Abdomen, No A2(10y/M)cr, A3(7m/M) Al(34y)c,d,f
limbs
Bc 4y/M Cervical Yes B 1 (20y/F)c d, B2(13y/M)c f, B7(40y)c
Bl(12y/M)b f, B4(10y/M)c,
B5(7y/M)bcf, B6(l lm/F)
£b,c,d,e,f 8y/M Abdomen, No C2(14y/F)c, C3(12y/M)c
limbs
£a,c,d,e 3 ly/F Legs, No El(5y/F)c, E2(9y/F)c,f, E3(6y/F)cf,
palate E4(6y/F)bcf, E5(13y/M)b'c'f,
E6(10y/M)bcf
p4,c,d*e 2y/M Foot No F2(7y/M)d Fl(35y)c,d
Gcde 34y/F Foot, leg, No Gl(32y)bc,d,f G2(23y/M)bc f, G3(19y/F)c,
palate G4(15y/M)c
Hcd 35y/F Leg Yes Hl(13y/F)cf, H2(12y/M)bcf,
H3(9y/M)c, H4(8y/M)
,c.d 36y/F Leg Yes ll(12y/M)c, 12(1 ly/F)
jc.d.e 28y/M Leg No Jl(22y)c J2(3y/M)
j^«,b,c,d.e,f 30y/F Leg Yes Ki(12y/M)bef
Mc,d 33y/M Leg, foot No M4(32y)c Ml(3y/M), M2(7m/F), M3(8y/F)c-d
Nc-d’f 30y/F Leg, No Nl(18y/F)
palate
pc,d.f 30y/M Leg, Yes Pl(28y)cd P2(2y/M)
Q*,b,c,d,e/ 24y/M
palate
Foot No Ql(21y)cd
Rcd 41y/M Leg Yes Rl(25y)cd R2(12y/M)c, R3(9y/M)b,f
Sc’d 40y/M Leg Yes Sl(37y)
jc ,d 33y/F Leg, foot Yes Tl(37y)cdef T2(l ly/M)b,c,f, T3(9y/M)b c-f’,
T4(4y/M)c,d,e
u c-df 32y/F Leg, foot, No Ul(14y/M)c, U2(12y/F), U3(8y/F)
gingiva
43y/F Leg, Yes Wl(36y)bc'd-f W2(20y/M)b-c-f, W3(19y/M)c,
palate W4( 13y/F)bcf, W5(6y/M)c d,
W6(7m/F)c,d
X c,d 4 ly/F Chest, Yes Xl(44y)bcd’f X2( 18y/F)b, X3( 11 m/M)
palate
Yc 32y/M Arm Yes Yl(38y)c Y2(8y/F), Y3(5y/F), Y4(3y/F)
^b,c.d,c^ 21m/M Cervical No Zl(5y/F)c Z2(22y)b,c,f
*KSHV Kl/Vl DNA amplified from blood (CD45 +); bKSHV Kl/Vl DNA amplified from saliva; TCSHV-seropositive; dHIV- 
1-seropositive; CKSHV ORF 26 DNA amplified from blood (CD45 +), fKSHV ORF 26 DNA amplified from saliva.
Table 2.1 Characteristics of the patients with Kaposi’s sarcoma and their family
members (reproduced from Cook et al, 2002b).
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monoclonal antibody, clone EOl) against CD45 and (mouse IgGl monoclonal 
antibody, clone 9G11) against CD31 were used. To 1 ml of whole blood, 50 pi of 
Dynabeads was added to give an approximate final concentration of 2 x 10 
beads/ml. The whole blood and Dynabead mixture was incubated at 4°C for 20 min. 
Dynabeads were collected using a magnetic particle concentrator (MPC) (Dynal), 
washed 3 times with 1 ml of phosphate buffer saline (PBS) containing 2% foetal calf 
serum, and eluted into 250 pi of nuclease-free water.
2.1.3 Preparation of oral samples
A sampling order of the oral components had been imposed to minimize cross­
contamination between compartments: the throat-gargle sample (collected after 30 s 
of gargling with 5 ml of PBS, while patient’s head tilted back), the mouth-rinse 
sample (collected after retaining 5 ml of PBS in the mouth for 2 min, during which 
gentle lateral flexions of the neck were encouraged), and the palatal-exfoliate sample 
(eluted in 1 ml of PBS after applying 5 rotations of an exfoliative cytology brush 
(Oral CDX, Henry Schein Company) to the palatal mucosa posterior to the upper 
incisors). All oral samples were subjected to low-speed centrifugation, after which 
the pellets were resuspended in 1 ml of PBS, split into 250-pL aliquots, and stored at 
-70°C until required.
2.1.4 Preparation of urine samples
Mid-stream urine samples were collected in a 5 ml tube then subjected to low-speed 
centrifugation, after which the pellets were resuspended in 1 ml of PBS, split into 
250-pl aliquots, and stored at-70°C until required.
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2.1.5 DNA extraction from blood
Dynabead preparations were extracted using the Geneclean III DNA extraction kit 
(BIO 101). 6M sodium iodide was added to the sample in the first step to lyse the 
cells and to inactivate any nuclease activity. A suspension of silica particles (EZ- 
glassmilk) was introduced and with mechanical agitation, the DNA became bound to 
the silica particles. The DNA was eluted in 50 pi of nuclease-free water.
2.1.6 DNA extraction from oral samples
200 pi aliquots of the pellet portion of the mouth rinse sample, gargle and brushed 
palatal samples were extracted using QIAamp kit (QIAGEN). Samples were eluted 
in 200 pi of nuclease-free water.
2.1.7 DNA extraction from urine
200 pi aliquots of the pellet portion of urine sample were extracted using QIAamp 
kit (QIAGEN). Samples were eluted in 200 pi of nuclease-free water.
2.1.8 PCR amplification of DNA from ORFs 26 and K1
The primary PCR for HHV-8 ORF 26 (also referred to as MKS330"), was carried out 
in a 25-pl reaction mixture containing nuclease-free water, PCR buffer (200 mM 
Tris HCL (PH 8.4), 500mM KC1), 4.0 mM MgCl2, 10 mM each dNTP, 1 unit Taq 
DNA polymerase (Invitrogen), 20 pmol each first round primer and 2 pi extracted 
DNA. The secondary PCR mix was identical except 20 pmol of each inner primer 
was used and 2 pi of the first round product was added as template.
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First-round PCR amplification of the first variable region of HHV-8 ORF K1 
(Kl/Vl) was carried out in a 50-pl reaction mixture containing nuclease-free water, 
IX buffer number 8 (Stratagene) containing (3.5 mM MgCb, 10 mM Tris-HCl (pH 
8.8), 75 mM KC1), 20 pmol each outer primer, 10 mM each dNTP and 1 unit Taq 
DNA polymerase (Invitrogen). To this 5 pi of extracted DNA was added. The 
second-round conditions were the same as the first except the addition of 20 pmol of 
each inner primer and 2 pi of the first round product was added as template.
Amplification of both regions was carried out under the same PCR thermocycling 
conditions. Samples were heated to 94°C for 5 min followed by 35 cycles of 94°C for 
1 min, 60°C for 1 min, and 72°C for 1 min followed by a 5 min extension period at 
72°C.
Primer sequences for ORF 26 and ORF K1 are shown in Table 2.2. PCR using outer 
KS330 primers produce a product 233 bp in length from position 355 to 588 and 
using the inner primers yield a 211-bp product from position 366 to 577. Nucleotide 
positions are numbered according to the sequence deposited in GenBank under 
accession number U75698. PCR using the ORF K1 outer primers produces a 255-bp 
fragment from position 568 to 823 in the BCBL-1 K1 sequence (GenBank accession 
number U86667), while PCR using the inner primers produced a 246-bp fragment 
from position 573 to 819 in the BCBL-1 K1 sequence.
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Region Position Name Sequence
ORF 26 Outer-sense KS 1§ 5 ’ AGCCG AAAGG ATTCCACCAT
Outer-antisense KS 2s 5 ’ T CCGT GTT GT CT ACGT CC AG
Inner-sense Ksinnl5 5 ’ TT CC ACC ATT GT GCT CG A AT
Inner-antisense Ksinn2s 5 ’TACGTCC AGACG ATATGTGC
ORF K l/V l Outer-sense K linn5t 5 ’CCCTGGAGTGATTTCAACGC
Outer-antisense K linn6t 5 ’ ACATGCTGACCACAAGTGAC
Inner-sense K l- lJ 5 ’ G AGT G ATTT CAACGCCTT AC
Inner-antisense K l-N j 5 ’TGCT G ACC AC A AGT G ACT GT
§ (Di Alberti et al, 1997) 
t  (Zong et al, 2002)
J(Cook etal., 2002b)
Table 2.2 Oligonucleotide primers used for the amplification of HHV-8 ORF 26 and 
ORF K1 fragments
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2.1.9 PCR amplification of ORF 73 DNA
The internal repeat domain (IRD) of HHV-8 ORF 73 was amplified by nested PCR 
from extracts of a selected samples that were PCR-positive for ORF K1 and/or ORF 
26. The IRD of ORF 73 is a highly variable region and the size of the product varies 
between 1300 bp to 1900 bp in HHV-8 infected cell lines (Zhang et al, 2000). For 
nested PCR, a primary PCR mixture was made up to 25 pi total volume containing 
nuclease-free water, 1.5 mM MgCl2, 10 mM each dNTP, 2X PCRx enhancer 
solution (Invitrogen), 1.25 units platinum Taq DNA polymerase (Invitrogen), 50 
pmol each outer primer, and 2 pi of extracted DNA. The second-round PCR was 
carried out under the same conditions except for the addition of 2 pi primary product 
and 50 pmol of each inner primer. The nucleotide sequences for first and second 
round primers are shown in Table 2.3. Amplification for both rounds of nested PCR 
was carried out for 35 cycles of 94°C for 30s, 58°C for 30s and 68°C for 2 min, 
preceded by a 5 min denaturation step and ending with a final extension step of 5 
min at 68°C (Zhang et al., 2000; Cook et al, 2002a).
2.1.10 Separation and visualisation of PCR products
PCR products were mixed with 2 pi Orange G loading dye and loaded onto a 2% 
agarose gel (SB fine gel, Severn Biotech Ltd.) along with 1 pg of 1 kb DNA ladder 
(Invitrogen) to estimate the size of the PCR product. Electrophoresis took place in a 
IX TRIS-borate-EDTA buffer (TBE, Invitrogen) after which the gel was stained in a 
solution of 5 pg/ml ethidium bromide in TBE buffer. The bands were visualised 
using short wave UV transillumination.
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Region Position Name Prim er Sequence
ORF 73 IRD Outer-sensef IRD1-F 5 ’ ACGCC A ACCGCCT AC AT CT
Outer-antisensef IRD1-R 5 ’TCATGT GT GCT AAC A AC AGG
Inner-sense* LNAII F 5 ’ AT GGGG AC A ACG AG ATT AGC
Inner-antisense* LNAII R 5 ’ CG ACCCGT GC A AG ATT AT G
f  (Cook et al, 2002a)
*(Zhang et al, 2000)
Table 2.3 Oligonucleotide primers used for the amplification of the IRD of HHV-8 
ORF 73.
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2.1.11 Procedures to minimise contamination
To minimize contamination during PCR, DNA extraction, PCR reagent preparation, 
thermocycling, and post-PCR procedures were conducted in dedicated rooms. 
Appropriate negative and positive control specimens were included in each PCR. In 
addition, DNA extraction and PCR were repeated for those samples showing intra­
individual HHV-8 subgenomic sequence variation.
2.2 Amplification of CMV sub-genomic DNA
2.2.1 PCR amplification of ORF UL73 (gN) DNA
The primary PCR for CMV ORF UL73 (gN) was carried out in a 50-pl reaction 
mixture containing nuclease-free water, PCR buffer (200 mM Tris HCL (PH 8.4), 
500 mM KC1), 25.0 mM MgCb, 10 mM each dNTP, 1 unit Taq DNA polymerase 
(Invitrogen), 10 pmol each of first round primers and 5 pi extracted DNA. The 
secondary PCR mix was identical except that 10 pmol of each inner primer was used 
and 2 pi of the first round product was added as template. Amplification of UL73 
region was carried out under the PCR thermocycling conditions: samples were 
heated to 96°C for 1 min followed by 35 cycles of 96°C for 1 min, 55°C for 1 min, 
and 72°C for 1 min followed by a 10 min extension period at 72°C. Primer sequences 
for ORF UL73 are shown in Table 2.4. The ORF UL73 outer primers produced a 
416-bp fragment from position 106668 to 107084 in the AD 169 sequence (GenBank 
accession number BK000394). The inner primers produced a 304 bp fragment from 
position 106728 to 107031 in the ADI69 sequence.
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2.2.2 PCR amplification of ORF UL74 (gO) DNA
The first round PCR for CMV ORF UL74 (gO) was carried out in a 50-pl reaction 
mixture containing nuclease-free water, PCR buffer (200 mM Tris HCL (PH 8.4), 
500 mM KC1), 25.0 mM MgCb, 10 mM each dNTP, 1 unit Taq DNA polymerase 
(Invitrogen, Paisley, UK), 10 pmol each of first round primers and 5 pi extracted 
DNA. The secondary PCR mix was identical except 10 pmol of each inner primer 
was used and 2 pi of the first round product was added as template. Amplification of 
UL73 region was carried out under the PCR thermocycling conditions: samples 
being heated to 95°C for 3 min followed by 35 cycles of 96°C for 1 min, 55°C for 1 
min, and 72°C for 1 min followed by a 10 min extension period at 72°C. Primer 
sequences for ORF UL74 are shown in Table 2.4. Outer ORF UL 74 primers 
generate a product 1400 bp in length from position 107056 to 108456 and the inner 
primers yielded a 433-bp product from position 107065 to 107503. Nucleotide 
positions are numbered according to the complete genome sequence of the AD 169 
strain of CMV deposited in GenBank under accession number BK000394.
2.3 DNA sequencing
2.3.1 Automated sequencing
All samples were sequenced using the Beckman CEQ2000 automated capillary array 
sequencer. Samples for sequencing were separated by electrophoresis on a 2% 
agarose gel and bands identified. Bands were then excised and purified using a spin 
column based purification kit (Amersham) following the manufacturer’s instructions. 
To estimate how much DNA to add the sequencing reaction, 2 pi of purified product 
was electrophoresed through an agarose gel and compared with 1 pg of 1 kb ladder 
(Invitrogen). Purified DNA was added to the PCR sequencing reaction consisting of
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Region Position Name Sequence
ORF UL73 Outer-sense gN-up8 5 ’ T GGT GT GATGGAGTGGAAC
Outer-antisense gN-lw8 5 ’TAGCCTTTGGTGGTGGTTGC
Inner-sense gN-3 5’GTAGTGGCAGAGAGTTCTGG
Inner-antisense gN-4 5 ’GT ACAATACAAAAAGCTCCC
ORF UL74 Outer-sense gO l1 5 ’ CTCCTCT GT CAT GGGG AG A A A
Inner-sense g02> 5 ’ G AA AG AC A AGT CAT GG A AGG
Outer/Inner-antisense UL74-21 5’GACATTGCTGGATCCAGAACT
TTA
§ (Pignatelli et al, 2003) 
{ (Paterson et al., 2002)
Table 2.4 Oligonucleotide primers used for the amplification of CMV ORF UL73 
and ORF UL74 fragments.
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the following components: purified DNA 3 pi, sterile water 3 pi, inner PCR primers 
(3pmol) 2 pi, and 12 pi Beckman CS sequencing kit mix (Beckman) to a total 
volume of 20 pi.
Sequencing PCR reactions were purified by ethanol precipitation. The 20-pl 
sequencing reaction was added to 5 pi of “stop solution” which consisted of sodium 
acetate, 0.5 M EDTA and glycogen (Beckman) in a ratio of 2:2:1 respectively. To 
this, 60 pi of ice-cold 95% molecular grade ethanol was added and the samples were 
spun at 13,000 rpm at 4°C for 25 min to precipitate the DNA. The DNA pellet was 
washed twice with 200 pi of ice-cold 70% molecular grade ethanol and vacuum 
dried for 10 min. DNA pellets were resuspended in 35 pi of deionized formamide 
and frozen at -20°C until they were loaded onto the automated sequencer.
The Beckman CEQ2000 uses a capillary system to electrophorese the sample 
through a polyacrylamide gel contained inside the capillary. In the sequencing PCR 
mix, chain terminating nucleotide bases labelled with different fluorescent tags are 
present and are incorporated into the DNA during PCR amplification. During 
electrophoresis a laser reads these fluorescent bases to determine the sequence of the 
sample.
2.3.2 Analysis of sequence data
Raw chromatograph data were analysed using SeqMan sequence analysis software 
and multiple alignments were made in Megalign, both programs from the 
LASARGENE sequence analysis package (DNAstar Inc., Madison, WI, USA). A 
Clustel V alignment was produced in Megaline to construct a guide tree using the
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UPGMA method of clustering analysis. Genetic distances were expressed as a 
percent nucleotide divergence over the entire tree.
Further analysis was performed after all sequence data had been collected. Multiple 
alignments were made in Clustel W (Thompson et al, 1994), which is part of the 
BioEdit software package (Hall, 1999). Pairwise alignments were made between 
nucleotide sequences to produce a guide tree estimating the final phylogenetic tree. 
Clustel W alignments were entered into the PHYLIP suite of programs (Felsenstein, 
1993) where further analysis took place. The following programs were used to 
analyse sequence data in PHYLIP: DNADIST and NEIGHBOR.
Alignments were first analysed using SEQBOOT to create 100 to 1000 multiple data 
sets, resampled from the input data set using random sampling methods with 
replacement. Trees generated in SEQBOOT were entered into the CONSENSE 
program and the branching patterns that occurred most frequently were reflected on 
the consensus tree. Values at each node indicate the percentage of trees containing 
each branching pattern and could be used to interpret the robustness of the resulting 
tree.
DNADIST creates a DNA matrix using one of three possible models of substitution; 
Jukes and Cantor (Jukes and Cantor, 1969), Kimura (Kimura, 1980) and a maximum 
likelihood model (Felsenstein, 1981). The Kimura “2-parameter” method is used 
most often and assumes that independent changes occur at all sites with equal 
probability and allows for differences in transition and transversions rates. The 
output format of DNADIST is a matrix where genetic distances between sequences
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are roughly equivalent to percent nucleotide divergence values created using 
Megalign. The genetic distance values between species can be used in other 
programs to estimate branch lengths and draw trees. The Kimura “2-parameter” 
method was used to create distance matrixes from sequence data in this study.
Trees were drawn using the NEIGHBOR program, which utilised either the 
neighbour-joining algorithm (Saitou and Nei, 1987) or the UPGMA method of 
clustering (Sneath and Sokal, 1973). NEIGHBOR creates successive clusters of 
closely related sequences and minimises branch lengths as the lineages join. No 
further rearrangements were made to the tree and because NEIGHBOR does not 
assume an evolutionary clock and the resulting tree is unrooted when viewed in 
TREEVIEW programme.
2.4 Restriction fragment-length polymorphism analysis of PCR 
sequence diversity in products
2.4.1 Amplification of ORF 73 DNA for RFLP analysis
The IRD of HHV-8 ORF 73 was amplified by nested PCR as described in Section 
2.1.9.
2.4.2 Detection of PCR products
PCR products were separated and visualised as described in Section 2.1.10 except 
that samples were run on a 1% agarose gel alongside 1 pg of a 1 kb ladder.
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2.4.3 Restriction digests of PCR products
Digests were carried out in a reaction mixture consisting of 5-7.9 pi of PCR product, 
0.1 pi bovine serum albumin (BSA), 1 pi Buffer C (Promega), 0.5 pi Mbol and 0.5 
pi Banll (Promega), plus nuclease-free water to 10 pi if necessary. Digests were 
heated to 37°C for 1 hr, the optimal temperature for enzyme activity, and at 85°C for 
30 min to inactivate the enzymes. Digests were stored at 4°C until they could be 
separated and visualised on a 2% agarose gel alongside 1 pg of 100 bp ladder 
(Invitrogen) to estimate the size of resulting bands. Digital images of gels were 
captured using the Kodak Digital Science DC40 camera (Zhang et al., 2000; Cook et 
al, 2002a).
2.5 Screening for intrasample K l/V l sequence differences by 
denaturing gradient gel electrophoresis
2.5.1 K l/V l Expand high fidelity PCR
From each person, samples that amplified positively for K l/Vl and for which 
sequences differed between body compartments were subjected again to nested PCR 
using same conditions as in Section 2.1.8 except that 0.7 units of the EXPAND High 
Fidelity PCR System (Roche Diagnostics) were used instead of Taq DNA 
polymerase. Clones were generated from each Kl/V l PCR product by use of the 
TOPO TA Cloning System (Invitrogen) as detailed in Section 2.5.2.
2.5.2 TA cloning
Secondary ORF K1 PCR products were cloned prior to automated DNA sequencing 
using the TOPO TA cloning kit (Invitrogen). This resulted in better quality 
sequencing results, and allowed multiple clones from one sample to be compared-
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thereby ensuring sequence fidelity. During PCR, Taq polymerase will add a single 
adenosine (A) to 3’ end of the PCR product through its non-template dependent 
terminal transferase activity (Marchuk et al., 1991; Shuman, 1994). The PCR4- 
TOPO vector is supplied linearised with the addition of a 3’ thymidine (T) overhang 
to complement the 3’ terminal A of the PCR product. Ligation of vector and PCR 
product occurs through the activity of topoisomerase I, covalently bound to the 
vector (Shuman, 1994). Chemically competent E. coli are used to transform the 
cloning reaction and are grown overnight on L agar (Luria agar: 1.0% tryptone, 5.0% 
yeast extract, 1.0% 0.17 M NaCl, 1.5% agar, pH 7.0) containing 50 mg/ml 
ampicillin.
2.5.3 GC-clamp colony PCR
For each colony, another round of PCR was done under conditions identical to the 
second-round high-fidelity PCR, except that a "clamping" primer was used in place 
of the forward inner sense primer. The clamping primer contains a guanine-cytosine 
rich domain with a high melting temperature, to prevent complete denaturation of the 
PCR product (Woodward et al.y 1994). This primer, Kl-1 clamp, has the following 
sequence:
5’CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGGAGTGATTT
CAACGC
The sequence for the reverse inner sense primer is as described in Table 2.2. Colony 
PCR products were separated and visualised on an agarose gel as described in 
Section 2.1.10.
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2.5.4 Preparing denaturing gradient polyacrylamide gels
Stock solutions of each acrylamide mix were prepared beforehand and cooled to 4°C 
prior to use. For the Kl/Vl colony PCR product, a gel gradient of 30% to 50% 
denaturants was necessary to achieve discrimination to a 1 base pair mutation. The 
50% solution contained 10% acrylamide, 0.6% TRIS-acetate-EDTA (TAE) buffer 
(Invitrogen), 20% formamide and 3.5 M urea. The 30% solution contained 10% 
acrylamide, 0.6X TAE, 12% formamide, and 2.1 M urea. Using a gravity driven 
gradient maker with pump drive (GRI, Braintree, UK), the gradient gel was poured 
using 30 ml of each solution. To allow the gel to polymerise 13 pi of N, N, 1ST, N’ - 
tetramethylethylenediamine (TEMED, Invitrogen) and 250 pi of 10% ammonium 
persulfate per each 30 ml of stock solution were added prior to pouring. A gradient 
gel was pumped between glass plates. A 48-well comb was inserted and the gel was 
left to polymerise for at least 2 hrs.
2.5.5 Loading and electrophoresis
Clamped colony PCR products (2 pi) generated as described in Section 2.5.3 were 
mixed with an equal volume of Orange G loading buffer. After all the samples were 
loaded into the wells, electrophoresis in 0.6X TAE buffer at 60°C and 100 V took 
place over 18 hr. The electrophoresis apparatus allowed for continuous flow of 
buffer to maintain a constant temperature of 60°C throughout the run (Igeny PhorU).
2.5.6 Staining of gels
Gels were stained in a solution of 0.5X SYBR Green I (Flowgen) in 200 ml of 0.6X 
TAE buffer for 20 min to 1 hr. Bands were visualised by ultraviolet transillumination 
and gel images captured using a Kodak Digital Science DC40 camera.
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3.1 Introduction
In Africa, HHV-8 commonly is acquired in childhood. Transmission tends to be 
intrafamilial, and the dominant route is from mother to child as suggested by a 
seroepidemiological survey of 1337 individuals in a village in French Guiana 
(Plancoulaine et al., 2000). Extrafamilial nonsexual transmission also has been 
identified (Cook et al., 2002a; Cook et al., 2002b). Studies among homosexual men 
in North America implicate the mouth and oropharynx as dominant sites of HHV-8 
shedding and saliva as an important vehicle of HHV-8 transmission (Corey et al., 
2002). Two reports show that, in Africa, too, HHV-8 has a predilection to be shed in 
saliva. The first is a study of Egyptian children with acute fever not due to a specific 
viral exanthem (Andreoni et al, 2002). In 86 children studied, 36 (41.9%) were 
HHV-8 seropositive, and HHV-8 DNA sequences could be amplified from saliva of 
11 (30%) compared to 3 (8.3%) in whom sequences could be amplified from plasma 
only. Moreover, HHV-8 DNA was detected in saliva of 6 of 50 HHV-8-seronegative 
children (12%) compared to 2 (4%) in plasma. Thus, children may carry HHV-8 
more in saliva than blood. The second report relates to a study conducted in Malawi 
of asymptomatic family members of patients with KS whose HHV-8 genome 
detection rate was found to be significantly higher in oral than in blood samples: 
HHV-8 DNA sequences could be detected in mouth-rinses of 18 (27%) out of 67 
family members but not in any blood samples (Cook et al., 2002b).
Saliva or saliva-contaminated objects might facilitate the intra- and extrafamilial 
spread of HHV-8 in Africa. Assuming that, in these communities there, the main 
portal of entry of HHV-8 is the mouth, exposure of susceptible persons to the virus is 
likely to begin early in life. Although it is unclear how immunological responses
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generated by the host after first exposure protect against infection from subsequent 
exposures, it would appear that humoral responses may not be neutralizing, because 
HHV-8 can actively replicate in people who are seropositive for the virus (Tedeschi 
et al., 2001). Accordingly, people growing up and living in regions where HHV-8 is 
hyperendemic are potential hosts to multiple HHV-8 strains. This chapter describes 
an investigation into the presence of the HHV-8 genome in blood and several 
different oral compartments, in a group of people residing in Malawi, and an 
evaluation of the extent to which, in each person, the genomes found in one 
compartment diverge from those in another.
3.2 Patients, materials, and methods
3.2.1 Patients and samples
The study group included patients with KS (n = 22) and their first-degree relatives (n 
= 67), a group of subjects described in detail elsewhere (Section 2.1.1 and Table 
2.1). Venous blood and the following oral samples: mouth rinse, throat gargle, and 
palatal exfoliate were obtained. A sampling order of the oral components was 
imposed to minimize cross-contamination between compartments as described in 
Section 2.1.3.
3.2.2 Sample processing
After preparation of the blood samples as described in Section 2.1.2, DNA was 
extracted from the fractionated leukocytes by use of Geneclean III as described in 
Section 2.1.5. Oral samples were prepared as detailed in Section 2.1.3, and DNA was 
extracted by use of the QIAamp kit as described in Section 2.1.6.
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3.2.3 Length polymorphism and RFLP analyses of DNA amplified from the 
ORF 73 internal repeat domain
A nested polymerase chain reaction (PCR) protocol was applied to sample extracts to 
amplify a DNA segment from the IRD of ORF 73, as described in Section 2.1.9. To 
further evaluate sequence polymorphism within IRD, PCR products were visualised 
and digested as described in Sections 2.4.2 and 2.4.3.
3.2.4 Sequencing analyses of DNA amplified from ORFs 26 and K1
The 211-bp KS330 was amplified from sample extracts by use of nested PCR, as 
described in Section 2.1.8. The 246-bp K l/V l was amplified from sample extracts 
by nested PCR, as described in Section 2.1.8. To minimize contamination during 
PCR specific measures were taken as described in Section 2.1.11. PCR products 
were sequenced, raw DNA sequence data were analyzed and phylogenetic analyses 
were performed as detailed in Section 2.3. Chromatograms from some samples, e.g., from 
Patients P and Y, which subsequently showed mixed infection following analysis of their PCR 
clones, did not yield evidence of mixed infection during direct sequencing (i.e., double peaks 
over certain base positions were not clearly evident). The inability of direct sequencing to 
identify mixed infection may be due to the presence of minority sequences that constitute 
<20% of the total population. Past studies have shown that minority sequences require to be 
present at >20% of the population for chromatographic peaks to be evident (Ngui and Teo, 
1997).
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3.2.5 Screening for intrasample K l/V l sequence differences by denaturing 
gradient gel electrophoresis
From each person, samples that amplified positively for Kl/Vl and for which sequences 
differed between body compartments were subjected again to nested PCR by use of the 
EXPAND High Fidelity PCR System as described in Section 2.5.1. Clones were generated 
from each Kl/Vl PCR product as described in Section 2.5.2. For each colony, another round 
of PCR was done using clamping primer as described in Section 2.5.3. The PCR products 
were subjected to DGGE as detailed in Sections 2.5.4 and 2.5.5, followed by 
nucleotide sequencing as described in Sections 2.3.
For the purpose of this study, subgenotypic differences were considered to be 
significant if the divergence between K l/V l sequences was set at ^5% to 
accommodate base incorporation errors due to Taq polymerase error-prone activity. 
Further indication that differences from sequences that show s^5% base variation are 
indeed due to the sequences that originate from distinct virus strains arises from very 
high bootstrap values (>95%) obtained from such sequences.
3.3 Results
3.3.1 Patient and sample characteristics
Table 3.1 summarizes the characteristics of 24 of the 89 people (27%) who were
i
found to carry amplifiable HHV-8 subgenomic DNA in >1 sample. Thirteen (54%) 
of the 24 were male. Patients with index cases of KS are assigned the "i" suffix, and 
their family members were assigned numerals; letters denote family assignments as 
described in Section 2.1.1. Ages ranged between 2 and 44 years (mean, 18 years). 
Seven (29%) patients had KS, 9 (38%) patients were human immunodeficiency virus
| (HIV)-1-seropositive, and 21 (88%) patients were HHV-8 seropositive. The rate of
!
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HHV-8 subgenomic DNA detectability varied according to the type of sample and 
the target of amplification within the HHV-8 genome (Table 3.1). In mouth-rinse 
samples, the detectability rates were 38% for (ORF) 73 internal repeat domain 
(IRD), 75% for KS330, and 92% for Kl/Vl DNA; in throat-gargle samples, the 
detectability rates were 22% for IRD, 48% for KS330, and 70% for K l/V l DNA; in 
palatal-exfoliate samples, the detectability rates were 0% for IRD, 38% for KS330, 
and 50% for K l/V l DNA; and, in blood samples, the detectability rates were 4% for 
IRD, 17% for KS330, and 21% for Kl/Vl DNA. The detectability rates according to 
the number of amplifiable subgenomic DNA segments were as follows: for all 3 
segments, 33% for mouth-rinse samples, 22% for throat-gargle samples, 4% for 
blood samples, and 0% for palatal-exfoliate samples; with at least 2 segments, 42% 
for mouth-rinse samples, 26% for throat-gargle samples, 21% for palatal-exfoliate 
samples, and 13% for blood sample; and, with at least 1 segment, 46% for palatal- 
exfoliate samples, 22% for throat-gargle samples, 21% for mouth-rinse samples, and 
4% for blood samples.
3.3.2 IRD length polymorphism detected by RFLP analysis
Figure 3.1 illustrates electrophoretic banding patterns of IRD PCR products derived 
from 5 people from whom products could be amplified from >1 sample. Length 
polymorphisms of the products are displayed in the upper panel, whereas RFLPs are 
shown in the lower panel. Intraperson length polymorphism and RFLP were absent 
in all patients except 1, T2, in whom the IRD amplicons generated from his mouth- 
rinse and throat-gargle samples were polymorphic for length, both without and with 
Banll and Mbo\ restriction.
I l l
Patient Age/sex
Anti HHV-8 
serostatus
Anti HIV 
serostatus
Mouth rinse Gargle Palate Blood
IRD KS330 Kl/Vl IRD KS330 Kl/Vl IRD KS330 Kl/Vl IRD KS330 Kl/Vl
B5 7y/M + - - + + - - - - + + - - -
Ci 8y/M + + + + + + + + - + - - - -
Ei 3 ly/F + + - - + - + + - - - + +
E4 9y/F + - - + + - + + - - - - - -
E6 6y/F + - - + + - + + - - - - - -
f i 2y/M + + + - - - + + - + 0 - + a
23y/M + - + + 0 + + B - - - - - -
H2 12y/M + - - + + - - + - - + - - -
11 1 ly/F - - - - + - - B - - + - - -
yjy 30y/F + + + + + - - - - + + - + +
K1 12y/M - - - -f + - - - - + + - - -
0 28y/F + + - + B - - + - - 0 - - -
Q> 24y/F + + - + + - - - - - - + + +
[ 1 lly/M + - + + B + + B - + - - - -
T3 9y/M + - + + + - - + - - - - - -
W1 36y/M + + - + + - + + - - - - - -
|W2| 20y/M + - + + B - + B - - - - - -
W4 13y/F + - + + + + + + - + - - -
jxl] 44y/M + + + -f + + + 0 - + - - -
UJ 32y/M + - - - + - - - - B - - -
Y1 38y/F + - - - - - - + - - + - - -
Y2 8y/F - - - - + - - - - - + - - -
Zi 2y/M + + - + + nd nd nd - - + - - +
22 22y/F + - + + - - - - + + - - -
Table 3.1 Patient’s demographic and virological characteristics. Anti-HHV-8 serostatus had been previously determined by anti HHV-8 IgG 
immunofluorescence assay (Cook et al 2002b). Anti-HIV status had previously been determined by anti-HIV particle assay (Cook et al 2002b). 
ND, not done. Samples from individuals whose Kl/Vl sequences were further studied (summarized in Figures 3.4, 3.5, and 3.6, and 3.7) are 
boxed. Sites affected by KS in patients with KS: Ci, abdomen and limbs; Ei, legs and palate; Fi, foot; Ki, leg; Qi, foot; Yi, arm; Zi, neck.
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Cir Cig G2r G2g T2r T2g X lr  X lg  W 4rW 4g
Figure 3.1 Gel-electrophoretic length polymorphisms of internal repeat domain 
amplicons without (A) and with (B) restriction by Mbo\ and BanW. DNA marker 
bands (1Kb) for (A) and (100 bp) for (B) are shown on the left. Letters after patient 
identifiers: g, gargle; r, rinse.
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3.3.3 Differences in KS330 consensus sequences
For 16 people, KS330 DNA could be amplified from at least 2 samples, and, for 6 
people (Ci, Fi, Ki, T2, W4 and XI), KS330 DNA was amplifiable from 3 samples. 
The sequences, which are deposited in GenBank (accession nos. 
AY219429-AY219458), cluster with ORF 26 sequences of known African HHV-8 
strains (Poole et al, 1999). Identical KS330 sequences were observed in the samples 
from 9 people (B5, Ci, E6, Fi, G2, K l, W2, XI, and Z2). Non identical sequences 
were found in samples from 4 subjects (Ei, E4, Qi, and W l). Identical and non 
identical sequences were observed in samples from 3 subjects (Ki, T2 and W4). A 
phylogenetic tree displaying the variation in consensus KS330 sequences among the 
samples is shown in Figure 3.2. For all subjects with non identical sequences in 
samples, intraperson divergences were <3%, and the sequences were genotypically 
identical except for one person, Ei, the sequence from the blood sample was 4.6% 
divergent from that from the throat-gargle sample, and their genotype assignments 
were different: genotype B/C for the blood sequence and genotype B for the throat- 
gargle sequence.
3.3.4 Differences in K l/V l consensus sequences
For 24 people, K l/V l DNA could be amplified from at least 2 samples. K l/Vl 
sequences were identical between at least 2 samples from 8 people (E6, H2, Ki, K l, 
PI, XI, Zi and Z2); for 1 person, Zi, sequences in 3 samples (mouth rinse, palatal 
exfoliate, and blood) were identical. Nonidentical sequences were found in samples 
from 16 people, with intraperson divergences ranging from 0.6% (between the 
mouth-rinse and throat-gargle samples of E4) to 28.9% (between the palatal- 
exfoliate and throat-gargle samples of Yl). A phylogenetic tree displaying the
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Figure 3.2 Predicted phylogenetic distribution of consensus KS330 sequences 
derived from blood and oral samples from 16 people. Bootstrapping for 1000 
replicates is noted as a percentage at major branch points. Horizontal line at bottom 
left represents 1% nt substitution for that horizontal branch length. Letters after 
patient identifiers: b, blood; g, gargle; p, palate; r, rinse.
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variation in consensus Kl/Vl sequences among the samples is shown in Figure 3.3. 
The sequences primarily cluster with those reported from African patients with KS 
(Poole et al., 1999; Cook et al., 2002b) and have been deposited in GenBank
(accession nos. AY219483 AY219535). Seven of the 16 people with nonidentical
intraperson K l/V l sequences yielded samples that carried sequences belonging to 2 
genotypes. These were the palatal- exfoliate and blood samples from Fi (A2 and B, 
respectively); mouth-rinse and throat-gargle samples from T3 (B and A2,
respectively); mouth-rinse and throat-gargle samples from W2 (B and A2,
respectively); throat-gargle and palatal-exfoliate samples from Y1 (A2 and B, 
respectively); and mouth-rinse and palatal-exfoliate samples from Y2 (A2 and A5, 
respectively). For Ki, the identical sequences from her blood and mouth-rinse 
samples (genotype A5) were different than those from her palatal-exfoliate sample 
(genotype A2), whereas for PI, the identical sequences from her mouth-rinse and 
throat-gargle samples (genotype A5) were different to those from her palatal- 
exfoliate sample (genotype B). For 1 other person, 12, K l/V l sequences belonged to 
3 genotypes (mouth rinse, Al; throat gargle, B; and palatal exfoliate, C2). For 3 
people whose samples were found to carry nonidentical sequences of the same 
genotype (all genotype B), intraperson/intersample sequences were >5% divergent: 
Cir/Cig (5.4%), T2g/T2r (5.4%), and Yir/Yip (5.9%).
3.3.5 Clonal analysis of intraperson/intersample K l/V l sequence differences
High-fidelity PCR of sample extracts from 9 people (Fi, G 2 ,12, Ki, PI, T2, W2, XI, 
and Yi) yielded K l/V l DNA. Clones were generated from which differences in 
nucleotide sequence could be analyzed by the combined DGGE-sequencing 
approach. Figure 3.4 is a composite of representative DGGE gel pictures showing
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Figure 3.3 Predicted phylogenetic method 
distribution of consensus KlA^l sequences derived 
from blood and oral samples from 24 people. 
Samples from individuals whose Kl/Vl sequences 
were further studied (summarized in Figures 3.4, 
3.5, 3.6, and 3.7) are boxed. Bootstrapping for 1000 
replicates is noted as a percentage at major branch 
points. Horizontal line at bottom left represents 10% 
nt substitution for that horizontal branch length. 
Letters after patient identifiers: b, blood; g, gargle; 
p, palate; r, rinse.
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Figure 3.4 Composite of 9 representative DGGE gel photographs. Each gel accommodates, for 
a given individual, Kl/Vl DNA amplified from up to 15 Kl/Vl clones generated per sample. 
Dots at bottom indicate polymerase chain reaction products that underwent sequencing; 
numerals indicate lane positions in the gel.
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migration distances achieved by amplicons generated from clonal inserts; each gel 
accommodates, for a given person, Kl/Vl DNA derived from up to 15 
clones/sample. All PCR products that yielded minority banding positions and some 
products representing the majority were sequenced (denoted by dots in Figure 3.4; 
numerals correspond to lane positions in the gel illustrated). Figure 3.5 is a 
nonrooted phylogenetic tree depicting the extent of intersample Kl/V l nucleotide 
sequence diversity. Sequences derived from the PCR clones have been deposited in 
GenBank (accession nos. AY220915-AY220981). Figure 3.6 shows an alignment of 
a stretch of amino acid sequences predicted from the nucleotide sequences studied. 
DGGE and nucleotide sequencing analyses confirm findings from direct Kl/Vl PCR 
sequencing that >1 genotype was carried by Fi, 12, Ki, PI and W2. Analysis of 
clones from minority sequences permitted intrasample K l/V l variability to be 
further characterized from individual samples. For the mouth-rinse sample from 12, 
the existence of a group of minority sequences comprising I2r 5 and 8 became 
evident, with both being 6.4% divergent from the majority sequence I2r4; all 3 
sequences belonged to genotype B. In addition, a small population of closely related 
genotype Al sequences (I2r 1,3, 13, and 14) was identifiable.
For Ki and PI, the presence of minority sequences belonging to genotypes not 
evident after direct sequencing could be revealed. In the mouth-rinse sample from 
Ki, the genotype of the minority sequences Kir 8/10 and 9 (B) was different than that 
of the majority sequence Kir 4 (A5). Similarly, from her palatal-exfoliate sample, the 
genotype of a set of related minority sequences Kip 17, 23, and 27 (A2) and of a 
unique sequence, Kip 29 (B), were different than that of the dominant sequence, Kip 
19 (A5). The 2 genotype B mouth-rinse nucleotide sequences, Kir 8/10 and 9, were
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Figure 3.5 Radical unrooted phylogenetic tree of sequences amplified from PCR 
clones with Kl/Vl inserts. Sequences are derived from blood and oral samples from 
9 people. Horizontal line at top left represents 10% nt substitution for that horizontal 
branch length. Letters after patient identifiers: b, blood; g, gargle; p, palate; r, rinse.
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5.0% and 5.4% divergent, respectively, from Kip 29 (Figure 3.5). There were, thus, 
a total of 4 different groups of sequences that originated from Ki's mouth-rinse and 
palatal-exfoliate samples. From the palatal-exfoliate sample of PI, an additional 
genotype (A5) could be assigned to a population of clones bearing the P ip 16/24/29 
sequence, contrasting with the genotype (B) assigned to the majority sequence (Pip 
17).
For 2 people, XI and Yi, direct sequencing of K l/V l from their samples generated 
sequences assignable as genotype B, but, for each person, clonal analysis revealed 
carriage of minority sequences belonging to another genotype. For the throat-gargle 
sample from XI, this was A5 (assigned to Xlg28); and for the palatal-exfoliate 
sample from Yi, it was A2 (assigned to sequences typified by Yip 17/28, 20, 21/26 
and 27/29). Xl's mouth-rinse sample carried the following minority sequences: 
Xlr6; and a closely related group of sequences, X Ir 3/11, 9, and 13, which were all 
5.0% divergent from Xlr6.
For T2, although direct sequencing yielded genotype B sequences from both his 
mouth-rinse and throat-gargle samples, analysis of the clones generated revealed that 
each sample carried its own distinct set of sequences: T2r 9 and 15 from the mouth- 
rinse sample, and T2g 16/18/24, 20, and 22 from the throat-gargle sample; the latter 
sequences were 5.9%, 6.4%, and 6.4% divergent, respectively, from T2r 9. The intra- 
and intersample distribution of genotypes and subgenotypically distinct sequences 
recovered from the 9 people described here is summarized in Figure 3.7.
122
Chapter 3 Intra-Person Oral HHV-8 Infection
Person
Sample
No genotypes 
Per sample Per person
No sequences with 
£5% divergence
Per sample Per person
Fi palate 1(A2) > 2 1 > 2blood 1(B) J 2 1 J 2
G2 rinse 1(A5) 1 ~u,
gargle 1(A5) S ' 1 S '
12 rinse 2 (A l, B) X 3 X
gargle 1(B) b 1 bpalate 1(C2) J 1 j
Ki rinse 2 (A5, B) >3 2
palate 3 (A2, A5, B) s 3 J 4
PI rinse 1 (A5) > 2 1 >2palate 2 (A5, B) J 2 2 J 2
T2 rinse 1(B) 1 > 2gargle 1(B) S ' 1 J 2
W2 rinse 1(B) > 2 1 >2gargle 2 (A2, B) J 2 2 J 2
XI rinse 1(B) > 2 2gargle 2 (A5, B) J 2 2 s
Yi rinse 1(B) > 2 1 > 3palate 2 (A2, B) J 2 2 S i
Figure 3.7 Intrasample and intraperson distribution of genotypically and 
subgenotypically distinct K l/Vl sequences.
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Possible linkages between the KS330 and K1 /VI genotypes (as determined by direct 
sequencing) were analyzed (Table 3.2): The KS330 B/C genotype was linked to the 
Kl/V l genotype B in 15 patients and to the Kl/Vl genotype in 20 patients. The 
KS330 genotype B was linked to the Kl/Vl genotype B in 7 patients, to the Kl/Vl 
genotype A2 in 2 patients and to the Kl/Vl genotype A5 in 6 patients.
3.4 Discussion
Multiple HHV-8 infection rarely has been considered. A study of different HHV-8 
DNA loci in 63 KS and PEL patients samples, showing that 13 had intertypic 
recombinations provided evidence of putative recombinant HHV-8 genomes (Poole 
et al., 1999), assuming dual infection in at least a single host cell. Most studies of 
humans who have developed KS (Stebbing et al., 2001; Meng et al., 2001; Zong et 
al., 2002) or multiple HHV-8-associated lesions (Codish et al, 2000) have not 
shown intraperson variation in HHV-8 subgenomic sequences amplified by PCR 
from blood and lesional tissues.
Gao et al. (1999) reported that, of 27 KS lesional samples studied, 2 were dually 
infected. Otherwise, there are no reports of mixed HHV-8 infection. This paucity 
may be due to a combination of factors. First, samples from homosexual men favor 
hosts who are exposed to HHV-8 later in life, rather than early in childhood, and 
favor HHV-8 strains transmitted via sexual routes, rather than those transmitted 
nonsexually within the household or community. Second, previous studies have been 
largely confined to patients with KS or patients who are at risk of developing KS. 
When sequence polymorphism of subgenomic HHV-8 DNA in the blood is sought 
from such people, the tendency is for none to be found, particularly when consensus
124
Chapter 3 Intra-Person Oral HHV-8 Infection
Patient sample KS330 genotype K l/V l genotype
B5r B/C B
B5p B/C B
Cig B/C B
Cir B/C B
Eig B B
Eib B/C B
E4r B/C B
E4g B/C B
E6r B/C B
E6g B/C B
Fib B/C B
Fip B/C A2
G2r B A2
G2g B A2
Kir B A5
Kib B A5
K ir B A5
K ip B A5
Qir B B
Qib B B
T2r B/C B
T2g B/C B
W lr B B
W ig B B
W2r B/C B
W2g B/C A2
W4r B/C B
W4g B/C B
X lr B B
X lg B B
Z2r B A5
Z2p B A5
Table 3.2 Linkage analysis of KS330 and K l/V l genotypes.
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sequencing is applied, because the high HHV-8 genome load (Tedeschi et al, 2001) 
favors the generation of sequences reflecting the dominant variants. When sequence 
polymorphism in KS lesional tissues is sought, it is also likely that none will be 
found, not because of the high viral genome load (Lallemand et al., 2000; Bezold et 
al, 2001) but because KS is largely a clonal tumor (Rabkin et al, 1997; Judde et al, 
2000). Third, in previous studies examining for HHV-8 genomic polymorphisms, the 
PCR products were directly amplified from the samples (Gao et al, 1999; Poole et 
al, 1999; Codish et a l, 2000; Stebbing et al, 2001; Meng et al, 2001; Zong et al, 
2002); in doing so, the existence of minor virus populations would have been 
revealed only if they constituted a relatively large fraction (>20%) of the entire 
population (Ngui and Teo, 1997). When consensus sequencing protocols are applied, 
the sequence information obtained will not differentiate minority sequences from the 
sequence of the dominant variant.
The present study focuses on whether intrahost HHV-8 subgenomic sequence 
polymorphism exists among and within oral and blood samples of Malawian 
individuals with and without KS and the extent of such polymorphism. This group of 
HHV-8-infected people is a subset of a population whose characteristics and 
possible routes of HHV-8 acquisition have been described elsewhere (Cook et al, 
2002a; Cook et al, 2002b). Although the report by Cook et al. (2002b) focused on 
interperson HHV-8 subgenomic sequence variation, the present study focuses on 
intraperson variation. Accordingly, sequence polymorphism data from 2 other oral 
components, in addition to the mouth-rinse sample (which principally permits 
characterization of HHV-8 carried in the nonkeratinized oral compartment), are 
presented here: the throat-gargle sample, to reflect HHV-8 carried predominantly in
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the pharyngeal compartment, and the palatal-exfoliate sample, which has 
consistently been shown in HIV-coinfected people to be the most common site of 
development for KS (Flaitz et al, 1997; Gorsky and Epstein, 2000), suggesting that 
HHV-8 might be particularly tropic for this anatomical site. These 2 other oral 
samples were collected at the same time as the blood and mouth-rinse samples.
The study presented in this chapter is limited by several factors. The first is the 
variability in PCR amplification yields from the various samples. This variability 
depends on the type of sample examined. That mouth-rinse and throat-gargle 
samples yielded higher amplification rates than did blood and palatal-exfoliate 
samples probably reflects active HHV-8 replication in the oral epithelium other than 
the hard palate, the high load of shedding into the oral cavity (Pauk et al., 2000), and 
the possible lower replicative activity of the virus systemically and in the palatal 
mucosa. Blood samples yielded HHV-8 subgenomic amplicons in a substantial 
proportion of patients with KS but not at all in those without KS. This result 
confirms previous data (Cook et al, 2002b) showing that, in HHV-8 infected 
African people not affected by KS, the virus is not shed into the circulation to a 
significant extent and that the principal site of viral shedding is the mouth. 
Variability in amplification rates also depended on the region within the HHV-8 
genome to be amplified. Higher yields from KS330 and K l/V l, rather than from the 
IRD, are due to the much longer amplicon that needs to be generated to permit 
subsequent analyses.
A further limiting factor was the difference in the degree to which the 3 approaches 
permitted evaluation of subgenomic HHV-8 sequence differences. Analysis of length
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polymorphisms in IRD amplicons was the least efficient approach to discriminating 
between HHV-8 variants, because of its dependence on the number of repeat 
sequences in the IRD and on the presence of restriction sites, both of which are few. 
Less finite are the individual nucleotide positions that differ between viral variants. 
Direct sequencing studies of a highly variable region, such as K l/V l, yield data that 
discriminate between variants better than one that is more conserved, such as KS330. 
KS330 sequence polymorphism generally does not provide sufficient resolution for 
inferences of HHV-8 genotype and strain variation to be made. Nevertheless, KS330 
sequence studies potentially provide useful information on genotype differences if 
variations are sufficiently wide and, furthermore, generate data that control for 
artifactual sequence differences due to PCR-induced nucleotide misincorporation.
Direct sequencing studies have an important limitation in that they are able to 
produce consensus sequence data that will not allow sequences of minority variants 
to be identified and characterized. Accordingly, the combined DGGE nucleotide 
sequencing protocol was developed and applied to K W 1 amplicons generated from 
clonal inserts. This approach, presents the third limiting factor. To reduce the degree 
to which PCR induces nucleotide misincorporation, which may lead to false 
representations of natural intraperson/intersample sequence polymorphism, high- 
fidelity PCR was applied to sample extracts. High-fidelity PCR was, however, 
relatively inefficient in generating the amplicons. This explains why, of extracts 
from the 24 people from whom intersample K l/V l sequence differences could be 
evaluated by direct sequencing, K l/Vl amplicons were generated from sample 
extracts from only 9 people.
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Evidence is provided here of multiple HHV-8 infection in a substantial proportion 
(60%) of the 24 Malawian people studied. The evidence was derived from 
intraperson genotype and subgenotype sequence differences found among and within 
samples. Genotypic differences are clear between the blood and oral samples from 3 
patients with KS: for Ei, from whom KS330 sequences were genotypically distinct; 
and for Fi and Ki, from whom Kl/Vl sequences were genotypically distinct. For 4 
other patients with KS, sequence variations in KS330 or K l/V l, or both, in blood 
and oral samples were either absent (for Zi) or not different enough to permit 
genotypic or subgenotypic discrimination (for Ci, Ei, and Qi). Because HHV-8 
genomic sequences carried in blood and oral samples from these 7 patients with KS 
could be either genotypically identical or different, conclusions cannot be drawn 
about the selective tropism of HHV-8 strains. Current evidence from other studies 
suggests that HHV-8 exhibits broad tropism (Dupin et al, 1999; Pauk et al, 2000; 
Blackboum et a l, 2000).
Evidence for the oral carriage of multiple strains of HHV-8 can be found for 16 
people using direct sequencing data on KS330, K l/V l and IRD length 
polymorphism or combination of them, 4 (Ci, Ei, Ki and Yi) with KS and 12 (B5, 
E4, 12, G2, PI, T2, T3, W l, W2, W4, Yl, and Y2) without KS. In 8 people, 
intersample genotype differences are clearly discernible in oral samples: for T2, from 
IRD length polymorphism findings; and for 12, Ki, PI, T3, W2, Y l, and Y2, from 
direct sequencing data on K l/V l. Of particular interest are the 3 samples from 12, 
each of which yielded K l/V l sequences belonging to a different genotype. Analyses 
of data from PCR clones revealed genotypic differences in individual samples from 
12 (mouth rinse), Ki (mouth rinse and palatal exfoliate), PI (palatal exfoliate), W2
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(throat gargle), XI (throat gargle), and Yi (palatal exfoliate). Sequences belonging to
3 different genotypes were found in the palatal-exfoliate sample from Ki.
For 2 people whose oral samples yielded genotypically identical but distinct HHV-8 
variants, clonal analyses further revealed subgenotypic differences: for T2, in mouth- 
rinse and throat-gargle samples; and for Yi, in palatal-exfoliate sample. For 2 other 
people whose oral samples yielded genotypically identical HHV-8 variants, analysis 
of PCR clones also revealed subgenotypic differences: for G2, in mouth-rinse 
sample; and for XI, in the mouth-rinse and throat-gargle samples. Whether, for these
4 people, the distinct but closely related variants originated from founder strains that 
underwent genetic drift after infection or were introduced at different exposure time 
points cannot yet be determined.
HHV-8 DNA could be detected in oral samples from 3 anti-HHV-8-seronegative 
people (12, KI, and Y2). All 3 subjects were children and were anti-HIV-1 
seronegative (Table 3.1). It is likely that the samples were obtained at the early phase 
of primary HHV-8 infection (before anti-HHV-8 is mounted to a detectable extent), 
but follow-up testing of the anti-HHV-8 serostatus would need to be done to monitor 
for HHV-8 seroconversion. That the KIW I amplicons obtained from these children 
were not due to PCR-related contamination is suggested by the uniqueness of KIWI 
sequences derived from I2's mouth-rinse, throat-gargle, and palatal-exfoliate 
samples, and Y2's mouth-rinse and palatal-exfoliate samples (Figure 3.3). The 
sequence derived from Kl's mouth-rinse and palatal-exfoliate samples was identical 
to that from the blood and mouth-rinse samples from Ki, his mother, a result that is 
consistent with the dynamics of intrafamilial transmission (Cook et al., 2002b).
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Although there is constant mixing of cellular components and secreted fluids from 
various anatomical compartments in the mouth and the oropharynx, the mouth-rinse, 
throat-gargle, and palatal-exfoliate samples may be considered to hold cells and 
fluids that originate from different compartments. This study determined that each of 
the compartments sampled can harbor distinct HHV-8 strains, suggesting that 
different strains may preferentially persist and replicate in different cell types. Why 
this is so remains unclear. The roles played by sequential exposure to HHV-8, 
differences in inoculation routes, inter- and intraspecies viral interference, difference 
in anatomical site susceptibility to dissemination of HHV-8 from other body sites, 
systemic and local immune responses, and coexisting oral diseases require further 
investigation.
The findings in regard to possible KS330-K1/V1 linkages show that the KS330 B/C 
genotype tends to be associated with the Kl/Vl genotypes B and A5 almost equally. 
Furthermore, the KS330 genotype B was linked almost equally to the Kl/Vl 
genotypes B and A5 (Table 3.2). Such findings do not suggest that there is linkage 
disequilibrium between these combinations, merely that KS330 genotypes B/C and 
B, and Kl/V l genotypes B and A5 are equally prevalent in the population studied. 
To determine if these associations are due to past recombination events, it would be 
necessary to study larger populations to assess if the linkages observed hold true in 
the presence of rarer genotypes identified.
The present study was confined to examination of HHV-8 carried in the blood and 
the mouth. Sampling of other body sites might reveal yet more evidence of multiple 
HHV-8 carriage. Multiple oral infection by other herpesviruses, e.g., CMV (Bar et
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ah, 2001) and EBV (Triantos et al., 1998) has been reported, but mainly in people 
who have been immunosuppressed. The present findings show that apparently 
healthy people in regions where HHV-8 is hyperendemic can be multiply infected by 
HHV-8.
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4.1 Introduction
The previous chapter describes an investigation into how HHV-8 spreads in a 
hyperendemic geographical setting (Malawi). Polymorphisms in HHV-8 subgenomic 
sequences amplified from oral and blood samples of patients with KS and their 
family members were characterised. It was revealed that in up to 60% of the study 
individuals, HHV-8 in oral but not blood samples were multitypic. The diversity of 
HHV-8 shed in urine is unknown, however.
Urine is another body fluid into which HHV-8 is shed. Cattani et al. (1999) studied 
the HHV-8 genoprevalence in central and southern Italy and found that of 24 urine 
samples collected from KS patients only 2 (8.3%) tested positive for HHV-8 DNA. 
In a study conducted by Pauk et al. (2000) of 101 urethral swabs from American 
men who had sex with men, 2 tested (2%) positive for HHV-8 DNA, one from an 
HIV-seropositive and the other from a seronegative person. These studies implicate 
the genitourinary tract as a possible but rare site of HHV-8 infection and persistence. 
Whether urinary HHV-8 shedding is that rare in Africa is not known. This chapter 
describes an investigation into the prevalence of HHV-8 shedding in urine, and into 
whether, like oral fluid, urine can carry multitypic HHV-8. This study evaluated, in 
particular, the extent of sequence variation in PCR amplicons derived from ORF KI 
of the HHV-8 genome. Where possible, it also compared the spectrum of urinary 
HHV-8 sequences with that of the sequences of orally shed HHV-8 derived from the 
same individual.
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4.2 Materials and methods
78 people from whom mid-stream urine could be collected (19 Malawian patients 
with KS and 59 of their first-degree relatives without KS), a subset of the study 
group detailed in Section 2.1.1, were studied. Urine samples were processed as 
described in Section 2.1.4. Nucleic acid in the cellular fraction of urine was extracted 
as described in Section 2.1.7. Nested PCR was applied to the extract to amplify the 
211-bp KS330 DNA segment of ORF 26 as detailed in Section 2.1.8. Nested PCR 
was also applied to the extract to amplify the 246-bp K l/V l DNA segment of ORF 
KI, as detailed in Section 2.1.8. For sequence polymorphism studies, DNA extracts 
from the urine and rinse samples were subjected to nested PCR using the EXPAND 
High Fidelity PCR System to amplify Kl/Vl DNA as described in Section 2.5.1. 
Clones were then generated from each Kl/Vl PCR product as described in Section 
2.5.2. Another round of PCR was carried out using GC-clamp primers as described 
in Section 2.5.3. Finally, the PCR products were subjected to DGGE followed by 
nucleotide sequencing, raw DNA sequence data analyzed and phylogenetic analyses 
performed as described in Sections 2.3 and 2.5.4.
4.3 Results
4.3.1 Patients and samples
From urine samples of 78 people, HHV-8 DNA (KS330 or K l/V l) was amplifiable 
in 2/20 (10%) patients with KS (Ni, Ui) and 4/58 family members (B5, G2,I1,P1) 
(7%) (overall rate: 7.7%) (Table 4.1). B5, G2 and PI had previously been identified 
to carry amplifiable K l/V l DNA and KS330 DNA in the mouth rinse (Table 3.1). It 
is noted that B5, G2 and II were seronegative, while Ni, PI and Ui were seropositive 
for HIV-1 (Table 2.1).
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Patient Age/gender HHV-8 KS330 HHV-8 OFJFK1
mouth rinse urine mouth rinse urine
B5 7y/M + — + +
G2 23y/M + + + +
11 12y/M — — — +
Ni 30y/F + — — +
PI 28y/F + + + —
Ui 32y/F + — — +
Table 4.1 Detectability results of KS330 or ORF Kl/V l DNA for mouth rinse and 
urine samples of individuals from whom at least one sample yielded amplifiable 
HHV-8 DNA.
136
Chapter 4 Inter- And Intra Person Urinary HHV-8 Infection
In the assessment to determine the spectrum of KS330 and Kl/V l sequences in the 
urine of these individuals, the sequence of their rinse samples were also included for 
analysis. Samples follow the identification system described in Section 2.1.1.
4.3.2 Polymorphism of KS330 sequences
For two people G2 (male, 23 y) and PI (female, 28 y), KS330 DNA could be 
amplified from their urine samples. These sequences were identical to those of their 
corresponding mouth rinses. All sequences belonged to the B genotype.
4.3.3 Polymorphism of K l/V l sequences
Five individuals who carried urinary Kl/Vl DNA were identified as B5 (male, 7 y), 
G2, II (male, 12 y), Ni (female, 30 y) and Ui (female, 32 y). B5 and G2 direct 
sequences were non-identical from those in their corresponding mouth rinses. The 
sequence present in urine sample of B5 (B5u) belonged to A5 genotype while that in 
rinse (B5r) belonged to B genotype, and G2r belonged to A5 genotype while G2u 
belonged to A2 genotype.
Figure 4.1 is a composite of representative DGGE gel pictures showing migration 
distances attained by the Kl/V l amplicons (DNA bands were revealed following 
SYBR Green I staining and ultraviolet transillumination). All PCR products yielding 
minority banding positions and some products representing the majority were 
sequenced (denoted by dots in Figure 4.1; numerals correspond to lane positions in 
the gel illustrated).
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Il-u rine  Ui-urine Ni-urine
•  •  •  • • • • • • • • •  •  •  •
3 8 13 3 6 8 1011 13 14 1 2 6 10 13
B5-rinse B5-urine
•  •  • • • • • • • • • • • • •  •  • •  •
1 3 5 6 7 8 9 10 11 12 13 1 4151  3 7 10 11 14
G2-rinse G 2-urine
•  •  •  • • •  • • •
1 4  10 1 4  6 11 12 14
Figure 4.1 Composite of 3 representative DGGE gel photographs. Each panel 
represents one gel. Each gel accommodated, for a given study individual, Kl/Vl 
amplified from up to 15 Kl/Vl clones generated per sample. PCR products that 
underwent sequencing are indicated by dots at bottom; numerals indicate lane in the 
gel.
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The extent of intra- and inter-sample Kl/Vl nucleotide sequence diversity is 
depicted in Figure 4.2. Sequences have been deposited in GenBank (Accession 
Numbers AY328315-AY328357). An amino acid alignment to illustrate the extent of 
intra- and inter-sample K l/V l sequences diversity is shown in Figure 4.3, and the 
total number of genotypes per study individual is summarized in Figure 4.4.
The sequences of the Kl/V l clones originating from the urine samples of the 5 
individuals belonged to single genotypes (B5 to genotype A5; G2 and II to genotype 
A2; and Ni and Ui to genotype B). The ranges of intra-sample nucleotide divergence 
were as follows: 0.9%-1.9% for B5, 0%-0.9% for G2, 0% for II, 0%-0.9% for Ni, 
and 0.5%-3.4% for Ui. For B5, the monotypy and the narrow divergence of the 
variants in the urine contrasted with the multitypy as well as the wide intra-typic 
divergences found in his rinse. K l/Vl sequences in the rinse segregated to 3 
genotypes (A2, A5 and B) (Figures 4.2, 4.3 and 4.4). Within the genotype A2 
cluster, divergences were 0.9%-3.9%, and within the genotype B cluster, they were 
0.9%-14.5%.
4.4 Discussion
The study described in this chapter reveals that the rate of HHV-8 DNA detection in 
urine samples of the patient group to be low: only 6 out of 78 (7.7%) tested positive 
for HHV-8 DNA. Four individuals (B5, II, Ni and Ui) (5.14%) were positive for 
K l/V l, one (PI) (1.3%) positive for KS330, and one (G2) (1.3%) positive for both 
Kl/Vl and KS330.
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B5rl
BSrlOB5r3
B 5rl4
A5
B5rl3.
A2B5r9
Figure 4.2 Radical unrooted phylogenetic tree of sequences amplified from PCR 
clones with K l/V l inserts. Sequences were derived from urine and mouth rinse (u = 
urine; r = rinse). Bootstrapping for 1000 replicates is noted as a percentage at major 
branch points. Horizontal line at top left represents 10% nucleotide substitution for 
that horizontal branch length.
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Figure 4.3 Alignment of amino acid sequences predicted from Kl/Vl sequences 
depicted in Figure 4.2. The variable 1 (VI) region is indicated at top. Dots indicate 
residues occupying positions aligned to residues of Ilu 3/8/13 at top. Positions at 
which residues have undergone intraperson/intersample and intraperson/intrasample 
changes are highlighted.
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Person Sample
No.of genotypes
Per sample Per person
B5 Rinse 3(B,A2,A5) 1-3
Urine 1(A5) J  3
G2 Rinse 1(A5)
Urine 1(A2) J 2
11 Urine 1(A2) 1
Ni Urine 1(B) 1
Ui Urine 1(B) 1
Figure 4.4 Intrasample and intraperson distribution of K l/V l genotypes.
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This low rate of detection is comparable to that reported from Italy and America 
(Cattani et al, 1999; Pauk et al., 2000), and contrasts with the high rate of urinary 
shedding of CMV. Shen et al. (1993b) for example, reported that of 63 Taiwanian 
children enrolled in kindergarten, 27 (43%) shed CMV into urine. The extent of 
environmental contamination by urinary HHV-8 in African locales may nonetheless 
be significant, considering that sanitary conditions there are poor and the rate of 
childhood HHV-8 infection is high.
Polymorphism studies were confined to Kl/Vl DNA. The data from Chapter 3 have 
shown that the IRD ORF73 and KS330 region do not yield sufficiently 
discriminating sequence polymorphism results for strain-to-strain HHV-8 
differentiation. Accordingly sequence polymorphism in the KS330 DNA amplified 
from urine samples was not further investigated here.
Kl/V l intra-sample nucleotide divergences in urine ranged from 0% for II to 3.4 for 
Ui. This narrow intra-typic divergence reflects either natural genetic drift or PCR- 
induced misincorporation, and is consistent with sequences in each sample having 
originated from a single founder variant. Urinary HHV-8 was found to be 
monotypic: K l/V l DNA of B5 belonged to A5 genotype, G2 and II belonged to A2 
genotype, and Ni and Ui belonged to B genotype. It has already been noted that 
HHV-8 in oral fluid may be multitypic: thus, Kl/Vl DNA sequences amplified from 
the mouth rinse of B5 belonged to three genotypes (B, A2, A5) (Figure 4.4). The 
monotypy of urinary HHV-8 contrasts with that situation, and may reflect fewer 
opportunities for direct inoculation into, or smaller variety of sites supporting HHV-
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8 persistence in, or poorer disposition towards preferential infection of selected 
variants in the genitourinary than the oral mucosa.
The genotype of HHV-8 shed in urine was also observed to be different from that 
shed into the mouth. For G2, the genotype of the single K l/V l sequence obtained 
from the mouth (A5) was different from that of the urinary cluster of sequences 
(A2), again suggesting segregation. All of the K l/V l sequences in B5's rinse, except 
for one sequence, B5rl3, clustered separately from the urinary sequences (Figure
4.2). Such findings suggest segregation of HHV-8 variants in each of the two body 
compartments.. The segregation is not complete, however, as is evidenced from the 
observation in B5 that the B5rl3 sequence, which is closely related to the urinary 
sequences, is also present in the mouth. The tendency for different genotypes to be 
preferentially shed into different body fluids can be a consequence of: i. the low rate 
of HHV-8 hematogenous carriage (none of the five individuals studied here carried 
amplifiable HHV-8 DNA in their blood, as has been previously determined (Cook et 
al, 2002b)), ii. the tendency for HHV-8 to persist locally at or near the site of 
infection; iii. the restriction in host cells permitting latent but not lytic infection 
(Bechtel et al, 2003).
The possibility cannot be excluded, however, that the monotypy or multitypy found 
in the samples may be related to the sampling process itself, as HHV-8 may be 
present in urine or oral fluid at such low levels as to be distributed in a Poisson 
manner. These differences in the spectra of K l/V l sequences from B5’s oral fluid 
and urine could be explained by Poisson sampling.
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5.1 Introduction
In African countries, CMV infection is acquired early in childhood. Seroprevalence 
studies show >80% of African children to be CMV-seropositive by their 4th birthday. 
A study conducted by Krech and Tobin of CMV seroprevalence in young children 
from ages 4 m to 4 y in 19 countries showed that African cities like Ibadan in 
Nigeria and Entebbe in Uganda yield seroprevalences of >90% (Krech and Tobin, 
1981). In another study in Kumba City in Cameroon, 23 children out of 26 (88.5%) 
ranged between 4-6 y were seropositive for CMV (Stroffolini et al., 1993). By 
contrast, young children aged between 4 m-4 y in Oxford and Los Angeles showed 
seroprevalences of 3% and 15%, respectively (Krech and Tobin, 1981). A study in 
Italy conducted between 1987 and 1989 showed that the seroprevalence of CMV 
reached up to 55% by age 6 y (de Mattia et al., 1991). A recent study reported by de 
Ory et al. (2004) showed that the CMV seroprevalence of children aged 2-5 y in the 
autonomous region of Madrid, Spain was 43%. Such contrasts reflect greater 
opportunities for CMV transmission in African than industrialised countries.
African people infected by CMV intermittently shed the virus into urine and saliva 
(Bello and Whittle, 1991; Bello, 1992), so these fluids act as major vehicles of 
transmission. In order to ascertain better the routes by which CMV may be acquired 
in an African context, identities and genotypic clusterings in DNA sequences derived 
from hypervariable domains of the CMV genome carried by the same Malawian 
population described in the preceding chapters was investigated.
This chapter describes sequence variations in 2 newly identified hypervariable 
regions in the CMV genome: glycoprotein gpUL 73 (gN) (Pignatelli et al, 2003) and
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glycoprotein gpUL 74 (gO) (Paterson et al., 2002). Where possible, the urinary 
sequences of CMV were compared with corresponding sequences derived from 
mouth rinses.
5.2 Methods and materials
The study group comprised the same group of 19 KS patients, and 59 of their first- 
degree relatives as described in Section 2.1.1. Mouth rinse samples were collected as 
described in Section 2.1.3, and urine was collected as described in Section 2.1.4. 
DNA was extracted from both oral and urine samples as described in Sections 2.1.6 
and 2.1.7. A 304-bp fragment of the gN-coding region of CMV was amplified from 
sample extracts using nested PCR, as described in Section 2.2.1. A 433-bp fragment 
of the gO-coding region was also amplified by nested PCR, as described in Section 
2.2.2. Measures were taken to minimise the contamination (Section 2.1.11). PCR 
products were sequenced, raw DNA sequence data analysed, and phylogenetic 
analyses performed as described in Section 2.3. Certain gO genotypes were 
investigated if they were in linkage disequilibrium with gN genotypes. Data from 
three people with mixed infection (B5, Ri, and R2) were excluded from the statistical 
analysis.
5.3 Results
CMV DNA could be amplified from 41 people (53%) in either the gN or gO region 
in at least one sample, from 14 people (18%) in both domains in at least one sample, 
and from 13 (17%) in either domain in both samples. Their characteristics are 
summarised in Table 5.1. Twenty-one (51%) of the 41 people were seropositive for 
HIV-1, 36 (88%) were HHV-8-seropositive, and 16 (40%) were KS patients.
147
Chapter 5 Inter- And Intra-Person Cytomegalovirus Infection
Patient Age/gender CMV gO PCR CMV gN PCR HIV sero status
mouth
rinse
urine mouth
rinse
urine
Ai 7.5 y/F + + - - +
A2 lOy/M - - - + -
Bi 4 y/M + + + + -
B1 20 y/F - + + + +
B5 7 y/M + + + + -
Ci 8 y/M + - + - +
Di 4 m/M - - + - -
Ei 31 y/F + - + - +
E2 9 y/F - - + - -
E3 6 y/F - - + - -
E4 6 y/F - + + + -
Fi 2 y/M - + - - +
FI 35 y/F - + - + +
F2 7 y/M - + + + +
Gi 34 y/F - - + - +
G2 23 y/M - - + + -
G3 19 y/F + + - - -
H3 9 y/M - + - - -
12 11 y/F - - - + -
Mi 33 y/M + - - - +
Ml 3 y/M + - - - -
M3 8 y/F - - - + +
Ni 30 y/F - - + + +
Pi 30 y/M - - - + +
Qi 24 y/M - - - + +
Ri 41 y/M - + + + +
R1 25 y/F - - + - +
R2 12 y/M - + + + -
R3 9 y/M - - - + -
Ti 33 y/F - - + - +
T3 9 y/M - + - + -
T4 4 y/M + + + + +
Ui 32 y/F - - + - +
U1 14 y/M - - + - -
U3 8 y/F - - + - -
W4 13 y/F - - + - -
W6 7 m/F - - + - +
Xi 41 y/F + - + - +
X2 18 y/F - - + - -
X3 11 m/M - - + - -
Zi 1 y/ 9 m/M + - + + +
Table 5.1 Characteristics of CMV-infected Malawian KS patients and their family 
members.
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Forty-six gN sequences recovered were found to belong to four genotypes: gNl 
(65.2%), gN3(a) (28.3%), gN3(b) (4.3%) and a previously undescribed genotype, 
(2.2%), to which was assigned gN3(c). Twenty-five gO sequences could be assigned 
to six genotypes: gOl(a) (44%), g02(b) (16%), g04 (16%), gOl(b) (12%), g02(a) 
(8%) and gOl(c) (4%). The gN and gO nomenclatures follow those of Pignatelli et 
al. (2003) and Mattick et al. (2004) respectively.
Figure 5.1 shows the extent of diversity of gN DNA sequences, and Figure 5.2 an 
alignment of aminoacid sequences derived from the study samples. Identical 
nucleotide sequences were found: in the B family, in the mouth rinse and urine 
samples of a boy (Bi) (4 y), the mouth rinse and urine of his sister (Bl) (20 y) and 
the urine only of his brother (B5) (7 y); in family E, among the mouth rinse of a 
woman (Ei) (31 y) and that of her daughter (E2) (9 y) and the urine sample of her 
daughter (E4) (6 y); in family F, between the urine of a woman (FI) (35 y) and both 
mouth rinse and urine samples of her son (F2) (7 y); in family G, between the mouth 
rinse of the mother (Gi) (34 y) and the mouth rinse and urine of her son (G2) (23 y); 
in family R, between the mouth rinse of a man (Ri) (41 y) and the urine of his son 
(R2) (12 y); in family T, between the urine of a boy (T3) (9 y) and the mouth rinse 
and urine of his brother (T4) (4 y); family U, between the mouth rinse of a boy (Ulr) 
(14 y) and the mouth rinse of his sister (U3) (8 y); and in family X, between the 
mouth rinses of a woman (Xi) (41 y), her daughter (X2) (18 y) and her son (X3r) (11 
m).
Intra-family divergences of gN sequences were observed in families B, E, R, T, U 
and W (Figures 5.1 and 5.2). Nucleotide divergence of 0.3% was found between
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F igure  5.1 Predicted phylogenetic distribution o f  consensus gN sequences derived from 
mouth rinses and urine samples. Bootstrapping for 1000 replicates is noted as a percentage at 
m ajor branch points. Horizontal line at bottom left represents 10% nucleotide substitution 
for that horizontal branch length. Sequences have been deposited in GenBank (Accession 
Numbers AY326987-AY327032). Letters after patient identifiers: r = rinse; u = urine. 
Samples from individuals whose gN sequences were further studied are boxed as follows:
^  intra-individual samples with multitypic sequences 
H | intra-individual samples with monotypic but divergent sequences 
j- j intra-individual samples with identical sequences
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B5r and Bir/Biu/Blr/Blu, all belonging to gNl genotype. Two genotypes were 
found in family E: gN3(a) for Eir/E2r/E4r/E4u and gNl for E3u, with nucleotide 
divergence between the 2 genotypes of 14%. Within family R, nucleotide divergence 
ranged from 1% (between Rir and Rlr, and R lr and R2u) to 22.4% (between Rlr 
and R2r), with the sequences segregating to 4 reported genotypes: gNl for Rir, Rlr 
and R2u, gN3(a) for R3u, gN3(b) for R2r, and gN3(c) for Riu. Nucleotide 
divergence of 0.3% was found between Tir and T3u/T4r/T4u, all belonging to gNl 
genotype. Two genotypes were found in family U: gN3(b) for Uir and gN3(a) for 
U lr and U3r, with a nucleotide divergence of 21.2% between the two genotypes. 
Nucleotide divergence of 1.3% was found between W4r and W6r, both of which 
could be assigned to gN3(a).
Figure 5.3 shows the extent of diversity of gO DNA sequences, and Figure 5.4 an 
alignment of amino acid sequences derived from the study samples. Identical gO 
nucleotide sequences could be recovered from 3 families: family B, among Bir, Biu, 
and B5r; family F, among Fiu and Flu; and family T, among T3u, T4r and T4u.
Intra-family divergences of gO sequences were revealed in families B, E, F, M and 
R. Within family B, nucleotide divergence ranged between 33.8% (Bir/Biu/B5r and 
Blu) to 55.9 % (Bir/Biu/B5r and B5u), with the sequences belonging to 3 genotypes: 
gOl(a) for Bir/Biu/B5r, gOl(b) for Blu and g04 for B5u. In family E, there was a 
divergence of 0.5% between Eir and E4u, the sequences belonging to genotype g04. 
Within family F, the divergence was 45% between Fiu/Flu (genotype g02(b)), and 
F2u (genotype gOl(a)).
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Figure 5.3 Predicted phylogenetic distribution of consensus gO sequences derived 
from mouth rinses and urine samples. Horizontal line at bottom left represents 10% 
nucleotide substitution for that horizontal branch length. Sequences have been deposited 
in GenBank (Accession numbers AY326961-AY326986). Samples from individuals 
whose gO sequences were further studied are boxed as in Figure 5.1.
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Figure 5.4 Alignment of amino acid sequences predicted from gO sequences depicted in Figure 5.3. Dots indicate 
residues occupying positions aligned to residues of Aiu at top. Samples from individuals whose gO sequences 
were further studied are boxed as in Figure 5.1.
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Mir and M ir in M family showed a divergence of 44.8%, the sequences belonging to 
genotypes g02(b) and gOl(c), respectively. In the R family, a 43.2% divergence was 
found between Riu (genotype g01(b)), and R2u (genotype g02(a)) (Figures 5.3 and 
5.4).
For 11 people, DNA from gN region could be amplified from >1 sample. gN 
sequences were identical in two samples from 7 people (Bi, B l, F2, G2, Ni, T4 and 
Zi). Non-identical sequences were found in samples from 4 people, with intra-person 
divergences of 0.3%, 0.3%, 11.6% and 21.1% for E4, B5, Ri and R2, respectively. 
For two individuals (Ri and R2), non identical intra-person gN yielded samples that 
carried sequences belonging to 2 genotypes: gNl and gN3(c) in Ri, and gN3(b) and 
gNl inR2 (Figure 5.1).
For 5 people, DNA from gO region could be amplified from >1 sample. gO 
sequences were identical in 3 (Bi, G3, and T4). Non identical sequences were found 
in samples from 2 people, with intra-person divergences of 65% and 56% for Ai and 
B5, respectively. For 2 individuals (Ai and B5), non identical intra-person sequences 
belonged to separate genotypes: g02(b) and g04 for Ai, and gOl(a) and g04 for B5 
(Figure 5.3).
The gO and gN genotype combinations analyzed were: g01(a)/gNl (n=6), gOl 
(b)/gNl (n=l), g01(b)/gN3(a) (n=l), g04/gN3(a) (n=2), g02(b)/gNl (n=l) ) Table
5.2).
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Patient CMV gO PCR CMV gN PCR
mouth rinse urine mouth rinse urine
Bi gO 1(a) gOl(a) gNl gNl
BI — gO 1(b) gNl
Ci 801(b) — gN3(a) -
Ei g04 — gN3(a) -
E4 — g04 gN3(a)
FI — g02(b) — gNl
F2 — gOl(a) gNl
T3 — gOl(a) — gNl
T4 gOl(a) 801(a) gNl gNl
Xi gOl(a) — gNl —
Zi gOl(a) — gNl
Table 5.2 Show linkage/ recombination of different genotypes of gN and gO regions 
from same sample.
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5.4 Discussion
The CMV gN and gO genes are among a disparate group of herpesvirus genes that 
exhibit wide nucleotide sequence polymorphisms. These genes include those 
encoding latent membrane protein-1 of EBV (Miller et al., 1994), Epstein-Barr 
nuclear antigen-2 (Ling et al., 1993), ORF K1 of HHV-8 (Zong et al., 1999) and 
UL11 of CMV (Hitomi et al., 1997). The gN protein, which binds with the gM 
protein to form a virus envelope complex, glycoprotein complex II (gCII), is able to 
induce neutralizing antibodies (Mach et al., 2000). The gN protein exhibits inter­
genotype amino acid sequence variability of up to 50% (Pignatelli et al., 2001). gCII 
is able to bind heparin of the cell surface, suggesting that it has a role in facilitating 
virus attachment to the host cell (Kari and Gehrz, 1992). The gO protein is a 
constituent of a heterotrimeric complex, glycoprotein complex III (gCIII), 
comprising gO, gH (encoded by UL75) and gL (encoded by UL115); this complex 
has fusogenic properties thought to be responsible for cell-to-cell spread (Paterson et 
al., 2002). There is no evidence yet to show that the gO protein elicits neutralizing 
antibody responses, although the gH protein is known to do so (Rasmussen et al., 
1984).The inter-genotype amino acid sequence variation in the gO protein is reported 
to be up to 46% (Rasmussen et al., 2002), but it was found in this study that the 
amino acid divergence can reach up to 65.9% (between Eir and Mir Figure 5.4).
Several other CMV protein-encoding genes also show strain-dependent differences, 
but the extents of their variability are not comparable to those encoding gN and gO. 
The most widely studied gene is UL55, which encodes gB. Dimers of covalent 
linked gB protein constitute glycoprotein complex I (gCI), which is responsible for 
virion entry and cell-to-cell spread (Navarro et al, 1993). The gB protein is a major
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target for neutralizing antibodies and for T-cell cytotoxic responses (Hopkins et al, 
1996; Alberola et a l, 2000). Amino acid variation in gB is nevertheless not >15% 
(Chou, 1992a). The UL144 gene encodes a homologue of the herpes simplex 
mediator, a member of the tumour necrosis factor receptor (TNFR) family. It is a 
type I transmembrane glycoprotein and is expressed early after infection; its function 
is unknown (Benedict et al, 1999). Variation in the UL144 protein is up to 21% 
(Lurain et al, 1999). The US9 and US28 genes show variability of about 4% at both 
nucleotide and amino acids levels (Rasmussen et al, 2003). The glycoprotein 
encoded by US9 may be a determinant of replication and cell-to-cell dissemination 
of CMV through its association with cytoskeleton proteins along lateral cell 
membrane such as actin and cadherin (Maidji et al, 1998). The US28 gene encodes 
the CC chemokine receptor, which can modify the environment of the CMV-infected 
cell by sequestering extra cellular CC chemokines that influence the inflammatory 
response and the infiltration by lymphocytes, monocytes and basophils. Thus, the 
cytotoxic potential of CD8+ lymphocytes and natural killer (NK) cells has been 
observed in vitro to be decreased (Bodaghi et al, 1998). The US28 product appears 
also to play a role in promoting smooth muscle cell migration (Streblow et al, 
2001). It and the rhesus CMV homologue RhUS28.5, are localised to the envelope of 
infectious virions, and may therefore play a role in viral entry (Penfold et al, 2003). 
A highly variable gene, UL11, encodes a protein which is expressed on the surface 
of CMV infected cells; its function is unknown but it exhibits >40% amino acid 
variability (Hitomi et al, 1997).
The nature of selection pressures acting to generate plasticity in the gN and gO genes 
is enigmatic. While gN is known to be able to induce neutralizing antibodies (Mach
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et al., 2000), and its amino acid sequence variation may therefore be attributed to 
pressures acting on the gene to evade neutralisation, such variability is nonetheless 
substantially greater than that for gH (up to 4% amino acid sequence variation) 
(Chou, 1992b) and gB (up to 15% variation) (Chou, 1992a), which are major targets 
of neutralising antibodies (Alberola et al, 2000). Furthermore, there is no evidence 
that the gO protein elicits neutralizing antibody responses. Hypervariability may 
perhaps be related to the pressure acting on the gene to effect T-cell cytotoxic 
responses. It has been reported that the extreme hypervariability in a stretch of the 
ORF K1 protein of HHV-8 is associated with domains that are targets of intense 
cytotoxic responses (Stebbing et al., 2003). Whether the CMV gN and gO proteins 
similarly carry epitopes eliciting T-cell responses is unknown.
There may be other selective forces operating that have yet to be defined. They may 
relate to tropism, virulence and host immune status, which would lead to an 
accumulation of specific viral variants in selecting environments. Thus, Meyer- 
Konig et al. (1998) observed that gB2 and gB3 preferentially infect monocytes and 
lymphocytes. A recent study showed that the gB2 CMV strain exhibits tropism for 
neurons (Tarrago et al., 2003). Several reports have also suggested an association of 
different gB genotypes with pathogenicity; a study in Hungary showed gBl to be 
dominant in congenital infections (Lukacsi et al, 2001) and another study by Woo et 
al. (1997) in Hong Kong reported the dominance of gBl strains in CMV-infected 
premature babies. Fries et a l (1994) and Hebart et al. (1997) demonstrated a 
correlation between the gB genotypes and severity of CMV disease in bone marrow 
transplant recipients.
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The study described in this chapter has exploited the hypervariability of the gN and 
gO genes to investigate extra-and intra-household, and intra-individual CMV 
variability in an African community setting in Malawi. In families with identical gN 
or gO sequences there were some in which identity was observed between mother 
and child: for gN sequences, between Ei and her daughters (E2 and E4), FI and her 
son (F2), Gi and her son (G2), Ti and her sons (T3 and T4), Xi and her daughter 
(X2) and son (X3); and for gO sequences, FI and her son (Fi). CMV sequence 
identities were also observed between members of the family. Thus, identical gN 
sequences could be found between a father (Ri) and son (R2), and between siblings: 
Bi and his sister (BI) and brother (B5), and U1 and his sister (U3), and identical gO 
sequences between Bi and his brother (B5), and between T3 and his brother (T4).
Both vertical and horizontal CMV infection probably account for CMV gN and gO 
sequence identity among members of the same household. Children may acquire 
infection vertically in utero, perinatally, or during breast-feeding (Bryant et al, 
2002; Revello et al, 2002). Horizontal infection is facilitated in close-living 
conditions, since CMV is often shed in saliva and urine (Pass et al, 1986; Adler, 
1989). While in the USA and Japan epidemiological studies have identified day care 
centres as main sources of infection which then spreads from the children to their 
parents (Pass et al, 1986; Kashiwagi et al, 2001), the sources and vehicles of intra­
household horizontal CMV infection remain to be identified in the African context. 
A study in the Gambia of 178 women and their babies followed up for 9-15 m, and 
in mothers and siblings of 22-infected infants showed that titres of CMV in urine 
were comparable to those in saliva, both in the infants (103 and 102 7 TCIDso/ml 
respectively) and mothers (1017 and 1014 TCID5o/ml respectively). Eighty percent of
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babies in this study generated more specimens yielding CMV over a longer time 
compared to 20% of the mothers. Furthermore, 36.6% of siblings excreted CMV in 
either urine or saliva compared to 6.1% of mothers. Thus, infected children are 
significant reservoirs of infection. The spread of CMV may be facilitated through 
bed-wetting, as families tend to sleep together (Bello, 1992). The tendency for 
members in African communities to engage in traditional behavioural activities 
based on saliva exchange may also facilitate the spread of CMV (Wojcicki, 2003). 
The activities include frequent kissing of infants by mother and other family 
members and hand-to-mouth eating from the same bowl.
Some families were observed to carry multiple genotypes. The gN sequences 
recovered from family R belonged to 4 genotypes: the gO sequences from family B 
to three genotypes, gN sequences recovered from family E and U to two genotypes, 
and gO sequences from family F, M and R to two genotypes. The multitypic 
sequences recovered from each of these families are consistent with extra-household 
transmission having taken place. How CMV extraneous to the household may lead to 
infection remains undefined. Contact with urine and saliva carrying CMV or objects 
contaminated with such fluids is one possibility. Transmission relating to sexual 
activities may also contribute. CMV has been observed to be shed into semen: 
Aynaud et al. (2002) showed that in 111 semen samples taken from HIV- 
seronegative Parisian male partners of women with histologically-detected human 
papillomavirus (HPV)-associated genital lesions, CMV DNA could be detected in 7 
(6.3%). CMV can also be shed from the cervix: Collier et al. (1995) evaluated 1481 
heterosexual women attending a sexually transmitted disease clinic at Seattle, from 
951 who were CMV seropositive cervix swabs were collected and showed that 86
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(9.4%) were culture-positive for CMV. In a similar study, Mostad et al. (1999) 
investigated the prevalence of CMV shedding in 311 cervical swab samples 
collected from women attending a sexually transmitted diseases clinic in Mombasa, 
Kenya, and detected CMV DNA in 183 (59%).
The study described in this chapter has also provided evidence for intra-host 
sequence polymorphism in CMV originating from mouth rinses and urine of 5 
people (Ai, B5, E4, Ri and R2) and 4 (Ai, B5, Ri and R2) could be identified to be 
carrying 2 genotypes each. All except Ri were children. Two individuals, Ai and Ri, 
were HIV-1 seropositive. Present studies have shown that HIV-infected people are 
particularly prone to mixed infections. Verbraak et al. (1998) studied CMV DNA 
sequences from aqueous humour and peripheral blood leukocytes of 13 AIDS 
patients with CMV retinitis in the Netherlands and found that in 7, sequences 
obtained from the eye and blood were different. In another study of samples taken 
from various tissues (including lung, stomach, adrenal gland and liver) obtained at 
autopsy of 12 AIDS patients in London, UL4 DNA were amplified from 10, of 
which 5 were found to carry >1 genotype (Bar et al., 2001). The presence of 
different sequences in the same compartment in HIV-infected patients also has been 
reported by Fidough-Houhou et al. (2001) who showed that in 98 HIV-seropositive 
patients in Paris, CMV gB DNA could be amplified from saliva samples in 37 
patients, of whom 5 (13.5%) showed mixed gB strains.
The finding that 3 of the 5 people, B5, E4, and R2, who were HIV-seronegative, 
substantiates other studies, which imply that immunocompetent children and adults 
are also prone to multiple infection. Past studies comparing the RFLP patterns of
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CMV DNA derived from cell culture isolates of immunocompetent adults have 
revealed mixed CMV infection. Chandler et al. (1987) who studied 34 cultured 
CMV isolates over a 14 m period from the cervix, urine and throat of 8 randomly 
selected healthy women attending a sexually transmitted disease clinic in Seattle 
showed that 2 shed different strains from the same site and another 2 shed different 
strains simultaneously from different body sites. Mixed CMV infection also has been 
reported by Collier et al. (1989) in an immunocompetent homosexual American 
patient who was infected by 4 different strains, 2 isolated from urine and 2 from 
semen. Shen et al. (1993a) amplified gB DNA from serial urine samples obtained 
from an immunocompetent child in Taiwan and documented mixed infection. Lasry 
et al. (1996) examined the CMV excretion in 439 urine samples from 93 healthy 
children <1 y in 6 day care centres in Paris by amplifying and sequencing the gB 
gene, and revealed mixed infection in 2 children. These various studies suggest that 
in western countries, mixed CMV infection can occur in immunocompetent people 
but is very rare, whereas in those who are immunocompromised, the incidence is 
higher.
The findings in regard to gO/gN linkages agree with those of Mattick et al. (20040 
who found that gOl(a) tends to be associated with gNl, and gOlb with gN3a. A 
study involving a larger sample set may confirm that there is linkage equilibrium 
between these combinations. Furthermore, the study reveals new linkages: gOl(b) 
with gNl,g04 with gN3(a), and g02(b) with gNl. These various linkages are 
suggestive of past recombination between CMV genes (Table 5.2).
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Multiple CMV carriage may be due to reactivation of endogenous CMV strains or to 
super-infection by new strains from exogenous sources. That the latter possibility 
may apply is suggested by the finding that for 2 individuals carrying mixed infection 
studied here, sequence identity could be identified in another member of the family: 
the gN sequence derived from the mouth rinse of Ri was identical to that in urine of 
his son, R2; and the gO sequence was identical between the mouth rinse of Bi and 
mouth rinse and urine of his brother B5.
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6.1 Introduction
People living in African regions are prone to be repeatedly exposed to HHV-8 and 
CMV. The current study involved samples collected from people living in Malawi, a 
region of high HHV-8 and CMV endemicity. Family groups in which one member 
had been affected by KS were selected to investigate if the hosts living in such a 
region carry multiple HHV-8 or CMV strains. In the study, several methods were 
utilised to investigate the molecular epidemiology of HHV-8 and CMV in samples 
obtained from different anatomical body compartments. The samples investigated 
were mouth rinse, gargles, palatal exfoliates, blood cells and urine.
6.2 Intra-individual oral HHV-8 infection
Multiple HHV-8 infection rarely has been considered (Gao et al, 1999). Most 
studies of humans who have developed KS (Stebbing et al, 2001; Meng et al, 2001; 
Zong et al, 2002) or multiple HHV-8 associated lesions (Codish et al, 2000) have 
not shown intraperson variation in HHV-8 subgenomic sequences amplified by PCR 
from blood and lesional tissues.
To effect such a study, sequence variation was sought in DNA segments derived 
from HHV-8 ORFs 73, 26 and K1 using restriction fragment-length polymorphism 
analysis, nucleotide sequencing, PCR cloning and denaturing gel gradient 
electrophoresis. DNA was amplified by PCR from mouthrinses, throat gargles, 
palatal exfoliates and blood. Twenty-four people were identified who carried 
amplifiable HHV-8 DNA in >1 sample; 9 (38%) were seropositive for HIV-1, 21 
(88%) were anti-HHV-8-seropositive and 7 (29%) exhibited KS. Amplification rates 
were variable depending on the region within the HHV-8 genome to be amplified.
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Highest yields were obtained after amplification from K l/V l, followed by KS330 
and the IRD. Mouth-rinse and throat-gargle samples yielded higher amplification 
rates than did blood and palatal-exfoliate samples, probably reflecting active HHV-8 
replication in the oral epithelium, and the possible lower replicative activity of the 
virus systemically and in the palatal mucosa. The palate was especially investigated 
since it is the site at which oral KS most often develops. Blood samples yielded 
HHV-8 subgenomic amplicons in a substantial proportion of patients with KS but 
not at all in those without KS. This finding confirms previous data (Cook et al., 
2002b) showing that, in HHV-8-infected African people not affected by KS, the 
virus is not shed into their circulation to a significant extent and that the principal 
site of viral shedding is the mouth. It supports the emerging consensus that oral fluid 
and saliva are important vehicles for HHV-8 shedding and transmission.
To examine for intra-individual HHV-8 diversity, the principal approach used was 
PCR of K l/V l combined with DGGE nucleotide sequencing of K l/Vl amplicons 
generated from clonal inserts. This was to permit sequences of minority variants to 
be identified and characterized. Such an approach was necessary to overcome the 
limitation imposed by consensus sequencing, which would represent the sequence of 
the dominant variant only. The data so obtained were amalgamated with data 
accrued from RFLP analysis of the IRD and consensus sequencing of KS330.
For 3 KS patients, intraperson genotypic differences, arising from nucleotide 
sequence variations in KS330 and K l/V l, were found in blood and oral samples. 
Evidence for the oral carriage of multiple strains of HHV-8 could be found for 16 
people out of 24 (>60%), 4 with KS and 12 without KS. For 1 patient with KS and
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for 7 people without KS, intra-person genotypic differences, originating 
predominantly from K l/V l, were found in oral samples. For the 2 patients with KS 
and for 4 individuals without KS, intra-sample carriage of distinct ORF K1 
sequences could be discernible in oral samples. Furthermore, subgenomic sequences 
could be identified in oral samples for 2 patients with an identical genotype and for 2 
patients with identical genotype but with distinct variants. These various data 
therefore reveal the presence of multiple HHV-8 infection inter- and intra- 
compartmentally.
It would be important to determine whether multiple HHV-8 carriage reflects 
simultaneous coinfection by >1 HHV-8 strain, reactivation of latent strains, or 
superinfection. If it reflects superinfection, then such transmissions may not be 
prevented by vaccination. Nonetheless, although the immune system might not 
prevent superinfecting virus from initiating replication in the host, it might, after 
vaccination, prevent the further spread of the initial infecting strain (following 
reactivation) and of the subsequent superinfecting strains. In view of the relentless 
march of HIV/AIDS in Africa, where HHV-8 is also hyperendemic, initiatives to 
develop vaccines against HHV-8 would be beneficial.
These findings also confirm the predominance of the mouth as a source of HHV-8 
shedding. They are indicative of the mouth as an important, if not the principal 
reservoir of HHV-8 and of oral fluid as the prime vehicle for its transmission.
Further work: The coexistence in a given host of >1 HHV-8 strain, particularly if 
the strains are genotypically different, potentially confounds molecular
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epidemiologic analyses of HHV-8 transmission. Strains that persist in the host as 
minority variants will not be revealed if appropriate methods are not applied, and 
such variants will be missed in the course of tracking the spread of HHV-8. 
Accordingly, future studies aiming to track the transmission of particular HHV 8 
variants should take into consideration transmission by minority variants if 
consensus sequencing at first reveals non identical variants between the transmitter 
and recipients of a transmission event.
The approach adopted in this study can be applied to other population groups. The 
mode of transmission in HHV 8-endemic regions in the Mediterranean deserves 
attention. There are already some indications that oral transmission of HHV 8 may 
be more significant than sexual transmission (Vieira et al, 1997; Pauk et al, 2000; 
Marcelin et al, 2004). Confirming the phenomenon of multiple HHV 8 infection 
within and among anatomical compartments in the given host in the Mediterranean 
context should clarify better how the virus spreads there.
In HHV-8 hyper-endemic area it may be useful to examine tissue specimens from 
various organs, e.g. lung, brain, spleen, liver, etc, obtained from individuals who 
died from KS or any other causes, in order to investigate HHV-8 sequences present 
in those tissues. Studies may also be done to determine if there is any link between 
multiple HHV-8 infection and the progression of HHV-8-associated diseases.
6.3 Inter- and intra-person urinary HHV-8 infection
As an extension of the study of polymorphism in HHV-8 subgenomic sequences 
ampilified from blood and oral samples, urine was collected from the same study
169
Chapter 6 Conclusions and Suggestions for Further Work
group. The extent of HHV-8 urinary sequences variation derived particularly from 
K l/V l was examined and compared with sequences derived from oral samples of the 
same individual.
Both direct sequencing and PCR combined with DGGE analysis of Kl/Vl clones 
technique were used. Variation in the KS330 region was investigated, but was found 
not to yield sufficient polymorphism to permit strain-to-strain HHV-8 differentiation.
The rate of HHV-8 DNA detection in urine samples of the patient group was low: 
only 6 out of 78 (7.7%) tested positive for HHV-8 DNA. Four individuals were 
positive for K l/V l, one positive for KS330, and one positive for both Kl/Vl and 
KS330. All K l/Vl intra-sample sequences obtained from 5 urine samples showed no 
or narrow intra-typic divergence, and were all monotypic.
The genotype of HHV-8 shed in urine was observed to be different from that shed 
into the mouth in two patients. One of the patients from whom urinary HHV-8 was 
characterised showed HHV-8 multitypy (up to three genotypes) in his mouth rinse 
sample. Segregation of HHV-8 variants in two body compartments is suggested from 
these data. Nonetheless, that the monotypy or multitypy found in our samples may 
be related to the sampling process itself cannot be excluded, as HHV-8 may be 
present in urine or oral fluid at such low levels as to be distributed in a Poisson 
manner.
Further work: How important urine might be in contributing to HHV-8 endemicity 
would require further investigation. Other than studying larger sample sizes and in
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different geographical regions, the assessments of the urinary viral load by, e.g., real­
time PCR quantification techniques, would be useful. Confirming monotypy or 
multitypy of urinary HHV-8 in the various anatomical compartments in larger 
sample sizes of study individuals may shed light on whether specific HHV-8 variants 
have a predilection to infect and persist in specific tissue types.
6.4 Inter-and intra-person cytomegalovirus infection
CMV is another herpes virus which is shed in body fluids like urine and saliva. From 
the same Malawian group, the routes by which CMV may be acquired, and the 
genotypic and intra-genotypic diversity were investigated both inter-and intra 
compartmentally. Two newly identified hypervariable regions in the CMV genome, 
gN and gO, were studied. Both urine and mouth rinse samples were examined, and, 
where possible, the urinary sequences of CMV were compared with corresponding 
sequences derived from mouth rinses.
CMV DNA could be amplified from 41 people (53%) in either the gN or gO region 
in at least one sample, from 14 people (18%) in both domains in at least one sample, 
and from 13 (17%) in either domain in both samples. Forty-six gN sequences 
recovered were found to belong to four genotypes, and 25 gO sequences could be 
assigned to six genotypes. Identical gN or gO sequences were found in 8 families. 
Identity was observed between mother and child for 5 families. Four families 
showed CMV sequence identities between other members of the family.
Both vertical and horizontal CMV infection probably account for CMV gN and gO 
sequence identity among members of the same household. Six families were
171
Chapter 6 Conclusions and Suggestions for Further Work
observed to carry multiple genotypes. The multitypic sequences recovered from each 
of these families are consistent with extra-household transmission having taken 
place. However, CMV extra-household transmission remains undefined. Contact 
with urine and saliva carrying CMV or objects contaminated with such fluids is one 
possibility. Transmission relating to sexual activities may be another.
Evidence was provided for intra-host sequence polymorphism in CMV originating 
from mouth rinses and urine of 5 people, with 4 of them carrying 2 genotypes. 
Multiple CMV carriage may be due to reactivation of endogenous CMV strains or to 
super-infection by new strains from exogenous sources. Four of the 5 were children 
and 3 of the five were HIV-seronegative, and presumably immunocompetent. Most 
previous studies have been focused on multiple infection in immunocompromised 
hosts. The findings for this study are significant in that multiple infection in the 
context of immunocompetent people living in a hyper endemic area is revealed.
Further work: The multiplicity of routes by which CMV spreads in the intra- and 
extra-household contexts, and the vulnerability of immunocompetent people to 
multiple CMV infection potentially influence the efficacy of vaccination against 
CMV. Continuing studies into how CMV genotypes circulate in different 
communities could help in the evaluation of the efficacy of CMV vaccines in the 
prevention of primary and congenital infection. Again, the DGGE technique as 
applied here may also be applied to future studies of CMV molecular epidemiology.
The study also shows that the degree of nucleotide sequence polymorphism in 
hypervariable regions of CMV (gN and gO) do not match that of HHV-8 ORF Kl.
172
Chapter 6 Conclusions and Suggestions for Further Work
Consequently, the molecular epidemiology of CMV could not be done in the refined 
manner as was carried out for HHV-8. It would therefore be worthwhile to search for 
sub-genomic regions of CMV to identify regions that exceed gN and gO in 
hypervariability. Such research may also be extended to study the ‘micro’ molecular 
epidemiology of the other herpes viruses. This form of investigation may help to 
understand better some longstanding questions in herpes viruses pathogenesis: is 
recurrent herpes labialis and genitalis due to reactivation of one particular HSV-1 or 
HSV-2 strain rather than many strains? Similarly, is herpes zoster a result of 
reactivation of one particular strain or >1 strains? With the advent of widespread 
vaccination against VZV, how might chickenpox or herpes zoster that develop in a 
vaccinee be determined not to be due to the vaccine strain? Is oral hairy leukoplakia 
due to reactivation of single EBV strain or from superinfection of many strains? If 
the latter, which anatomical compartments sequester these various strains?
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Relation age Index case Mouth rinse Garale Palate Blood Urine Anti HIV 
serostatus
Anti HHV-8 
serostatus
IRD ORF 26 K1/V1 gN g o IRD KS330 K1/V1 IRD KS330 K1/V1 IRD KS330 K1/V1 KS330 K1/V1 gN g o
Group A
Daughter 7.5 Ai - -(-) - (-) - + - - - - - - * + + - * - + + +
Mother 34 A1 - + (+) -(-) + + + +
son 10 A2 - - ( +) * (-) - - - - - - + - - - - - - + * - +
son 7months A3 - -(-) -(-) nd nd nd - -
Group B
son 4 Bi - -(-) - (*) + + • + + + - +
daughter 20 B1 - -(-) ‘ (-) + - - + + * - - - - - - - + + + +
son 13 B2 - -(+) -(-) + - +
son 12 B3 - + (+) + (+) - -
son 10 B4 - -(-) -(-) - +
son 7 B5 - - ( +) + (+) + + - - - - + + - - - - + + + - +
daughter 1 yr/1 m B6 - -(-) -(-) nd nd nd - + - - - - Nd nd nd nd - -
mother 40 B7 - -(-) -(-) - +
Group C
son 8 Ci + + (+) - (+) + + + + + - + + - * - - - - - + +
father 45 C1 - -(-) -(-) + -
daughter 14 C2 - -(-) nd nd nd nd - +
son 12 C3 - -(-) -(-) nd nd nd nd - +
Group D
son 4 months Di - -(-) * (-) + - - - -
mother 18 D1 - + (+) + (+) - +
Tabel 1
Tables 1-5 DNA detectability for different regions of HHV-8 and CMV for different samples obtained from all patients (with Kaposi’s sarcoma and their 
families members) in this study. Detestability results between brackets for mouth rinses obtained from (Cookb et al., 2002). ND, Not done.
24
3
Relation age Index case Mouth rinse Garale Palate Blood l^rine Anti HIV serostatus Anti HHV-8 serostatus
IRD KS330 K1/V1 gN g o IRD KS330 K1/V1 IRD KS330 K1/V1 IRD KS330 K1/V1 KS330 K1/V1 gN gO
Group E
mother 31 Ei - -(-) + (-) + + - + + - - - - + + nd nd nd nd + +
daughter 5 E1 -(-) - +
daughter 9 E2 + (+) -(-) + - - + - +
daughter 6 E3 + (+) -(-) + - - + - +
daughter 6 E4 + <+) -<+) - + - + + - - - - - - - - + + - +
son 13 E5 + (+) + (+) - - - + + - + - - - - - - - - - +
son 10 E6 + (+) + (+> - - - + + - +
Group F
son 2 Fi + -(-) -(-) - - - + + - + + - + + - - - + + +
mother 35 F1 - -(-) -(*) - + - - - - - - - - - - - + + + +
son 7 F2 - -(-) -(-) + * * - - - - - - - - - - + + + -
Group G
mother 34 Gi - -(-) -(-) + - - - - - - - - + - - - - - + +
daughter 32 G1 - -(+) + (+) + + +
son 23 G2 - + (+> + (+) * - + + + - - - - - - + + - - - +
daughter 19 G3 - -(-) -(-) - - - - + - +
son 15 G4 - -(-) -(-) - - - - + - +
Group H
mother 35 Hi - -(-) -(-) + +
daughter 13 H1 - + (+) -(-) - +
son 12 H2 - + (+) *(+) - - - + + - + + - - - - - - - - +
son 9 H3 - + (-) + (-) - + - + - * - - - - - - - * - - +
son 8 H4 - -(-) -(-) - -
Group 1
mother 36 li - -(-) + (-) - - - - + - - - - - - nd nd nd nd + +
son(4th) 12 11 - -(-) *(-) - - - * - - - - - - - - + - - - +
daughter 11 12 ■ -(-) + (-) * • ■ • + - * + * ■ * - - + - - -
Tabel 2
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Relation age Index case Mouth rinse Gargle Palate Blood Urine Anti HIV 
serostatus
Anti HHV-8 
serostatus
IRD KS330 K1/V1 gN go IRD KS330 K1/V1 IRD KS330 K1/V1 IRD KS330 K1/V1 KS330 K1/V1 gN go
Group J
father 28 Ji - + (-) -(-) - + + - - - - - - - - + +
wife 22 J1 - -(-) + (-) - - - - - - - - - - - - +
son 3 J2 - -(-) -(-) - - - - - + - - - - - - -
Group K
mother 30 Ki + + (+) + (+> - - - - + + - + + - - + +
son 12 K1 - + (+) + (+) - - - - + + - - - - - - -
Group L
husband 30 Li - -(-) -(-) - - - - + + - - - - - + =
wife 28 L1 - -(-) -(-) + -
Group M
father 33 Mi - -(-) -(-) + - + +
son 3 M1 - -(-) -(-) + - - - - - + - - - - - * -
daughter 7 months M2 - -(-) -(-) - - - - - - - nd nd nd nd - -
daughter (of mother) 8 M3 - -(-) -(-) - + + +
mother 32 M4 - -(-) -(-) - +
Group N
mother 30 Ni - + (+> -(-) + - - + - - - - - - - - + + - + +
daughter 18 N1 - -(-) -(-) - -
GroupP
husband 30 Pi - + (-) -(-) - + - - - + - - - - - + + +
wife 28 P1 - + (-) + (-) - - + - - + - + + + - + +
son 2 P2 - -(-) -(-) - - ♦ + - - - - - - -
<N
Table 3
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Relation age Index case Mouth rinse Garale Palate Blood Urine Anti HIV 
serostatus
Anti HHV-8 
serostatus
IRD KS330 K1/V1 gN go IRD KS330 K1/V1 IRD KS330 K1/V1 IRD KS330 K1/V1 KS330 K1/V1 gN go
Group Q
husband 24 Qi + +(-) - - - - - - - + + + - - + - + +
wife 21 Q1 - +(-> +
Group R
father 41 Ri - -(-) -(-) - + - - - - - - - - - + + + +
mother 25 R1 - -(*) -(-) - - - - - - - - - - - + - + +
son 12 R2 - -(-) -(-) + - - - - - - - - - - + + - +
son 9 R3 - + (+) + (+) - - - - - - - - - - - + - - -
GroupS
husband 40 Si - -(-) -(-) + +
wife 37 S1 - -(-) -(-) - - - - - - - - - - - -
Group T
wife 33 Ti - -(-) -(-) + - - - - - - - - - + +
husband 37 T1 - -(+) -(-) - - - - - - - - - - + +
son 11 T2 + + (+) -(+) - - + - - - - - - + - +
Son 9 T3 + + (+) •(+) - - + - - - - - + + - +
son 4 T4 - -(*) -(+) + + - - - - - - + + + +
Group U
mother 32 Ui - + (+) -(-) - - - - + - - + +
son 14 U1 • -(-) -(-) + - - - - - - - - - - • +
daughter 12 U2 - -(-) -(-) - - - - - - - - - - - - - - -
daughter 8 U3 - -(*) -(-) + - * - * - - - - - - - - - -
Table 4
24
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age Index case Mouth rinse Garale Palatal Blood Urine Anti HIV 
serostatus
Anti HHV-8 
serostatus
IRD ORF26 ORF K1 gN go IRD ORF 26 ORF K1 IRD ORF 26 ORF K1 IRD Ks330 K1/V1 KS330 K1/V1 gN go
Group W
mother 43 Wi - *(-) + (-) - - - - - - - - - - - - - - + +
father 36 W1 - + (+> + (+) - - - + - - + - - - - - - - + +
son 20 W2 + + (+) + (+) - - + + - - - - - - - - - - - +
son 19 W3 - -(-) + (-) - - - - - - - - - - - - - - - +
daughter 13 W4 + + (+) + (+) + + + + - + - - - - - - - • - +
son 6 W5 - -(-) -(-) - - - - - - - - - - - - - - + +
daughter 7 months W6 - + (-) -(-) + nd nd nd - - - - - - nd nd nd nd + +
Group X
mother 41 Xi - -(-) -(-) + + - - - - - - - * - - - - - + +
father 44 X1 + + (+) + (+) - + + + - + - - * - nd nd nd nd + +
daughter 18 X2 - -(-) -(+) + - - - - - - - - - - - - - - -
son 11 months X3 - -(-) *(•) - nd nd nd - - - - - - nd nd nd nd - -
Group Y
father 32 Yi - -(-) + (-) * * - • - - - + - - - - - - - - +
mother 38 Y1 - -(-) -(-) - - - - + - - + - - - - - - - - -
daughter 8 Y2 - -(-) + (*) - - - - - - - + - - - - - - - - -
daughter 5 Y3 - -(-) -(-) - - - - - - - - - - - - - - - - -
daughter 2y/8mont Y4 - nd nd - - - - - - - * - nd nd nd nd -
Group Z
son 1y/9mont Zi + -(+) +(+) + + nd nd Nd - - + - - + - - + - + +
daughter 5 Z1 * -(-) -(-) - - - - - - - - - - - - - * - - +
mother 22 Z2 - + (+> + (♦) - - - + + - + + - - - - - - - - +
Table 5
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